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Wound healing is an essential process for the repair of tissue damage after an injury. This 
process results in either the regeneration of parenchymal tissue or replacement with 
connective tissue (scars). Majority of damaged tissues in adults heal with scars. Normal 
scarring is well-regulated. However, pathological scarring, also called fibrosis, is out of 
control. 
 
Fibroproliferative diseases involve many organs of the body. The hallmark is the 
excessive deposition of collagen, which destroys the original structure and impairs its 
function as well. Peri-implantational fibrosis occurs after implantation. It represents the 
end stage of a foreign body reaction directed by the host to implants. Peri-implantational 
fibrosis, characterized by a collagenous capsule, compromises the performance of 
implants and causes implantation failure.  
 
To this day, there is neither effective treatment for fibroproliferative diseases nor 
effective prevention of peri-implantational fibrosis. To explore new antifibrotic drugs, we 
have been investigating the therapeutic potential of histone deacetylase inhibitors 
(HDACis). They are small organic molecules which change gene expression profiles at 
the epigenetic level. HDACis are of prime interest in cancer research because they induce 
apoptosis in malignant cells. Interestingly, recent work suggested that HDACis might 
also inhibit collagen production in fibroblasts. Therefore, we evaluated the antifibrotic 
effects of HDACis in vitro.  
 vi
 
First, a microplate reader-based quantitative immunocytochemistry (QICC) method using 
PHERAstar with a unique focusing lens system was established. Significant higher 
signal-to-background ratios in measuring the fluorescence intensities were achieved with 
PHERAstar. We further demonstrated that QICC can be used to enumerate cells and 
quantify the relative amount of the deposited collagen. 
 
Next, the antifibrotic effects of three hydroxamate HDACis, including trichostatin A 
(TSA), M344 and suberoylanilide hydroxamic acid (SAHA), were tested on fetal lung 
fibroblasts (FLF) treated with the pro-fibrotic cytokine transforming growth factor β1 
(TGFβ1) to induce myofibroblast transdifferentiation. The three HDACis can inhibit 
TGFβ1-induced collagen deposition and myofibroblast marker α-smooth muscle actin (α-
SMA) expression non-cytotoxically, while TSA being the most potent.  
 
In the framework of an indication-discovery approach, the effects of SAHA (an FDA-
approved anti-cancer drug) were further characterized on FLF, adult lung fibroblasts 
(ALF) and idiopathic pulmonary fibrosis fibroblasts (IPF). SAHA abrogated the pro-
fibrotic effects of TGFβ1 on all the fibroblast lines without inducing apoptosis. Matrix 
metalloproteinase 1 (MMP1) activity and tissue inhibitor of MMPs 1 (TIMP1) production, 
however, was modulated without a clear fibrolytic effect. SAHA also inhibited serum-
induced fibroblast proliferation. We also found that SAHA reduced TGFβ1-induced 
expression of collagen α1(I) (COL1A1), α-SMA, heat shock protein 47 (HSP47) and 
connective tissue growth factor (CTGF) at the mRNA level. The mRNA level of MMP1-
 vii
2 and TIMP1-4 were regulated by TGFβ1 and SAHA differentially. 
 
The antifibrotic effects of SAHA were also studied on primary normal skin fibroblasts 
(NSFs), hypertrophic scar fibroblasts (HSFs) and keloid fibroblasts (KFs). SAHA 
inhibited the inducing effects of TGFβ1 on skin fibroblasts. However, higher dose of 
SAHA was required in HSFs and KFs than NSFs in inhibiting TGFβ1-induced collagen 
deposition.  
 
Taken together, these data demonstrated the antifibrotic properties of HDACis, 
suggesting their potential in treating fibroproliferative diseases and preventing peri-
implantational fibrosis. 
 viii
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1. INTRODUCTION 
Part I Literature Review 
1.1 Fibroproliferative diseases 
Fibroproliferative diseases involve many organs of the body, including lung, liver, 
cardiovascular systems, eye, kidney, skin. These diseases share some common 
pathological features of hyperproliferation of fibroblasts/myofibroblasts, excessive 
production and deposition of extracellular matrix and chronic inflammation. The 
hallmark of fibroproliferative diseases is the excessive deposition of collagen. Among 
this group of diseases, we focus here on idiopathic pulmonary fibrosis and keloid. 
 
1.1.1 Idiopathic pulmonary fibrosis 
The interstitial lung diseases constitute a diverse set of lung disorders with different 
levels of inflammation and fibrosis resulting in an irreversible loss of lung function and 
ultimately respiratory failure. The most common representative of interstitial lung 
diseases is idiopathic pulmonary fibrosis (IPF). IPF is defined as “a specific form of 
chronic fibrosing interstitial pneumonia of unknown etiology, limited to the lung and 
associated with the histological entity of usual interstitial pneumonia (UIP)” (ATS 2002).  
 
The incidence and mortality rate of IPF have significantly increased in the past 15 years. 
The incidence rate of IPF has been reported to increase dramatically in the US and UK. 
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Raghu G et al (2006) found that the annual incidence and prevalence of IPF were 
estimated to be 6.8 per 100,000 and 14 per 100,000 respectively based on biopsy 
procedure or high-resolution computed tomography in the US from 1996 to 2000. 
However, with more liberal diagnostic criteria, these figures rose strikingly to 16.3 per 
100,000 and 42.7 per 100,000 respectively. In the UK, the overall incidence rate per 
100,000 person-years was 4.6 IPF between 1991 and 2003 with an annual increase of 
11%. Crude incidence from 2000 to 2003 was 6.78 per 100, 000 (Gribbin J et al 2006). 
Apart from a progressively increased incidence rate, the mortality rate of pulmonary 
fibrosis also rose 29.4% (from 49.7 deaths per 1,000,000 in 1992 to 64.3 deaths per 
1,000,000 in 2003) in men and 38.1% (from 42.3 deaths per 1,000,000 in 1992 to 58.4 
deaths per 1,000,000 in 2003) in women in the US. The total number of decedents were 
175, 088 from 1992 to 2003 in the US (Olson AL et al 2007). The increased mortality 
rate is partially caused by the fact that IPF affects mostly people 50 to 75 years of age and 
patients only have a median lifespan of 2 to 3 years after diagnosis (ATS 2002). 
 
The pathological feature of IPF is still under dispute. Originally, UIP was described as 
the unique pathological feature of IPF, which is characterized by the presence of fibrosis 
and patchy chronic inflammation, fibroblastic foci and microscopic honeycombing in the 
interstitial space of the lung (Liebow AA & Carrington CB 1969). However, this has 
been questioned recently as nonspecific interstitial pneumonia (NSIP) was also reported 
in IPF biopsies (Flaherty KR et al 2002; Monaghan H et al 2004). It is generally believed 
that NSIP shows homogeneous interstitial fibrosis and inflammation, which is distinct 
from the heterogeneous pattern of UIP. Nonetheless, the prognosis of IPF seems to be 
 3
determined by UIP, as IPF patients with UIP-NSIP have similar clinical outcomes as UIP 
alone (Monaghan H et al 2004). Currently, it is not clear whether NSIP and UIP belong to 
different entities or a spectrum of the same entity. 
 
Therefore, the pathogenesis of IPF has not been fully elucidated yet. This is due to the 
limited amount of biopsies from IPF patients and the limitation of current animal models 
of pulmonary fibrosis. Currently, there are two different theories. In the 1970s and 1980s, 
the inflammation theory was first proposed. It adopts the common principle that 
inflammation typically precedes fibrosis in fibroproliferative diseases, and claims that 
unremitting inflammation of lung from some unknown injury initiates the repair process 
and leads to the final uncontrolled fibrosis in the interstitial space. The inflammatory 
theory was established on the observation that the accumulation of macrophages and 
neutrophils in the pulmonary alveoli and interstitium of IPF patients (Crystal RG et al 
1976, reviewed by Rogliani P et al 2008). In addition, more neutrophils and eosinophils 
were detected in the broncho-alveolar lavage fluid from IPF patients than from healthy 
controls (Merrill WW & Reynolds HY 1983). Furthermore, proinflammatory cytokines 
interleukin (IL)-1 and IL-6, chemokines IL-8, monocytes chemotactic protein 1 (MCP-1), 
macrophage inflammatory protein 1α (MIP-1α), Th1 cytokines interferon γ (INFγ), TNFα, 
IL-12 and IL-18, and Th2 cytokines IL-4, IL-5, IL-10 and IL-13 are involved in the 
pathogenesis of pulmonary fibrosis, yet there are conflicting results on the roles of these 
cytokines (reviewed by Gharaee-Kermani M & Phan SH 2005). Based on this theory, 
anti-inflammatory drugs like corticosteroids plus immunosuppressive reagents were first 
thought to be able to stop the fibrotic process (reviewed by Kim R & Meyer KC 2008). 
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However, many studies have pointed out that the anti-inflammatory regimen appears not 
to improve either the typical clinical and high-resolution computed tomography features 
of idiopathic UIP (Douglas WW et al 1998) or the survival of IPF patients (Turner-
Warwick M et al 1980; Douglas WW et al 2000). This raised doubts on the initial role of 
inflammation in the progression of IPF (Gauldie J 2002; Strieter RM 2002), and led to the 
development of the alternative theory which emphasize the initial role of aberrant 
epithelial-mesenchymal interactions in IPF. In contrast to the inflammatory theory, it 
argues that fibrosis arises as a consequence of chronic epithelial injury and failure of 
repair due to aberrant epithelial–mesenchymal interactions in the absence of preceding 
chronic inflammation (Nobel PW & Homer RJ 2004). 
 
While the initial factors in the pathogenesis of IPF are still controversial, there is no 
doubt on the downstream outcome, i.e. the excessive deposition of a collagen matrix. 
Therefore, it is a significant therapeutic goal to control collagen matrix deposition and 
turnover by correcting the activated state of IPF fibroblasts/myofibroblasts (Maher TM et 
al 2007). Some antifibrotic drugs, such as pirfenidone and IFNγ (Rogliani P et al 2008), 
are under clinical trials, their full efficacy is unclear yet. Therefore, there is still an urgent 
need for the development of effective antifibrotic drugs. Moreover, it would be promising 
to discover new antifibrotic indication of drugs already used in clinical practice for other 
diseases since they are already FDA-approved and thus safe and well-tolerated by the 





1.1.2 Keloid  
 
1.1.2.1 Histology of keloid 
Keloids occur in the process of pathological cutaneous wound healing with excessive scar 
formation (Fig. 1a). They seldom regress, and tend to extend beyond the boundary of 
original wound with time. The scar does not improve with time. Besides its unattractive 
visual effect, it may cause tingling, burning, and itching. Blacks, Hispanics and Asians 
are more prone to develop keloids compared with whites. The incidence of keloid varies 
from 4.5% to 16% in Black and Hispanic populations (Akoz T et al 2006). The general 
causes of keloids include acne, folliculitis, chicken pox, vaccinations, and various kinds 
of trauma, such as burns, ear piercing, lacerations and surgical wounds (Robles DT & 
Berg D 2007; Juckett G & Hartman-Adams H 2009). Keloids occur on the chest, 
shoulders, upper back, back of the neck, earlobes and cheeks most commonly after injury 
or inflammation of the skin in predisposed individuals (Bayat A et al 2004; Juckett G & 
Hartman-Adams H 2009). Surgical excision combined with auxiliary therapies, such as 
steroid injections, silicone sheeting, and compression, are the current treatments for 
existing lesions (Slemp AE & Kirschner RE 2006). However, established keloids are 
difficult to treat, and they show a high recurrence rate regardless of therapy. Surgical 
excision of keloids alone results in a high recurrence rate from 60% to 80% (Kal HB et al 
2009), which is believed to even stimulate the formation of an even larger keloid (Brody 
GS 1990; Norris JE 1991). 
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The histology of keloid is characterized by nodules of large and thick and hyalinized 
collagen fibers (Lee JY et al 2004) (Fig. 1b). The nodules contain dense mass of 
fibroblasts and are surrounded by a mucinous extracellular matrix with eosinophils, mast 
cells and lymphocytes and numerous microvessels (Blackburn WR & Cosman B 1966). 
Contrary to keloids, hypertrophic scars undergo regression after some time and stay 
confined to the original wound. Hypertrophic scars exhibit nodular structures composed 
of more fibroblastic cells, small vessels, and fine and randomly organized collagen fibers 
(Ehrlich HP et al 1994). Less α-smooth muscle actin (α-SMA)-positive fibroblasts are 
observed in keloids than hypertrophic scars (Lee JY et al 2004). 
 
Fig. 1 Appearance and histology of keloid. (a) Keloid on the earlobe (Reused with 
permission from Wolters Kluwer Health Ltd: Slemp AE, Kirschner RE. Keloids and scars: 
a review of keloids and scars, their pathogenesis, risk factors, and management. Curr 
Opin Pediatr 2006; 18(4): 397. Copyright @ 2006 Lippincott Williams&Wilkins) (b) 
Hyalinized collagen fibers with keloid fibroblasts in between stained with hematoxylin 
and eosin (original magnification × 100) (Reused with permission from Lippincott 
Williams&Wilkins: Lee JY, Yang CC, Chao SC, Wong TW. Histopathological 
differential diagnosis of keloid and hypertrophic scar. Am J Dermatopathol 2004; 26(5): 
383. Copyright @ 2004 Lippincott Williams&Wilkins) 
 
1.1.2.2 Pathogenesis of keloid 
Although the exact pathogenesis of keloid is still not clearly demonstrated today due to 
the complexity of disease, proposed molecular basis of keloid includes an altered growth 
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factor milieu, hypoxia, abnormal epithelial-mesenchymal interactions, altered immune 
function and genetic predisposition (Slemp AE & Kirschner RE 2006). 
 
As in other fibroproliferative diseases, the pro-fibrotic cytokine TGFβ is also the central 
cytokine in the pathogenesis of keloid and hypertrophic scar (Tuan TL & Nichter LS 
1998). The expression of TGFβ1 and TGFβ2 is elevated both at the mRNA (Bock O et al 
2005) and protein level (Lee TY et al 1999) in keloids. Keloid fibroblasts are more 
responsive to TGFβ1 than normal skin fibroblasts as indicated by a 12 times greater 
production of collagen (Younai S et al 1994). DNA synthesis is also accelerated in keloid 
fibroblasts (Bettinger DA et al 1996). TGFβ receptors I and II are increased in keloid 
fibroblasts (Chin GS et al 2001; Tsujita-Kyutoku M et al 2005). Other growth factors 
such as platelet-derived growth factors (PDGF), connective tissue growth factor (CTGF), 
insulin-like growth factor (IGF)-1 are also involved in the progression of keloid (Urioste 
SS et al 1999). 
 
Apart from TGFβ1, hypoxia may also play a role in the pathogenesis of keloid. 
Histological evaluation shows partial to full occlusion of microvessels in keloid due to 
excessive proliferation of endothelial cells. This occlusion causes a hypoxic 
microenvironment in keloid, and may stimulate excessive production of collagen 
(Kischer CW 1992). Elevated level of hypoxia inducible factor 1α (HIF1α) is present in 
keloid tissues and keloid fibroblast (Zhang Q et al 2003). HIF1α and its induced VEGF 
might promote the excessive accumulation of extracellular matrix from keloid fibroblasts 
partially through upregulation of plasminogen activator inhibitor 1 (PAI-1), a potential 
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inhibitor of extracellular matrix breakdown (Zhang Q et al 2004; Wu Y et al 2004). 
Moreover, keloid fibroblasts are shown to be more angiogenic compared with normal 
skin fibroblasts, which may promote the proliferation of the endothelial cells and worsen 
the occlusion of the microvessels and hypoxia. Concentrations of VEGF and TGFβ1 are 
significantly increased in culture medium of keloid fibroblasts compared with normal 
fibroblasts. Endothelial cells exhibit stronger chemotaxis to conditioned medium from 
keloid fibroblasts. Keloid fibroblasts form more angiogenic and larger nodules than 
normal fibroblasts in severe combined immunodeficiency (SCID) mice (Masao F et al 
2005). In addition, abundant production of VEGF was also detected in the epidermis of 
keloids by in situ hybridization (Gira AK et al 2004). 
 
Abnormal epithelial-mesenchymal interaction is also proposed to involve in the 
pathogenesis of keloid. This concept was proved in two-chamber co-cultures of 
keratinocytes and fibroblasts in vitro. In this system, keloid-derived keratinocytes (KKs) 
affect the behavior of normal skin fibroblasts (NSFs) by inducing a faster proliferation 
(Lim IJ et al 2001) and secretion of collagen in a keloid-like manner by NSFs (Lim IJ et 
al 2002) compared with normal human keratinocytes (NKs). Keloid-derived fibroblasts 
(KFs) also induce more secretion of CTGF from KKs into the conditioned media than 
NKs (Khoo YT et al 2006). The proliferative response of KKs to IGF is stronger when 
co-cultured with KFs than with NSFs. The possible reason may lie in the level of soluble 
IGF-binding protein 3 (IGFBP3) from KFs is lower in the paracrine microenvironment 
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compared with NSFs, which might increase the bioavailability of IGF to its receptor and 
augment the downstream signaling pathway of IGF-1 in KKs (Phan TT et al 2003). 
 
1.2 Tissue responses to implants  
Implantation procedures and the presence of implants initiate a tissue response including 
inflammatory and wound healing responses, foreign body reactions and ultimately a 
collagenous encapsulation of an implant, be it a biomaterial, a medical device, a 
biosensor, a prosthesis, or a tissue-engineered construct. 
 
1.2.1 Biological processes of tissue responses to implants 
1.2.1.1 Formation of provisional matrix 
Implantation causes injury to the host tissue. The extrinsic and intrinsic coagulation 
system, the complement system, the fibrinolytic system, the contact system and platelets 
are activated due to the damage of vascular structures. Fibrin is converted from 
fibrinogen by thrombin and builds the network of thrombus or blood clot which is formed 
on the surface of the implant. Blood proteins deposited on the implant surface represent a 
provisional matrix. This matrix mainly includes fibrin and adhesive molecules such as 
thrombospondin and fibronectin as well as chemical mediators such as mitogens, 
chemoattractants, cytokines, and growth factors released by activated platelets, 
inflammatory cells and endothelial cells. The provisional matrix is considered to be a 
structural network for cell adhesion and migration as well as sustained factors release 
systems to recruit the relevant inflammatory cells (Anderson JM 2001). 
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1.2.1.2 Inflammation reaction  
Inflammation, initiated by exudation of serum and its compound and blood cells from the 
vascular system, follows the formation of a provisional matrix. Neutrophils infiltrate the 
wound in the early and acute stage of inflammation, lasting from minutes to days. 
Migration of neutrophils is partially controlled by chemotaxis. It is speculated that 
neutrophils mainly release leukocyte products at the surface of implants, instead of 
phagocytosis which is the general function of neutrophils in dealing with microorganisms 
and foreign materials. The reason lies in the size disparity between the biomaterial 
surface and the attached cell (Henson PM 1971). The presence of the implant creates a 
constant inflammatory stimulus and leads to chronic inflammation characterized by the 
existence of large numbers of macrophages, lymphocytes and plasma cells. It is well-
known that macrophages release a great number of biological active products. Growth 
factors such as PDGF, fibroblast growth factor (FGF), and TGFβ are important for the 
migration and growth of fibroblasts and endothelial cell in the implant site (Wahl SM et 
al 1989). Lysosomal proteinases and reactive oxygen-derived free radicals are potent 
mediators in the degradation of biomaterials. Furthermore, macrophages are proposed to 
serve as antigen presenting cells in the immune responses against biomaterials (Anderson 
JM 2001). Last but not least, shape and chemical and physical properties of the implants 
may be also responsible for variations in the intensity and time duration of the 




1.2.1.3 Formation of granulation tissue and foreign body reaction 
Fibroblasts and endothelial cells are attracted by the growth factors released from 
macrophages and grow into the provisional matrix to form granulation tissue. Endothelial 
cells proliferate actively to form the new and small vessels. Fibroblasts are active in 
synthesizing and remodeling extracellular matrix, especially collagen and proteoglycans. 
In the wound healing process of implants, the granulation tissue is usually remodeled to 
an avascular and collagenous fibrous capsule that is typically 50–200 μm thick (Ratner 
BD & Bryant SJ 2004). 
 
The end stage of tissue responses to implants is the foreign body reaction. One important 
feature of this stage is the formation of the multinucleated foreign body giant cells 
generated by the fusion of macrophages. Macrophages and multinucleated giant cells as 
well as the fibrous capsule are the major components involved in the foreign body 
reaction. The collagenous capsule walls off the implant and separates it from the local 
tissue environment (Fig. 2). 
 
The presence of multinucleated foreign body giant cells on the surface of the implants 
may reflect the frustrated phagocytosis process of the foreign body, and may persist at the 
tissue-implant interface during the lifetime of the implant. IL-4 is shown to induce the 
formation of foreign body giant cells from macrophages in vitro (McNally AK & 
Anderson JM 1995). Moreover, the unique non-specific protein absorption to the surface 
of implants may participate in prompting the development of multinucleated foreign body 
giant cells because this phenomenon never occurs in the normal wound healing process. 
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Additionally, the surface chemistry of the substrate onto which the cells adhere may be 




Fig. 2 Illustration of the different stages of foreign body reaction (Reused with 
permission from Elsevier Ltd: Ratner BD. Reducing capsular thickness and enhancing 
angiogenesis around implant drug release systems. J Control Release 2002; 78: 213. 
Copyright @ 2002 Elsevier Science B.V.) 
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1.2.2 Current attempts to inhibit foreign body reaction 
Undoubtedly, the uncontrolled fibrous capsulation compromises the performance of 
many implanted devices, such as drug delivery systems, implant electrodes and breast 
implants (Ratner BD 2002). For engineered tissues, excessive fibrosis can reduce the 
viability of cells inside and greatly prevent the process of the real in vivo implantation 
(Polak JM & Bishop AE 2006). 
 
Nowadays bioengineers are solving this problem focusing on both biomaterials and the 
host to reduce the formation of collagenous capsule and to improve vascularization. Non-
fouling surfaces of implants are developed to reduce or eliminate the non-specific 
absorption of proteins and other biomaterial (Table 1). The potential weakness of these 
surfaces is that they do not generate signals to the host tissue and might not promote 
normal wound healing process. In addition, different porous materials with pore size of 5-
15 µm has been shown to turn the direction more to normal healing than to foreign body 
reaction (Sharkawy AA et al 1997; reviewed by Ratner BD 2002). The size of fibers also 
has an impact on the wound healing type. Implantation of fibers with >5 µm in diameter 
usually results in foreign body reaction, <5 µm little or invisible fibrous capsule, and <1 







Table 1 Non-fouling (protein resistant) surfaces (Ratner BD 2002) 
 
 
(Reused with permission from Elsevier Ltd: Ratner BD. Reducing capsular thickness and 
enhancing angiogenesis around implant drug release systems. J Control Release 2002; 78: 
215. Copyright @ 2002 Elsevier Science B.V.) 
 
Antifibrotic drug, which can inhibit collagen production, has been shown to be effective 
in preventing the formation of peri-implantational capsules. Halofuginone, a specific 
inhibitor of collagen α1 (I) gene expression (Choi ET et al 1995), was tested to determine 
its effect on the formation of fibrous capsule around subcutaneously implanted silastic 
disks into the rats. Histological study shows that halofuginone can significantly reduce 
the collagen index values, indicating inhibition of collagen deposition within the capsule 
around the implanted disks (Olbrich KC et al 2005).  
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Several matricellular proteins from the host have been shown to play important roles in 
foreign body reaction. Thrombospondin (TSP) 2 is a member of TSP family, and well 
known for their anti-angiogenic properties and their ability to modulate cell-matrix 
interactions (Bornstein P et al 2004). TSP2 knock-out mice shows an altered foreign body 
reaction to implanted biomaterials with increased vascularity and unoriented distribution 
of collagen fiber in the fibrous capsules around implants (Kyriakides TR et al 1999). 
Enhanced blood vessel formation and altered collagen fibrillogenesis in the polyvinyl 
alcohol (PVA) sponge granuloma and capsule are also seen through delivery of TSP2 
antisense-expressing plasmids by using gene-activated matrix (GAM) into wild type mice 
(Kyriakides TR et al 2001). Therefore, TSP2 seems to participate in enhancing foreign 
body reaction and is a potential target in preventing this reaction. Another matricellular 
protein osteopontin (OPN) is a potential macrophage chemoattractant with multiple 
phosphorylation sites, cell adhesion sequence RGD, thrombin cleavage site, heparin and 
calcium binding cites. OPN is shown to reduce the fusion of macrophages into giant cells 
in vitro and in vivo. The knock-out mice develop more foreign body giant cells but fewer 
macrophages surrounding the PVA sponge implants than their wild type counterparts 
(Tsai AT et al 2005). Hence, OPN may prevent the formation of foreign body reaction 
giant cells and reduce the foreign body reaction at the early stage.  
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1.2.3 Special chapter on aseptic loosening of total joint replacements 
Total joint replacements are a largest class of prostheses and have been widely used in 
clinical practice since 1970s (Montin L et al 2008), especially for total hip and total knee. 
The prostheses can relieve the pain in the joint, restore joint function and improve life 
quality of patients. However, one major complication after the surgery is the aseptic 
loosening of the prostheses causing revision and failure of prostheses (Glazebrook MA et 
al 2009). Intraoperative examination revealed that the loosed implants are surrounded by 
a fibrous tissue membrane of varied thickness (2-15 mm) (Horikoshi M et al 1994; Kim 
KJ et al 1991). A radiolucent line (2 mm wide), stem migration and osteolysis were 
observed on radiographs in all patients with failed hip or knee prostheses (Horikoshi M et 
al 1994; Kim KJ et al 1993). The intervening fibrous membrane (peri-prosthetic fibrosis) 
prevents the fully contact between bone and cement (cemented implant) or bone and 
prosthesis (cementless implant, which initiates or further deteriorates the prosthetic 
loosening.  
 
Histology study showed that the interfacial membrane around either cemented or 
cementless implant possesses the same pathological feature although small difference 
exists between types of the membranes (Horikoshi M et al 1994; Kim KJ et al 1993; 
Korovessis P & Repanti M 1993). The membrane is basically characterized by a fibrous 
tissue stroma with macrophages, foreign-body giant cells and wear debris within and 
surrounded by the cells (Kim KJ et al 1993). The wear debris includes cement (only in 
cemented membrane), polyethylene, and/or metal. There are more foreign-body giant 
cells in cemented membranes than cementless membranes, while metal debris is more 
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frequently seen in cementless membranes than in cemented membranes (Kim KJ et al 
1993).  
 
Wear debris plays a critical role in the development of the interfacial membrane and 
prosthetic loosening. Wear debris is defined as the removal of particulate material from 
the prosthesis and/or cement (McKellop HA et al 1995). Implant-derived wear debris 
induces foreign body reaction as reflected by the presence of interfacial fibrous 
membrane (Goodman SB et al 2009). The bioreactivity of particles has been shown to be 
related to the size and composition of particulate wear (Reviewed by Archibeck MJ et al 
2001). Phagocytosable (< 7 μM) polymethylmethacrylate particles stimulate release of 
more TNFα from macrophages than does larger particles (Horowitz SM et al 1993). 
However, polyethylene particles (mean = 67 μM) induce more fibrous tissue formation 
than do smaller particles (Goodman SB et al 1990). Titanium-aluminum-vanadium 
particles stimulate the strongest release of IL-6 and PGE2 compared to particles of cobalt-
chromium-molybdenum and stainless steel at a similar size (Haynes DR et al 1998). As a 
response to the wear debris, macrophages and fibroblasts release proinflammatory 
cytokines (TNFα, IL-1, IL-6 and PGE2 etc) as well as collagenases and stromelysins, 
resulting in further formation and activation of osteoclasts and sequently adjacent bone 
resorption (Glant TT et al 1993; Kim KJ et al 1993; Shanbhag AS et al 1995; Yao J et al 
1995). In summary, wear debris elicits peri-prosthetic fibrosis and peri-prosthetic 
osteolysis, and hence leads to the aseptic loosening of implants at the later stage. 
 
Another important factor causing the aseptic loosening is micromotion, which has been 
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shown to increase instability of joint and dental implants.  Micromotion is defined as 
“small movements between a prosthesis (whether cemented or noncemented) and the 
surrounding bone with the application of a given load because of a difference in the 
elasticity of bone and a metallic or plastic implant.” (Goodman SB 1994). Micromotion 
results in the formation of a fibrous tissue at the bone-implant interface instead of 
ossteointegration of implants. Movement (150 μM or more) induces ingrowth of 
connective tissue into porous-surfaced implants in dogs whereas bone ingrowth can still 
occur with very small movement (up to 28 μM) (Pillar RM et al 1986). Similarly, Søballe 
observed that around 150 μM axial micromotion between bone and porous titanium alloy 
implants inhibits bone ingrowth and leads to the development of a fibrous membrane in 
knee (Søballe K et al 1992). Using a rat micromotion chamber model, Goodman and 
Aspenberg demonstrated that micromotion with a larger amplitude (0.75 mm/day) yields 
less bone ingrowth into titanium chambers than a smaller amplitude (0.5 mm/day) 
(Goodman S & Aspenberg P, 1992). In addition, Aspenberg and Herbertsson reported 
that bone-titanium contact can be re-established after the cession of the movement. 
However, the application of phagocytosable high-density polyethylene particles after the 
movement causes the membrane to persist (Aspenberg P & Herbertsson P 1996). This 
suggests that micromotion may be synergistic with wear debris in producing aseptic 
prosthetic loosening as the fibrous membrane may function as a conduit for the migration 
of wear debris (Goodman SB 1994).  
 
Both the clinicians and researchers are putting their efforts to reduce the aseptic 
loosening of the prostheses. Micromotion should be minimized after the surgical 
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procedure to maintain the stability and facilitate the ossteointegration of implants. 
Research has also been carried out to develop or modify prosthetic materials and to 
inhibit the biological response to the debris. Articulations using materials with increased 
wear resistance such as highly cross-linked polyethylenes, bioceramics and metals have 
been used in clinical practice. However, other important concerns such as material 
oxidation of cross-linked polyethylenes, ceramics fracture and release of metal ions have 
been raised up (Goodman SB et al 2009).  In addition, some substances with potential to 
decrease the biological response to particulate debris have been studied in animal models 
and cell cultures. Bisphosphonate alendronate reduces bone resorption induced by wear 
debris through oral administration in a canine total hip replacement model (Shanbhag AS 
et al 1997) or through topical administration in a rat titanium plate model (Astrand J & 
Aspenberg P 2004). In a rat calvaria/macrophage coculture, indomethacin reduces the 
production of PGE2 and inhibits the bone resorption induced by macrophage exposed to 
bone cement particles (Horowitz SM et al 1996). However, only very limited substances 
have been studied so far, and there is an unmet demand to investigate more potential 
substances to prevent and reduce the biological response to wear debris. HDACi with 
antifibrogentic and anti-inflammatory property might have potential application on 
preventing aseptic loosening of implants by inhibiting the formation of the fibrous 
membrane (peri-prosthetic fibrosis) and osteolysis. 
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1.3 Chromatin structure and histone acetylation 
1.3.1 Histone structure  
DNA is packaged into a nucleus through multiple levels of organization (Felsenfeld G & 
Groudine M 2003) (Fig. 3). The basic level of organization is a nucleosome which 
consists of a histone octamer and a 147bp DNA wrapped around it. The details of folding 
are still uncertain beyond the level of nucleosome. 
 
 
Fig. 3 Organization of DNA into chromatin (Reused with permission from Macmillan 
Publishers Ltd: Felsenfeld G, Groudine M. Controlling the double helix. Nature 2003; 




One question raised is how chromatin responds to the biological events involving DNA, 
such as gene transcription, DNA replication and repair and chromosome segregation. It is 
proposed that chromatin structure can be altered through the movement of histone 
octamer along DNA by an ATP-dependent chromatin remodeling complex (Becker PB & 
Hörz W 2002), covalent modifications of histones (Strahl BD & Allis CD 2000) and 
substitution of core histones by histone variants (Ahmad K & Henikoff S 2002; Redon C 
et al 2002). Among them, histone modifications, including acetylation, methylation, 
phosphorylation, ADP-ribosylation, ubiquitination and sumoylation, have been shown to 
play important roles in regulating gene transcription (Strahl BD & Allis CD 2000). 
 
1.3.2 Histone acetylation 
Histone acetylation is the most studied and appreciated among the histone modifications. 
Reversible histone acetylation usually occurs on the ε-NH3+ groups of highly conserved 
lysine residues embedded in the N-terminal tails of core histones. Histone 
acetyltransferases (HATs) and histone deacetylases (HDACs) are the two types of 
enzymes responsible for this reaction. HATs transfer the acetyl moiety from acetyl 
coenzyme A to the e-NH3 groups of internal lysine residues. Introduction of the acetyl 
group to lysine neutralizes the positive charge and increases the hydrophobicity of 
histones. In the opposing deacetylation reaction, HDACs remove the acetyl groups re-





Fig. 4 Biochemical reaction of histone acetylation (Reused with permission from John 
Wiley & Sons, Inc.: Kuo MH, Allis CD. Roles of histone acetyltransferases and 
deacetylases in gene regulation. Bioessays 1998; 20: 616. Copyright @ 1998 John Wiley 
& Sons, Inc.) 
 
 
In many cases, histone acetylation results in transcription activation, although notable 
exceptions exist (Deckert J & Struhl K 2001). Both broadly and locally, histone 
acetylation is considered as a switch between repressive and permissive chromatin. Broad 
acetylation of histone H3/H4 leads to partial decondensation of chromosomal domains, 
and marks regions of transcriptional competency. Two good examples are broad 
acetylation of β-goblin loci and dosage compensated male X chromosome in drosophila 
(Eberharter A & Becker PB 2002). In most cases, localized histone acetylation is 
observed in promoter and enhancer elements. The link between histone acetylation and 
transcription activation is not totally clear. One general view is that chromatin becomes 
less condensed when the negative charge of histone is neutralized by histone acetylation, 
and hence DNA is easier accessed by the transcriptional apparatus. Moreover, patterns of 
acetylation at the specific lysines within the histone N-terminal is shown to determine the 
transcriptional state of certain gene (Vogelauer M et al 2000; Deckert J & Struhl K 2001).  
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1.4 HDACs and their roles in regulating gene expression 
1.4.1 Classification of HDACs 
The first mammalian HDAC was discovered in 1996 (Taunton J et al 1996). To this day, 
18 HDACs have been identified, and are divided into classical and non-classical groups 
(de Ruijter AJ et al 2003). Non-classical HDACs include class III called sirtuins, which 
are NAD+-dependent and most related to the yeast protein Sir2. Classical HDACs include 
class I, II and IV. The class I (HDAC1, 2, 3 and 8) are similar to the yeast transcriptional 
regulatory factor RPD3, and class II HDACs (HDAC4, 5, 6, 7, 9 and 10) to yeast HDA1. 
Class IV only includes HDAC11 (Fig. 5). The classical HDACs share a highly 
homologous zinc-dependent catalytic domain and a less conserved accessory domain 
which seems to fulfill regulatory functions. Class I HDACs are found exclusively in the 
nucleus and are ubiquitously expressed in many types of tissues and cell lines. Class II 
HDACs shuttle between the cytoplasm and the nucleus, and exhibit a tissue-specific 
pattern of expression. Class IV is also found in the nucleus with tissue specificity, but is 








Fig. 5 Schematic representation of human classical HDACs (Reused with permission 
from Elsevier Ltd.: Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the 
histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 
2004; 338, 18. Copyright @ 2004 Elsevier Ltd.) 
 
1.4.2 Roles of classical HDACs in gene transcription 
Both HATs and HDACs are recruited to target genes in complexes with sequence-
specific transcription factors and cofactors with diverse effects. Generally, HATs work as 
transcription co-activators, while HDACs as transcription co-repressors.  
 
Among HDACs, HDAC1 and HDAC2 are the best characterized. They are the chief 
constituents of the multiprotein transcriptional repression complex SIN3–HDAC and the 
nucleosome remodelling deacetylase NuRD–Mi2–NRD complex. Complexes containing 
class I HDACs bind to numerous transcription factors, either directly or indirectly 
through the nuclear-receptor corepressors (NCOR) and silencing mediator for retinoid 
and thyroid hormone receptors (SMRT). Once recruited to chromatin, class I HDACs 
deacetylate histone tails and induce transcriptional repression. Class II HDACs are not 
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part of the SIN3–HDAC and NuRD–Mi2–NRD complexes, but bind to hormone 
corepressors and transcription factors such as the myocyte enhancer factor 2 (MEF2) 
family to mediate transcriptional repression. However, the substrate specificity of diverse 
HDACs has not been clearly defined. 
 
HDACs coordinate with DNA methylation in the repression of gene transcription. DNA 
is methylated predominantly within the CpG dinucleotide by DNA methyltransferases 
DNMT1, DNMT3A and DNMT3B. HDACs can be recruited by both DNA 
methyltransferases and methylated CpG binding proteins, such as methyl-CpG binding 
protein 2 (MECP2), methyl-CpG binding domain protein (MBD) 1, MBD2 and MBD3, 
resulting in histone deacetylation and transcriptional repression (Johnstone RW 2002). 
 
Taken together, HDACs and HATs play important roles in regulating gene expression. 
Deregulation of histone acetylation has been linked to the progression of cancers, and 
diverse human disorders, like the Rubinstein-Tabi and Fragile X syndromes 
(Timmermann et al 2001). The deregulated function of HDACs and HATs causes 
aberrant gene expression. Correction of the abnormal functional state of HDACs would 
provide new therapy opportunities for these diseases.  
 
1.4.3 Non-histone substrates of HDACs 
Although histones are the abundant substrates, HDACs can bind to, deacetylate and 
regulate the activity of a number of other proteins, including transcription factors, such as 
p53, E2F1 and NF-κB, and cytoplasmic protein, such as α-tubulin, Ku70 and Hsp90.  
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Hyperacetylation of transcription factors augments their gene-regulatory activities and 
contributes to the changes in gene expression observed in addition to the direct HDACs-
mediated histone hyperacetylation. Hyperacetylation of cytoplasmic proteins such as 
Ku70 and Hsp90 could be important for some biological processes such as apoptosis, cell 
cycle and cell movement (Bolden JE et al 2006). 
 
1.5 HDAC Inhibitors 
1.5.1 Classification and structure of HDAC inhibitors (HDACis) 
In a dogmatic view, HDACs may participate in critical and basic cellular functions, so 
inhibition of HDACs may not be a suitable strategy for drug development. Fortunately, 
the use of HDAC inhibitors pre-dated the discovery of the HDACs themselves. In fact, 
the inhibitors were instrumental in the purification and cloning of mammalian HDACs. 
Furthermore, the systemic administration of HDACi SAHA seems to be well tolerated by 
patients (Marks PA & Breslow R 2007). 
 
The inhibitors mentioned below are the inhibitors of classical HDACs. A relatively wide 
range of inhibitors, either derived from natural sources (Fig. 6a) or synthetic routes (Fig. 
6b), have been identified (Minucci S & Pelicci PG 2006). With a few exceptions, they 
can be divided into chemical classes including hydroxamic acid derivatives 
(hydroxamate), carboxylates, benzamides, electrophilic ketones and cyclic peptides. So 





Fig. 6 Representative structures of the main classes of known HDAC inhibitors (natural, 
upper; synthetic, lower) (Reused with permission from Macmillan Publishers Ltd: 
Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and 
more) treatments for cancer. Nat Rev Cancer 2006; 6: 44. Copyright @ 2006 Nature 
Publishing Group.) 
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Trichostatin A (TSA) is a classical hydromaxate HDACi (Fig. 7). A hydrophobic head, 
aliphatic chain and active functional group (hydroxamate moiety) are the three essentials 
of a hydroxamate HDACi (Vanhaecke T et al 2004). 
 
 
Fig. 7 Chemical structure of TSA 
 
1.5.2 Inhibitory mechanism of hydroxamate HDACis 
Finnin MS et al (1999) revealed the structure of HDAC catalytic core by crystallizing the 
structure of a homologue from the hyperthermophilic bacterium aquifex aeolicus. This 
homologue HDLP is inhibited by TSA and suberoylanilide hydroxamic acid (SAHA) in 
vitro. The structures of HDAC, HDAC-TSA and HDAC-SAHA revealed that the active 
site consists of tubular pocket, a zinc-binding site and two Asp-His charge-relay systems. 
The residues composed of the active site and contacted the inhibitors are conserved 
across the HDAC family. The hydroxamate moiety coordinates the zinc ion through its 
carbonyl and hydroxyl group at the bottom of the tubular pocket in a pentavalent complex 
and simultaneously interacts with the two Asp-His charge-relay systems (H131-D166 and 
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H132-D173), thereby blocking substrate access. The aliphatic chain forms multiple van 
der Waals contacts with the hydrophobic amino acids of the wall. The hydrophobic 
carbon ring group projects out of the pocket on the surface of HDLP (Fig. 8). The 
saturated aliphatic chain of SAHA forms poorer hydrophobic interactions than TSA, 
partially explaining its lower potency. 
 
 
Fig. 8 Structural interaction between TSA and HDAC1-analog HDLP. Schematic 
representation of HDLP (red)-TSA (black) interactions (Van der Walls contacts, thatched 
semi-circles; hydrogen bonds, green lashed lines) (Reused with permission from 
Macmillan Publishers Ltd: Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, 
Marks PA, Breslow R, Pavletich NP. Structures of a histone deacetylase homologue 
bound to the TSA and SAHA inhibitors. Nature 1999; 401: 190. Copyright @ 1999 
Macmillan Magazines Ltd) 
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1.5.3 Cellular effects of HDACis 
The main effects of HDACis involve in inducing cell cycle arrest in tumor and normal 
cells, apoptosis and terminal differentiation in tumor cells. In addition, HDACis may also 
have anti-inflammation effects. 
 
1.5.3.1 HDACis-induced cell cycle arrest 
HDACis induce G1 and G2 arrest in both normal fibroblast and tumor cells by 
upregulating the transcription of CDKN1A encoding p21waf1/cip1. This product inhibits the 
formation of cyclin E- cyclin-dependent kinase (cdk) 2 and cyclin A-cdk2 complexs, 
which regulates the progression of G1/S and S phase respectively. HDACis are also 
found to induce a G2 checkpoint in normal human fibroblasts and some tumor cell lines, 
although the exact molecular events are still not clear (Johnstone RW 2002). 
 
1.5.3.2 HDACis-mediated apoptosis 
HDACis usually induce apoptosis in tumor cells, but not normal cells. HDACis have 
been reported to activate both the death-receptor and mitochondrial apoptotic pathways. 
In the death-receptor pathway, HDACi apicidin and carboxycinnamic acid bis-
hydroxamide (CBHA), increase the expression of CD95 and CD95 ligand (CD95L), 
while HDACi butyrate stimulates the death-receptor pathway without changing the 
expression level of CD95 or CD95L. The mitochondrial pathway seems plays a more 
important role in HDACis-induced apoptosis. HDACis were reported to upregulate of 
pro-apoptotic Bax and Bak, and downregulate pro-survival BCL-2 and BCLXL. 
Moreover, disruption of mitochondrial membrane results in the production of ROS 
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(reactive oxygen species) which is also important for cell death (Johnstone RW 2002). In 
normal cells, a natural ROS scavenger called thioredoxin (TXN) is accumulated after the 
treatment of HDACis. TXN neutralizes ROS and protects normal cells to survive from 
apoptosis. On the contrary, tumor cells or transformed cells lack TXN, and are hence 
prone to undergo apoptosis. This could partially explain the different sensitivity between 
normal cells and tumor cells to HDACis-induced apoptosis (Minucci S & Pelicci PG 
2006). 
 
1.5.3.3 Anti-inflammatory property of HDACis 
TSA and butyrate are shown to reduce IL-8 and induce differentiation in colonic epithelia 
cells. This observation suggests that HDACis can be used for the effective treatment of 
ulcerative colitis through reducing the production of pro-inflammatory cytokines. Recent 
research shows that HDACis reduce the production of pro-inflammatory cytokines and 
NO in vitro and in vivo. The anti-inflammatory effect of HDACis seems to depend on the 
inhibition of cytokines and NO production, key transcription factors (NF-κB and STAT), 
and proliferation or induction of differentiation. NF-κB is crucial for the expression of 
numerous pro-inflammatory mediators, such as NO synthase (iNOS), IL-6, IL-8, IL-10 
and IL-12. Several studies have demonstrated the inhibition of NF-κB transcriptional 
activity after treatment with HDACis. The mechanisms leading to NF-κB inhibition by 
HDACis seem to vary in different cell lineages. Apart from the reduced activity of NF-
κB dependent promoters, HDACis also prevent the nuclear translocation and DNA 
binding of NF-κB, and stabilize inhibitor IκB. In addition, STAT factors are activated by 
numerous cytokines receptors, such as IFN, IL-2 and IL-6 receptors. For example, 
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STAT1 and STAT2 have been shown to associate with HDAC1, and lead to enhanced 
gene expression after IFN-α treatment. By this way, HDACis can inhibit the expression 
of IFN-α-induced genes. However, TSA and SAHA have also been reported to enhance 
microglial inflammation by increasing the expression of IL-6, TNFα and NO after LPS 
stimulation. Therefore, the effects of HDACis on inflammation perhaps might rely on cell 
type, expression of different set of HDAC isoforms as well as the stimuli (Blanchard F & 
Chipoy C 2005). 
 33
Part II Purpose & Significance 
The current strategies to treat fibroproliferative diseases and prevent peri-implantational 
fibrosis are far from satisfactory. On one hand, current therapies of keloid and idiopathic 
pulmonary fibrosis are not successful. Recurrence is the major problem after surgical 
removal of keloids, even if combined with adjunctive therapies, such as steroid injections, 
silicone sheeting, and compression (Slemp AE & Kirschner RE 2006). While patients 
with keloids are mainly burdened with cosmetical imperfection, patients with idiopathic 
pulmonary fibrosis die from respiratory failure. Moreover, current anti-inflammatory 
regimes have no improvement on the present situation. Thus it is generally accepted that 
anti-inflammation drugs alone cannot stop or reverse ongoing lung interstitial fibrosis. 
Antifibrosis should be the prime consideration for treating idiopathic pulmonary fibrosis. 
Although some antifibrotic drugs, such as pirfenidone and IFNγ (Rogliani P et al 2008), 
are under clinical trials for idiopathic pulmonary fibrosis, their beneficial effect is not 
seen yet. On the other hand, although the overall mechanism of peri-implantational 
fibrosis has been elucidated, there is rather limited research on how to prevent the 
formation of peri-implantational fibrosis (see literature review). Obviously, there is a 
necessity to develop effective preventive methods as this kind of fibrosis plays a key role 
in impairing the normal function of implants.  
 
There is an urgent need to explore effective anti-fibrotic drugs in order to treat 
fibroproliferative diseases and prevent peri-implantational fibrosis. It is important to 
develop the compounds to tackle the common pathological outcomes of fibrosis, such as 
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collagen production and deposition and the transdifferentation of fibroblasts into 
myofibroblasts. For this purpose, we were interested in exploring the therapeutic 
potential of HDACis. Originally, they were of prime interest in cancer research because 
they induce apoptosis and cell cycle arrest in malignant cells and have anti-angiogenic 
properties (Bolden JE 2006). Recent work also suggests that HDACis might also inhibit 
collagen production in different fibroblast types. Phenylbutyrate decreases basal and 
TGFβ1-stimulated collagen α1(I) mRNA and protein levels in the fetal lung fibroblast 
IMR-90 (Rishikof DC 2004). TSA was reported to inhibit synthesis of collagen type I 
and III and α-SMA both at the protein and mRNA level in primary cultured rat hepatic 
stellate cells (Niki T et al 1999) and in TGFβ1-stimulated rat skin fibroblasts (Rombouts 
K et al 2002). In addition, collagen production from systemic sclerosis fibroblasts is 
inhibited and total collagen deposition is reduced in bleomycin-induced skin fibrosis in 
mice by TSA (Huber LC et al 2007). 
 
In this study we investigated the antifibrotic profiles of three HDACis (TSA, M344 and 
SAHA). The antifibrotic effect of SAHA was fully characterized on normal fibroblasts of 
lung and skin, and pathological fibroblasts of idiopathic pulmonary fibrosis, hypertrophic 
scar and keloid as SAHA is a FDA-approved drug which is safe and well-tolerated by 
patients. 
 
The result of this study should lay the foundation for the antifibrotic property of HDACis, 
especially for SAHA, which has not been explored before. It should be noted that this 
study would shed light on a new antifibrotic indication for SAHA which is now used as a 
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third-line drug for cutaneous T cell lymphoma. In addition, this work may provide a new 




2. MATERIALS & METHODS 
2.1 Compounds and reagents 
TSA was purchased from Sigma. M344 and SAHA were provided by Prof Manfred Jung 
(University of Freiburg, Freiburg, Germany). SAHA was synthesized as described 
(Stowell JC et al 1995). TSA was dissolved in absolute ethanol to 2 mg/ml. M344 and 
SAHA was dissolved in DMSO to 50 mM and stored at -80 °C respectively. All reagents 
were purchased from Sigma-Aldrich (St. Louis, MI, USA) unless stated otherwise. 
 
2.2 Treatment of lung fibroblast lines 
Normal human fetal lung fibroblasts IMR-90 (CCL-186, ATCC, Manassas, VA, USA), 
adult lung fibroblasts CCD-19 Lu (CCL-210, ATCC) and IPF fibroblasts LL29 (CCL-
134, ATCC) were cultured in 10% FBS DMEM (GIBCO-Invitrogen, Singapore). Cells, 
except for proliferation assays, were seeded at 1 × 104/well in 96-well, 5 × 104/well in 24-
well or 2.5× 105/well in 6-well plates. After 24 h, fibroblasts were treated with different 
concentrations of SAHA with or without TGFβ1 (5 ng/ml, R&D Systems, Minneapolis, 
MN) in serum-free DMEM plus 30 µg/ml ascorbic acid phosphate (Wako, Osaka, Japan) 
in the presence of 100 µg/ml dextran sulfate 500 kDa (pK Chemicals A/S, Koge, 
Denmark) for the enhanced deposition of collagen I within 24 h (Lareu RR1, 2 et al 2007). 
After the deposition, collagen matrix was created by 3 cycles of cell lysis. For each cycle, 
the cell layer was solubilized with 0.5% sodium deoxycholate for 10 mins on ice, 
followed by washing twice with distilled water. 
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2.3 Treatment of normal skin, hypertrophic skin and keloid fibroblasts 
Normal skin fibroblasts (NSFs), hypertrophic skin fibroblasts (HSFs) and keloid 
fibroblasts (KFs) were kindly provided by Associate Professor Toan Thang Phan 
(Department of Surgery, National University of Singapore, Singapore). NSF13, 14 and 
152, HSF 16 and 114, and KF 12 and 108 were tested. The seeding density and treatment 
were the same as lung fibroblast lines (section 2.2) 
 
2.4 Quantitative immunocytochemistry (QICC) 
Fibroblasts cultured in 96-well Lumox plates with an optical bottom (Greiner BioOne) 
were fixed with absolute methanol and air dried for 15 mins, respectively. Cell layer was 
blocked with 3% bovine serum albumin in phosphate buffered saline (PBS) for 30 mins 
followed by incubated with primary antibodies for 90 mins. Secondary antibodies and 
nuclear stain 4, 6-diamidino-2-phenylindole (DAPI, Invitrogen Molecular Probes, 
Carlsbad, CA, USA) were stained for 30 mins. Cell layer was washed with PBS for 3 
times after each step. Antibodies against collagen type I (1:500), α-SMA (1:100, Dako, 
Glostrup, Denmark), or acetylated α-tubulin (1:500) were from mouse and acetylated 
histone 3 (1:200, Upstate, New York, NY, USA) from rabbit. Secondary antibodies were 
Alexa Fluor (AF) 594 goat anti-mouse and AF 488 goat anti-rabbit (both 1:400, 
Invitrogen Molecular Probes). The fluorescence intensity was quantified using the 
PHERAstar microplate reader with a focusing lens system (BMG LABTECH, VIC, 
Australia). The ratio of the fluorescence intensity of the AF dye to DAPI was used to 
normalize relative amount of the antigen to cell number. Images were taken with an 
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Olympus LX71 epifluorescence microscope (Olympus, Tokyo, Japan). 
 
For cell enumeration, different numbers of fetal lung fibroblasts IMR-90, ranging from 
625 to 40,000, were seeded into 96-well Lumox plate. After 16 h, the cells were fixed 
with absolute methanol and air dried for 15 mins respectively. The cell layer was stained 
with DAPI (0.5 μg/ml) for 5 mins, and washed 3 times with PBS. The fluorescence 
intensity of DAPI was measured by PHERAstar. The calibration curve between 
fluorescence intensity and cell number was calculated based on linear regression by Excel. 
 
2.5 Biochemical assay of deposited collagen 
Deposited collagen was extracted from cell cultures and analyzed as described (Lareu 
RR1’ 2 et al 2007). Briefly, cell layers in 24-well plates were digested in situ with 250 
µg/ml porcine gastric mucosa pepsin (Roche, Basel, Switzerland) in 0.1 M HCl for 2 h 
and neutralized with 1 M NaOH. Extracts were visualized using SDS-PAGE gels with 
silver staining kit (Invitrogen) scanned by GS-800 gel scanner (Bio-Rad, Hercules, CA, 
USA). Densitometry analysis was performed with Quantity One software (Bio-Rad). 
 
2.6 Western blot 
Western blots were performed according to the reference (Lareu2 et al 2007). Briefly, 
proteins were extracted with loading buffer (50 mM Tris-Cl pH 6.8, 2% SDS, 0.1% 
bromophenol blue and 10% glycerol) with 5 mM DTT and separated on 10% SDS-PAGE 
gels. Primary antibodies against acetylated α-tubulin (1:2500), α-SMA (1:500) and β-
actin (1:1000) were from mouse, and acetylated histone 3 (1:3000, Upstate) from rabbit. 
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Secondary antibodies were goat anti-mouse and goat anti-rabbit HRP (both 1:1000, 
Pierce, Rockford, IL, USA). Blots were developed with AmershamTM ECL plus Western 
blotting detection system (GE Healthcare, Buckinghamshire, UK) and 
chemiluminescence was captured with a VersaDoc Imaging System model 5000 (Bio-
Rad). 
 
2.7 Flow cytometry analysis of α-SMA expression 
Fibroblasts in suspension were fixed with 2% paraformaldehyde in PBS and 
permeabilized with 0.1% saponin in PBS for 15 mins, respectively. The suspension was 
incubated with mouse anti-α-SMA (1:1000) and AF 488 chicken anti-mouse (1:100, 
Invitrogen), each for 30 mins at 4 °C. The cells were washed with PBS twice after each 
step. AF 488 was detected by flow cytometry. 
 
2.8 Adherent cytometry  
For proliferation assay cells were seeded at 2×104/well in 24-well plate and cultured in 
10% FBS in the presence or absence of 5 μM SAHA. After 3 days, fibroblasts were 
stained with DAPI after methanol fixation. Nine image sites covering 71% of the total 
well area were acquired at 2X magnification using A Nikon TE600 fluorescence 
microscope with an automated Ludl stage (BioPrecision 2, Ludl Electronic Products Ltd) 
and analyzed using the Metamorph ® Imaging System software (Molecular Devices, 
Downingtown, PA, USA). A nucleus was defined as a fluorescent region with a length of 
10-15 μM and a pixel intensity value of 10 units above background. 
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2.9 Carboxyfluorescein succinimidyl ester (CFSE) labeling and detection 
Fibroblasts at 106/ml were pre-labeled with 2 μM CFSE (Invitrogen), 1×105 cells/well 
were seeded into 6-well plate, and cultured in 10% FBS with or without 5 μM SAHA. 
After 3 days, fibroblasts were trypsinized and washed twice with PBS, and CFSE was 
detected by flow cytometry. 
 
2.10 MMP1 activity and TIMP1 enzyme-linked immunosorbent assay 
(ELISA)  
Fibroblasts were treated with or without TGFβ1 (5 ng/ml) and SAHA at 5 μM for 24 h. 
MMP1 activity and TIMP1 production were determined using the Fluorokine E kit and 
the Quantikine human TIMP1 kit (both R&D Systems) according to the manufacturer’s 
protocol. 4-aminophenylmercuric acetate (APMA)-activated MMP1 was detected by the 
cleavage of fluorescence-labeled substrate peptide. Concentrations of active MMP1 and 
TIMP1 were calculated from standard curves obtained from standards run in parallel 
respectively. 
 
2.11 Apoptosis assay 
Briefly, 106 fibroblasts were stained with 100 μl FITC-annexin V and propidium iodide 
(PI) labeling solution for 15 mins at room temperature using Annexin-V-FLUOS staining 
kit (Roche, Penzberg, Germany) according to the manufacturer’s protocol. The 
percentages of annexin-V single positive, annexin-V/PI double-positive and double-
negative cells were determined by flow cytometry. 
 41
 
2.12 Cytotoxicity assay 
Cytotoxicity assay was done by the Vybrant Cytotoxicity Assay Kit (Invitrogen) 
according to the manufacturer’s protocol. The release of the cytosolic enzyme glucose 6 
phosphate dehydrogenase (G6PD) from damaged cells into the surrounding medium was 
detected, which correlates with the number of dead cells in the sample (Fig. 9). In brief, 
50 μl medium from cells treated with different concentrations of HDACis for 24 h were 
collected and added into 96-well microplate, followed by adding equal volume of 2× 
reasazrin/reaction mixture (diaphorase, glucose-6-phosphate, NADP+, reaction buffer). 
The microplate was incubated at 37 °C for 60 mins. The fluorescence intensity (FI) was 
measured by PHERAstar with the optical module of EX 540 nm/EM 590 nm. The 
percentage of dead cells under different treatment was calculated from (FI (treated with 
HDACi) - FI (control))/ (FI (total lysed sample) - FI (control)).  
 
 
Fig. 9 Principle of the cytotoxicity assay. Illustration of the coupled enzymatic assay for 
detection of glucose 6-phosphate dehydrogenase (G6PD) activity. Oxidation of glucose 
6-phosphate by G6PD results in the generation of NADPH, which in turn leads to the 




2.13 RNA extraction, reverse transcription and quantitative PCR 
RNA was extracted from 6-well plate by TRI reagent (Ambion, Austin, TX, USA) 
following the manufacturer’s protocol. 1ml TRI reagent was added into the cell layer of 
every well. RNA extracted from 1 ml TRI reagent was dissolved in 30 μl RNase-free 
water and quantified with Nanodrop 1000 (Thermo scientific, Wilmington, DE, USA). 
 
Reverse transcription was conducted with SuperScript TM III Reverse Transcriptase kit 
(Invitrogen) following the manufacturer’s protocol. 200 ng total RNA was used for 
reverse transcription into cDNA per reaction. The reaction system included:  
Total RNA……………………………………….. 200 ng 
Oligo (dT) 12-18 (0.5 μg/μl, Invitrogen)…………... 1 μl 
dNTP Mix (10mM, Invitrogen)………………….. 1 μl 
Add RNase-free water to………………………… 13 μl 
 
The mixture was heated at 65 °C for 5 mins and incubated on ice for at least 1 min. The 
following components were added: 
5X First-strand buffer……………………………. 4 μl 
0.1 M DTT……………………………………….. 1 μl 
RNaseOUTTM Recombinant RNase Inhibitor…… 1 μl 




The whole mixture was incubated at 50 °C for 50 mins followed by heating at 70 °C for 
15 mins. No-RT controls were included without adding SuperscriptTM III RT. 
 
Q-PCR was carried out using the MaximaTM SYBR Green qPCR Master Mix (2X) kit 
(Fermentas, Ontario, Canada) following the manufacturer’s protocol. The reaction system 
included: 
Master Mix (2X)…………………………………. 12.5 μl 
Forward Primer………………………………….. 0.3 μM 
Reverse Primer…………………………………... 0.3 mM 
cDNA…………………………………………….. 2 μl 
RNase-free water………………………………… to 25 μl 
 
For non-template control (NTC), cDNA was substituted by RNase-free water.  
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Table 2 Primers sequences of the tested genes 
Gene name  Primers 
COL1A1 Forward: 
Reverse: 
5’- AGCCAGCAGATCGAGAACAT -3’ 
5’- TCTTGTCCTTGGGGTTCTTG -3’ 
α-SMA Forward: 
Reverse: 
5’- TTCAATGTCCCAGCCATGTA -3’ 
5’- GAAGGAATAGCCACGCTCAG -3’ 
CTGF Forward: 
Reverse: 
5’- GGAAAAGATTCCCACCCAAT -3’ 
5’- TGCTCCTAAAGCCACACCTT -3’ 
HSP47 Forward: 
Reverse: 
5’- CCCTGAAAGTCCCAGATCAA -3’ 
5’- GGGAGAGGTTGGGATAGAGC -3’ 
MMP1 Forward: 
Reverse: 




5’- AACTACGATGACGACCGCAAGT -3’ 
5’- AGGTGTAAATGGGTGCCATCA -3’ 
TIMP1 Forward: 
Reverse: 
5’- GACGGCCTTCTGCAATTCC -3’ 
5’- GTATAAGGTGGTCTGGTTGACTTCTG -3’ 
TIMP 2 Forward: 
Reverse: 
5’- GAGCCTGAACCACAGGTACCA -3’ 
5’- AGGAGATGTAGCACGGGATCA -3’ 
TIMP 3 Forward: 
Reverse: 
5’- CCAGGACGCCTTCTGCAA -3’ 
5’- CCCCTCCTTTACCAGCTTCTTC -3’ 
TIMP 4 Forward: 
Reverse: 
5’- CACCCTCAGCAGCACATCTG -3’ 
5’- GGCCGGAACTACCTTCTCACT -3’ 
GAPDH Forward: 
Reverse: 
5’- GTCCACTGGCGTCTTCACCA -3’ 
5’- GTGGCAGTGATGGCATGGAC -3’ 
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Table 3 Thermal cycling conditions of q-PCR 
Step Temperature (°C) Time Number of cycles 
Initial denaturation 95 10 min 1 
Denaturation 95 15 s 
Annealing/Extension 60 60 s 
40 
60 30 s Dissociation 
95 30 s 
1 
 
Q-PCR reactions were performed and monitored on an Mx 3000PTM q-PCR instrument 
(Stratagene, La Jolla, CA, USA). Data analysis was performed using the MxPro software 
(Stratagene). For each reaction, the Ct value was defined as the cycle number at which 
the fluorescence intensity reached the amplification based-threshold computed by the 
MxPro software. Each sample was assayed in duplicates. Relative expression level of 
certain gene was calculated by normalizing the average of the Ct to the Ct of GAPDH. 
The relative fold change of the expression level of certain gene was calculated from the 
method of 2-Ct. Ct is defined as (Ct induced target gene - Ct induced GAPDH) - (Ct control target gene 
- Ct control GAPDH). 
 
2.14 Statistical analysis 
Statistical analysis was performed using SPSS 12.0 (SPSS Inc., Chicago, IL, USA). 
Equality of error variances was tested by Levene’s test. Data with equal variances were 
compared by Turkey test and Data with unequal variances by Dunnet’s T3 test. 
Probability values of p<0.05 were accepted as the level of statistical significance. 
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3. RESULTS 
3.1 Establishment of a microplate reader-based QICC method 
To screen the antifibrotic effect of HDACis in vitro, a drug testing tool was developed, 
which was a combinational use of fluorescent immunochemistry and microplate reader 
technology, named as microplate reader-based quantitative immunocytochemistry 
(QICC). We showed that the microplate reader PHERAstar with a focusing lens system 
can quantify the fluorescent signal of immunocytochemistry from the cell layer more 
accurately than a microplate reader without a focusing system. We also quantified the 
deposited collagen and cell numbers using this method. 
 
3.1.1 Illustration of the QICC system 
 
The overall setup of QICC system included the microplate reader PHERAstar with a 
focusing lens system and the optical LumoxTM 96-well cell culture plate. The cells were 
seeded and treated in LumoxTM 96-well plate. After the immunocytochemistry procedure, 
the fluorescence intensity was measured by PHERAstar. There were three optical 
modules customized for measuring fluorescence intensity (Table 4). The schematic 
layout of the optical pathway of PHERAstar was illustrated and the focusing lens system 
was highlighted with * in Fig. 10a. Focal height was defined as the distance between the 
focus of the light beam and the bottom of the plate (Fig. 10b). We finally chose the 
LumoxTM 96-well plate because it was both suitable for cell culture and optical 
















FI 340/460-- 340 > 460 DAPI 345 458 
FI 485/520-- 485 > 520 AF 488 494 515 




Fig. 10 Illustration of the setup of QICC system. (a) Schematic layout of the optical 
pathway of PHERAstar. The focusing lens system was highlighted with *. (b) Schematic 
illustration of the focal height. (c) Lumox TM 96-well plate catered to the QICC system. 
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3.1.2 PHERAstar with the focusing lens improves the signal/background 
ratio 
 
First we quantified the fluorescence intensity of fluorophore DAPI, AF 488, and AF 594. 
The representative pictures generated by the three fluorophores and the curve of 
fluorescence intensities of cell layer labeled with or without fluorophores (background) 
over the focal height measured by the PHERAstar were shown in Fig. 11a. It was clear 
that there was an optimal focal height for measuring the fluorescence from the cell layer 
for every tested fluorophore. The focal height for the lumoxTM 96-well plate was around 
4.6 mm. Among the fluorophores tested, the background fluorescence of AF 594 was 
much lower than AF 488 and DAPI (Fig. 11a), which can also be seen from the 
signal/background ratios as measured by PHERAstar (Fig. 11b). In order to further prove 
that PHERAstar with a focusing lens system can quantify fluorescence intensity more 
accurately than microplate reader without a focusing lens system, we compared the 
signal/background ratio of fluorescence intensity generated by PHERAstar with that of 
FLUOstar without the focusing lens system. The signal/background ratio of PHERAstar 
was around 10 for AF 594, 4 for AF 488 and 3.5 for DAPI, which was significantly 









Fig. 11 PHERAstar with the focusing lens improves the signal/background ratio. (a) The 
representative staining of the three dyes (left) (AF 594, red; AF 488, green; DAPI, blue). 
Bars indicated 100 μm. Focal curves of AF 594, AF 488 and DAPI generated by 
PHERAstar (right). (b) Signal/background ratios of the three fluorophores measured by 
PHERAstar and FLUOstar. Statistically significant differences in signal/background ratio 




3.1.3 QICC is feasible for cell enumeration 
 
As seen from Fig. 12a, Cell numbers from 5,000 to 40,000 were linear with the 
fluorescence of DAPI as measured by PHERAstar. However, PHERAstar cannot detect 
the linear difference in the fluorescence intensities of DAPI represented cell numbers 
ranging from 625 to 2,500 (Fig. 12b). Therefore, PHERAstar can be used to enumerate 
cell number ranging from 5,000 to 40,000 in Lumox 96-well plate.  
 
Fig. 12 QICC is feasible for cell enumeration. Different numbers of FLF from 625 to 
40,000 per well were seeded into Lumox 96-well, and stained with DAPI after the 
attachment of the cells. Averages of the fluorescence intensity of DAPI from 
quadruplicates quantified by QICC were shown. (a) Calibration curve of the linear range 
of cell numbers measured by QICC (5,000 to 40,000 per well) in 96-well plate. (b) 
Averages of the fluorescence intensity of DAPI from cell number ranging from 625 to 
5,000. 
 
3.1.4 QICC quantifies the deposited collagen 
To prove the feasibility of QICC in assessing the relative fold change of the deposited 
collagen, we compared the result of QICC with that of our benchmark biochemical assay 
to evaluate the matrix deposition under normal cell culture and matrix enhancement 
condition. The matrix enhancement condition was created by adding 100 μg/ml 
macromolecule dextran sulfate 500 into the culture medium in the presence of 30 μg/ml 
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ascorbic acid for 24 h (see materials and method section for details). As shown in Fig. 13, 
around 6-7 fold enhanced total collagen deposition can be detected by QICC and the 
matrix created after cell lysis by 0.5% sodium deoxycholate were around 40% of total 
deposited collagen under the enhanced condition, which was well-comparable with that 
of biochemical assay.  
 
Fig. 13 QICC quantifies the deposited collagen. Total collagen deposition and matrix 
under normal cell culture and enhanced condition were quantified by QICC and 
biochemical assay. (a) Representative pictures of deposited collagen I from 
immunocytochemistry. Bars indicated 100 μm. (b) A representative SDS-PAGE of 
biochemical assay from 3 independent experiments. (c) Averages of fold change of 
collagen deposition from quadruplicates were quantified by QICC and 3 independent 
SDS-PAGE gels by biochemical assay (CL, cell layer; M, matrix). 
 
 52
3.2 Prescreening of the antifibrotic potential of hydroxamate HDAC 
inhibitors 
3.2.1 Molecular structures of the selected hydroxamate HDACis 
We chose 3 hydroxamate HDACis TSA, M344 and SAHA as recommended by Prof 
Manfred Jung. The molecular structures of these HDACis were illustrated in Fig. 14.  
 
Fig. 14 Molecular structures of HDAC inhibitors TSA, M344 and SAHA (from PubChem 
Substance) 
 
3.2.2 The tested HDACis inhibit the pro-fibrotic effect of TGFβ1 on FLF 
line IMR-90 
 
The antifibrotic effect of the three hydroxamate HDACis were tested on the FLF line 
IMR-90. The expression of α-SMA was assessed by QICC (Fig. 15a) and the collagen 
deposition by biochemical assay (Fig. 15b) and QICC (Fig. 15c). TGFβ1 induced around 
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6-fold increased expression of α-SMA. All the three hydroxamate HDACis abrogated the 
inducing effect of TGFβ1 dose-dependently with the range of TSA from 0.25 to 1 μM, 
M344 and SAHA from 2.5 to 10 μM respectively (Fig. 15a). For collagen deposition, 
both the biochemical assay and the QICC showed that IMR90 increased collagen 
deposition to 1.5~2 fold in response to TGFβ1. TSA, M344 and SAHA abolished 
TGFβ1-induced collagen deposition dose-dependently in IMR-90. TSA at 0.5 μM and 
M344 and SAHA at 5 μM brought collagen deposition to the non-induced levels. 
Interestingly, all the three HDACis alone did not significantly affect the basal level of 
collagen deposition in the FLF line IMR-90. 
 
The above result demonstrated that all the tested hydroxamate HDACis had similar 
antifibrotic potential in vitro on TGFβ1-stimulated fetal lung fibroblasts, although the 
effective dose ranges were different. TSA was the most potent among the three HDACis, 
which requires a 10 times less dose of M344 and SAHA in abrogating the inducing effect 
of TGFβ1 in inhibiting collagen deposition and α-SMA expression. Therefore, we 
deduced that this group of hydroxamate HDACi might all have the similar antifibrotic 
effect in vitro based on their similar chemical structure and working mechanism in 
inhibiting the activity of class I and II HDACs (as mentioned in the literature review). 
Therefore, we decided to further explore the antifibrotic effect of SAHA after this 
prescreening as SAHA is an FDA-approved anticancer drug for cutaneous T cell 







Fig. 15 TSA, M344 and SAHA abrogate the pro-fibrotic effects of TGFβ1. FLF line 
IMR-90 were treated with or without TGFβ1 (5 ng/ml) and increasing concentrations of 
TSA (0.25 to 1 μM), M344 (1.25 to 10 μM) and SAHA (2.5 to 20 μM) for 24 h. The 
expression of α-SMA was evaluated by QICC. The deposition of collagen was evaluated 
by biochemical assay and QICC (a) Averages of the fold change of α-SMA from 
quadruplicates were quantified by QICC. Statistically significant differences in α-SMA 
expression (*) were denoted in comparison with untreated control (P<0.05). (b) 
Representative SDS-PAGEs of collagen from 3 independent experiments respectively. (c) 
Averages of fold change of collagen deposition were quantified from quadruplicates by 
QICC and 3 independent SDS-PAGE gels by biochemical assay. Statistically significant 
differences in collagen deposition quantified by QICC (*) and biochemical assay (**) 
were denoted in comparison with untreated control (P<0.05). 
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3.2.3 TSA, M344 and SAHA are not cytotoxic to IMR-90 
The cytotoxicity of TSA, M344 and SAHA were assayed by the release of cytosolic 
enzyme glucose-6-phosphate dehydrogenase (G6PD) from damaged cells into the 
surrounding medium, which is correlated with the number of dead cells in the sample. 
The percentages of dead cells after the treatment of the three HDACis were not 
significantly higher than the non-treated controls indicating that the three HDACis were 
not cytotoxic to the FLF line IMR-90 at the tested concentrations (Fig. 16). 
 
 
Fig. 16 TSA, M344 and SAHA are not cytotoxic. FLF line IMR-90 were treated with or 
without TGFβ1 (5 ng/ml) and increasing concentrations of TSA (0.25 to 1 μM), M344 
(1.25 to 10 μM) and SAHA (2.5 to 20 μM) for 24 h. The media were collected and the 
G6PD in the media was assayed. The percentages of dead cells under different treatments 
were calculated from the ratio of G6PD released from the cells to that of the lysed 
positive controls. Averages of the percentage of dead cells from quadruplicates were 
plotted. Statistically significant differences in the percentages of dead cells (*) were 
denoted in comparison with untreated control (P<0.05). 
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3.3 Characterization of the antifibrotic potential of SAHA on lung fibroblast 
lines 
 
3.3.1 SAHA induces hyperacetylation of histone 3 and α-tubulin  
Basal acetylation levels of histone 3 and α-tubulin were noted in the untreated FLF, ALF 
and IPF fibroblasts. In the presence of SAHA, the acetylation of histone 3 significantly 
increased at around 4 fold in FLF, 2 fold in ALF and 2.5 fold in IPF fibroblasts. The 
acetylation of α-tubulin significantly increased at around 20 fold in FLF, 10 fold in ALF 
and 8 fold in IPF fibroblasts as assessed by QICC (Fig. 17a-b). In addition, Western blot 
analysis also demonstrated that SAHA induced hyperactylation of histone 3 and α-tubulin 
(Fig. 17c), indicating that SAHA inhibited HDACs activity. TGFβ1 did not change the 





Fig. 17 SAHA induces hyperacetylation of histone and α-tubulin. FLF, ALF, and IPF 
fibroblasts were treated with or without TGFβ1 (5ng/ml) and 5 μM SAHA for 24 h, and 
the acetylation of histone 3 and α-tubulin were quantified by QICC and Western blot. (a) 
Immunocytochemistry of acetylation of histone 3 (green) and α-tubulin (red). Bars 
indicated 50 μm. (b) Averages of the fold change of acetylation of histone 3 and α-tubulin 
from quadruplicates were quantified by QICC. Statistically significant differences in 
acetylation of histone 3 (*) and α-tubulin (**) were denoted in comparison with untreated 






3.3.2 Dynamics of hyperaceylation of hisone 3 and α-tubulin induced by 
SAHA 
 
FLF IMR-90 were treated with SAHA at 2.5 μM for 0, 0.25, 0.5, 1.25, 2.25, 7.25, 11.25, 
24.25 h. The hyperactylation of histone 3 and α-tubulin were accessed by QICC. After 
0.5 h, acetylation of histone 3 and α-tubulin was significantly elevated by SAHA. In the 
first 2.5 h, histone 3 and α-tubulin underwent rapid hyperacetylation. However, the 
acetylation of α-tubulin slowed down after the initial 2.5 h, and the acetylation of histone 
3 reached the plateau after the initial 2.5 h (Fig. 18).  
 
 
Fig. 18 Dynamics of hyperacetylation of histone 3 and α-tubulin induced by SAHA. FLF 
line IMR-90 were treated with 2.5 μM SAHA for 24 h, and the acetylation of histone 3 
and α-tubulin were quantified by QICC. Averages of the fold change of acetylation of 
histone 3 and α-tubulin from quadruplicates were quantified by QICC. Statistically 
significant differences in acetylation of histone 3 (*) and α-tubulin (**) were denoted in 
comparison with untreated control (P<0.05).  
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3.3.3 SAHA inhibits TGFβ1-induced myofibroblast transdifferentiation  
Untreated cell cultures of all the fibroblasts lines showed low levels of α-SMA expression 
by immunocytochemistry (Fig. 19a), Western blot (Fig. 19b), and flow cytometry 
analyses (Fig. 19d). Microscopy revealed that this was due to a few interspersed cells 
positive for α-SMA. Although TGFβ1 triggered transdifferentiation of the majority of 
fibroblasts into myofibroblasts in all three fibroblast lines, IPF fibroblasts were the most 
responsive with a 14-fold enhanced α-SMA expression followed by 8-fold in ALF and 5-
fold in FLF, as assessed by QICC (Fig.19c). SAHA abolished this effect in a dose-
dependent manner from 2.5 to 10 μM by both reducing the expression of α-SMA and 







Fig. 19 SAHA inhibits TGFβ1-induced myofibroblast transdifferentiation. FLF, ALF, 
and IPF fibroblast were treated with or without TGFβ1 (5 ng/ml) and increasing 
concentrations of SAHA (2.5, 5 and 10 μM) for 24 h. The expression of α-SMA was 
evaluated by QICC and Western blot. (a) Representative pictures from 
immunocytochemistry (α-SMA, red; DAPI, blue). Bars indicated 50 μm. (b) Averages of 
fold change of α-SMA expression from quadruplicates were quantified by QICC. 
Statistically significant differences in α-SMA expression (*) were denoted in comparison 
with untreated control (P<0.05). (c) Western blots of α-SMA. (d) Flow cytometry 
analysis of the percentages of α-SMA positive cells. 
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3.3.4 SAHA inhibits TGFβ1-induced collagen production  
Both QICC (Fig. 20a) and quantitative gel electrophoresis (Fig. 20b) demonstrated 
increased collagen deposition in response to TGFβ1. IPF fibroblasts were the most 
responsive with an increase of 3-4 fold in comparison with 1.5-2 fold in FLF and ALF 
respectively (Fig. 20c). SAHA abrogated TGFβ1-induced collagen deposition dose-
dependently in all the fibroblast lines. At 10 μM, SAHA completely counteracted the 
effect of TGFβ1 on IPF by limiting collagen deposition to pre-treatment levels, and 5 μM 
on FLF and ALF. However, SAHA alone did not significantly affect the basal level of 




Fig. 20 SAHA inhibits TGFβ1-induced collagen production. FLF, ALF and IPF fibroblast 
were treated with or without TGFβ1 (5 ng/ml) and increasing concentrations of SAHA 
(2.5, 5, 10 and 20 μM) for 24 h. The expression of collagen I was quantified by QICC 
and SDS-PAGE. (a) Representative immunocytochemistry (collagen I, red; DAPI, blue). 
Bars indicated 50 μm. (b) Representative SDS-PAGEs from 3 independent experiments, 
respectively. (c) Averages of the fold change of collagen deposition were quantified from 
quadruplicates by QICC and 3 independent SDS-PAGE gels by biochemical assay. 
Statistically significant differences in collagen deposition quantified by QICC (*) and 
biochemical assay (**) were denoted in comparison with untreated control (P<0.05). 
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3.3.5 SAHA regulates MMP1 and TIMP1 differentially 
TGFβ1 reduced the total potentially activated (APMA-activated) MMP1 in FLF to one-
third, but doubled it in ALF and IPF fibroblasts. 5 μM SAHA had no effect on TGFβ1-
reduced MMP1 in FLF whereas it brought down MMP1 to the basal level in ALF and 
IPF fibroblast lines. SAHA alone inhibited APMA-activated MMP1 in FLF by around 
50%, but did not affect MMP1 in ALF and IPF fibroblast lines (Fig. 20a). TIMP1 was 
increased by TGFβ1 in all three fibroblast lines to 2-2.5 fold. It was further induced by 
SAHA only in FLF, but remained unchanged in ALF and was reduced slightly in IPF. 
SAHA alone did not change TIMP1 production significantly (Fig. 20b). 
 
Fig. 21 SAHA regulates MMP1 and TIMP1 differentially. FLF, ALF and IPF fibroblast 
were treated with or without TGFβ1 (5 ng/ml) and SAHA at 5 μM for 24 h. Media were 
collected and analyzed for 4-aminophenylmercuric acetate (APMA)-active MMP1 
activity and TIMP1 by enzyme-linked immunosorbent assay (ELISA). The experiments 
were performed for 3 times with 3 different batches of samples, and one representative 
result was used to show the averages of APMA-activated MMP1 (a) and TIMP1 (b) from 
duplicates of each condition. Statistically significant differences in MMP1 or TIMP1 
expression (*) were denoted in comparison with untreated control (P<0.05). 
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3.3.6 SAHA is not pro-apoptotic in the tested fibroblasts  
Annexin V and PI staining showed that SAHA at 5 μM did not induce apoptosis in all 
three fibroblast lines in the presence or absence of TGFβ1 (Fig. 22). 
 
Fig. 22 SAHA is not pro-apoptotic. FLF, ALF and IPF fibroblast lines were treated with 
or without TGFβ1 (5 ng/ml) and SAHA at 5 μM for 24 h. Cell were stained with annexin 
V and propidium iodide (PI). Percentages of apoptotic (annexin-V single positive) and 
necrotic (annexin-V/PI double-positive) were labeled at the corresponding regions of 




3.3.7 SAHA inhibits serum-induced fibroblast proliferation  
Adherent cytometry revealed that 5 μM SAHA inhibited proliferation of the three 
fibroblast lines in 10% FBS after the first day and stopped cell proliferation afterwards 
(Fig. 23a). Higher fluorescence intensity of CFSE was detected in SAHA-treated 
fibroblasts suggesting reduced cell proliferation (Fig. 23b). 
 
Fig. 23 SAHA inhibits fibroblast proliferation. FLF, ALF and IPF fibroblast lines were 
cultured in 10% FBS with or without SAHA at 5 μM. (a) Averages of cell numbers from 
triplicates were quantified by adherent cytometry at each time-point up to 3 days. 
Statistically significant differences in cell number of fibroblasts treated with SAHA plus 
10% FBS (*) were denoted in comparison with fibroblasts cultured in 10% FBS at the 
same time point (p<0.05). (b) Changes of CFSE fluorescence intensity after 3 days. 
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3.3.8 SAHA modulates the expression of selected genes differentially 
 
Because SAHA is an epigenetic regulator of gene transcription, we characterized the 
effect of SAHA on the mRNA of COL1A1, α-SMA, HSP47, CTGF, MMP1, MMP2, and 
TIMP1-4 in FLF line IMR-90. The genes were grouped into two categories. One group 
was TGFβ1-induced genes including COL1A1, α-SMA, collagen specific chaperon 
HSP47, and CTGF. The other group of genes was MMPs and TIMPs involved in the 
turnover of extracellular matrix, including MMP1, MMP2 and TIMP1-4. After 24 h 
treatment, RNA was extracted and q-PCR was performed. 
 
TGFβ1 induced a 3-fold increase in the expression of COL1A1. The expression of SMA 
was increased by 35-fold. HSP47 was increased by 5-fold. CTGF was increased by 6-fold 
with TGFβ1 exposure. SAHA inhibited the expression of all the tested TGFβ1-induced 
genes significantly. The induced expression of COL1A1 was back to the basal level in 
the presence of SAHA. Interestingly, the basal level expression of COL1A1 was also 
reduced around 50%. TGFβ1 had the strongest inducing effect on α-SMA among the 
tested genes and SAHA inhibited this induced expression significantly, although it was 
still significantly higher than the basal level of the expression of α-SMA. The expression 
of collagen chaperon HSP47 was significantly inhibited both at the basal and inducing 
level under SAHA treatment. SAHA also abrogated TGFβ1-induced expression of CTGF 
without affecting its basal level expression (Fig. 24a). 
 
We tested MMP1, MMP2 and their inhibitors TIMP1-4. It seemed that TGFβ1 itself had 
a diverse effect on the expression of MMPs and TIMPs. MMP1 was reduced by TGFβ1, 
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whereas MMP2 and TIMP1-3 were increased by TGFβ1. TGFβ1 had no effect on the 
expression of TIMP4. SAHA alone inhibited the expression of MMP1 and MMP2, but 
did not interfere with the basal level expression of TIMPs. The combination of SAHA 
and TGFβ1 had no further effect on the expression of MMP1 and TIMP1. However, 
SAHA inhibited the elevated expression of MMP2, TIMP2 and TIMP3 by TGFβ1. What 
we found interesting was that SAHA enhanced the expression of TIMP4 in the presence 




Fig. 24 SAHA modulates the expression of selected genes differentially. FLF line IMR-
90 were treated with or without TGFβ1 (5 ng/ml) and 5 μM SAHA for 24 h. The 
expression of the tested genes was quantified by q-PCR. (a) Averages of fold change of 
TGFβ1-induced gene expression were quantified from duplicates. (b) Averages of the 
fold change of MMP1 and MMP2 expression were quantified from duplicates. (c) 
Averages of fold change of TIMP1-4 expression were quantified from duplicates. 
Statistically significant differences in gene expression (*) were denoted in comparison 
with untreated control (P<0.05). 
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3.4 The antifibrotic potential of SAHA on normal and pathological skin 
fibroblasts- a preliminary study 
We evaluated the antifibrotic potential of SAHA on hypertrophic scars and keloids in 
vitro. The primary skin fibroblast cultures were kindly provided by A/P Toan Thang Phan 
(Department of surgery, National University of Singapore). Normal skin, hypertrophic 
scar, and keloid fibroblasts were isolated from the skin biopsies of 7 patients (see Table 5 
for details). The effects of SAHA on the basal and TGFβ1-induced collagen production 
and α-SMA expression were evaluated by QICC and biochemical assay. 
 
Table 5 Details of normal and pathological skin fibroblasts 
Fibroblast Gender Race Age 
(years) 
Origin Duration of 
scar (years) 














































NA: not applicable 
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3.4.1 The antifibrotic effects of SAHA on normal skin fibroblasts 
 
3.4.1.1 SAHA inhibits TGFβ1-induced collagen production in NSFs 
We tested normal skin fibroblast (NSF) 13, 14 and 152. Fig. 25 showed the effect of 
SAHA on the basal and TGFβ1-induced collagen production from NSFs. By the means of 
QICC (Fig. 25a), TGFβ1 induced around 4.5, 4 and 3-fold increased collagen deposition 
in NSF13, 14 and 152 respectively. SAHA at 2.5 to 10 μM inhibited TGFβ1-induced 
collagen production significantly in the three NSFs tested. Similar data from biochemical 
assay showed that SAHA at 5 μM inhibited TGFβ1-induced collagen production in the 
tested NSFs. TGFβ1 induced around 10, 6 and 4-fold increased collagen deposition, but 
SAHA at 5 μM suppressed this induced collagen production to 40%, 55% and 60% in 
NSF13, 14 and 152 respectively. What we found interesting was that SAHA at 5 μM 
actually increased the basal level of collagen production in NSFs by around 30% in 
NSF152 and around 80-90% in the basal level of collagen in NSF13 and NSF14. 
 
3.4.1.2 SAHA inhibits TGFβ1-induced α-SMA expression in NSFs 
The effect of SAHA on TGFβ1-induced α-SMA expression was tested on NSF 13, 14 and 
152. TGFβ1 induced around a 2-fold increase of α-SMA expression while the basal 
expression levels of α-SMA were low in the three NSFs strains. SAHA at more than 2.5 
μM inhibited TGFβ1-induced α-SMA expression to the basal level. Compared to lung 





Fig. 25 SAHA inhibits TGFβ1-induced collagen production in NSFs. NSF13, 14 and 152 
were treated with or without TGFβ1 (5 ng/ml) and increasing concentrations of SAHA 
(2.5, 5 and 10 μM) for 24 h. The deposition of collagen I was quantified by QICC and 
SDS-PAGE. (a) Representative immunocytochemistry (upper; collagen I, red; DAPI, 
blue). Bars indicated 100 μm. Averages of the fold change of collagen deposition were 
quantified from quadruplicates by QICC (lower). Statistically significant differences in 
collagen deposition (*) were denoted in comparison with TGFβ1-induced samples 
(P<0.05). (b) SDS-PAGEs from biochemical assay (upper). The fold changes of collagen 





Fig. 26 SAHA inhibits TGFβ1-induced α-SMA expression in NSFs. NSF 13, 14 and 152 
were treated with or without TGFβ1 (5 ng/ml) and increasing concentrations of SAHA 
(2.5, 5 and 10 μM) for 24 h. The expression of α-SMA was evaluated by QICC. 
Representative pictures from immunocytochemistry (upper; α-SMA, red; DAPI, blue). 
Bars indicated 100 μm. Averages of the fold change of α-SMA expression from 
quadruplicates were quantified by QICC (lower). Statistically significant differences in α-
SMA expression (*) were denoted in comparison with untreated control (P<0.05). 
 74
 
3.4.2 The antifibrotic effect of SAHA on hypertrophic scar fibroblasts  
 
Next we tested the antifibrotic effects of SAHA on hypertrophic scar fibroblasts (HSFs). 
As shown in Fig. 27, SAHA also inhibited TGFβ1-induced collagen production and α-
SMA expression in HSF 16 and 114. TGFβ1 induced a 2-fold increase of collagen 
deposition in both the HSF stains. SAHA at 5 to 20 μM inhibited TGFβ1-induced 
collagen production dose-dependently as assessed by QICC and biochemical assay. We 
noticed that SAHA did not interfere with the basal level of collagen production in the 
HSFs but it does this in the NSFs. We further investigated whether SAHA inhibited 
TGFβ1-induced α-SMA expression in HSF 16 and 114 (Fig. 28). The response of HSFs 
on α-SMA expression to SAHA was similar as that of NSFs and SAHA at 5 μM 





Fig. 27 SAHA inhibits TGFβ1-induced collagen production in HSFs. HSF16 and114 
were treated with or without TGFβ1 (5 ng/ml) and increasing concentrations of SAHA (5, 
10 and 20 μM) for 24 h. The deposition of collagen I was quantified by QICC and SDS-
PAGE. (a) Representative immunocytochemistry (upper; collagen I, red; DAPI, blue). 
Bars indicated 100 μm. Averages of the fold change of collagen deposition were 
quantified from quadruplicates by QICC (lower). Statistically significant differences in 
collagen deposition (*) were denoted in comparison with TGFβ1-induced samples 
(P<0.05). (b) SDS-PAGEs from biochemical assay (upper). The fold changes of collagen 









Fig. 28 SAHA inhibits TGFβ1-induced α-SMA expression in HSFs. HSF16 and 114 were 
treated with or without TGFβ1 (5 ng/ml) and increasing concentrations of SAHA (5, 10 
and 20 μM) for 24 h. The expression of α-SMA was evaluated by QICC. Representative 
pictures from immunocytochemistry (upper; α-SMA, red; DAPI, blue). Bars indicated 
100 μm. Averages of the fold change of α-SMA expression from quadruplicates were 
quantified by QICC. Statistically significant differences in α-SMA expression (*) were 
denoted in comparison with untreated control (P<0.05). 
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3.4.3 The antifibrotic effect of SAHA on keloid fibroblasts  
Keloid fibroblasts (KFs) were another type of pathological skin fibroblast tested. Fig. 29 
showed the collagen deposition and Fig. 30 the α-SMA expression from KF12 and 
KF108 with or without TGFβ1 in the presence or absence of SAHA. TGFβ1 induced a 2-
fold increase of collagen deposition in KF108 and a 3.5-fold increase in KF12. We 
titrated the dose of SAHA from 2.5 to 40 μM and found that SAHA only inhibited 
TGFβ1-induced collagen production at more than 20 μM significantly. The basal levels 
of collagen production in KFs were not affected by SAHA as seen from the biochemical 
assay. TGFβ1-induced α-SMA expression was inhibited by SAHA at 5 μM in both stains, 





Fig. 29 SAHA inhibits TGFβ1-induced collagen production in KFs. KF12 and 108 were 
treated with or without TGFβ1 (5 ng/ml) and increasing concentrations of SAHA (2.5, 5, 
10, 20, 30 and 40 μM) for 24 h. The deposition of collagen I was quantified by QICC and 
SDS-PAGE. (a) Representative immunocytochemistry (upper; collagen I, red; DAPI, 
blue). Bars indicated 100 μm. Averages of the fold changes of collagen deposition were 
quantified from quadruplicates by QICC (lower). Statistically significant differences in 
collagen deposition (*) were denoted in comparison with TGFβ1-induced samples 
(P<0.05). (b) SDS-PAGEs from biochemical assay (upper). The fold changes of collagen 




Fig. 30 SAHA inhibits TGFβ1-induced α-SMA expression in KFs. KF12 and 108 were 
treated with or without TGFβ1 (5 ng/ml) and increasing concentrations of SAHA (5, 10 
and 20 μM) for 24 h. The expression of α-SMA was evaluated by QICC. Representative 
pictures from immunocytochemistry (upper; α-SMA, red; DAPI, blue). Bars indicated 
100 μm. Averages of α-SMA fold changes from quadruplicates were quantified by QICC. 
Statistically significant differences in α-SMA expression (*) were denoted in comparison 
with untreated control (P<0.05). 
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4. DISCUSSION 
4.1 Implementing the PHERAstar microplate reader for quantifying 
immunocytochemical signals 
 
We successfully established a microplate reader-based QICC method. In this study, we 
used it as a drug screening tool to evaluate the in vitro antifibrotic property of HDACis. 
The unique feature of this QICC method was the exploitation of PHERAstar microplate 
reader with a focusing lens system to quantify the immunocytochemical signal from the 
fluorophore-labeled cell layer. An optimal focal height was achieved by quantifying the 
fluorescence signal using PHERAstar for all the three tested fluorophores AF 594, AF 
488 and DAPI. Thus the signal/background ratio of the fluorescence signal from the cell 
layer was significantly improved compared with the microplate reader FLUOstar which 
does not possess a focusing lens system. 
 
In comparison with biochemical assay of collagen described as pepsin digestion followed 
by SDS-PAGE (Lareu RR1, 2 et al 2007), we demonstrated that the microplate reader-
based QICC method was feasible to measure the deposited collagen non-destructively. 
Traditional methods to quantify collagen include radioactive labeling (Diegelmann RF et 
al 1990), hydroxyproline determination (Bergmann I & Loxley R 1970), sirius red-based 
colorimetry (Tullberg-Reinert H & Jundt G 1999), pepsin digestion followed by SDS-
PAGE (Lareu RR1’ 2 et al 2007) and Western blot (Lareu RR1 et al 2007). However, these 
methods require destroying the cell layer before the measurement, and thus it is 
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impossible to retrieve morphology of the deposited collagen using those methods. 
Although morphology analysis is available with sirius red staining, the dye bound to 
collagen matrix still needs to be dissolved before the optical measurement using a 
microplate reader ((Tullberg-Reinert H & Jundt G 1999). The QICC method described in 
this study has the advantage of preserving the morphological information as well as 
measuring the relative amount of collagen in situ.  
 
Apart from quantifying collagen matrix, this microplate reader-based QICC method was 
also accurate enough to quantify the relative fold change of the expression of α-SMA, 
acetylated histone 3 and acetylated α-tubulin. Moreover, as the fluorescence intensity of 
the nucleic stain DAPI was linear with the number of cells from 5,000 to 40,000 in the 
96-well LumoxTM plate, this microplate reader-based QICC method can also be used to 
enumerate cells. By this means, the relative fold change of certain antigen per cell was 
calculable after being normalized to the fluorescence intensity of DAPI. Therefore, it is 
foreseeable that QICC using PHERAstar is a convenient and accurate method to quantify 
the relative change of the expression of the extracelluar and intracellular proteins in situ.  
 
4.2 Prescreening the antifibrotic effects of three HDAC inhibitors 
 
We found that the three hydroxamate HDACis TSA, M344 and SAHA worked equally 
well in inhibiting TGFβ1-induced collagen production and α-SMA expression in FLF line 
IMR-90. This cellular effect was also in accordance with their ability in inhibiting 
HDACs in vitro. All the three inhibitors can repress the activity of class I and class II 
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HDACs in vitro. For HDAC selectivity TSA and SAHA are unselective, while M344 was 
reported to be more selective for HDAC6 (IC50 HDAC6= 90 nM; IC 50 HDAC1= 250 nM) 
(Heltweg B et al 2004). 
 
In addition, we found that the effective dose ranges of the three inhibitors were different. 
TSA required a 10 times lower dose of M344 and SAHA in achieving the same 
antifibrotic effect. The lower dose of TSA at the cellular level may mirror its stronger 
ability on inhibiting HDAC activity in vitro. The IC50 of TSA is around 5 nM on maize 
HDAC2 (Jung M et al 1999), which is 10 to 20 times lowers than that of M344 (around 
100 nM) (Jung M et al 1999) and SAHA (around 50 nM) ((Moradei O et al 2005). The 
potency of TSA can be partially explained by its binding mode to a HDAC1 analog 
HDLP (Finnin MS et al 1999). As deduced from the chemical structures of TSA, M344 
and SAHA, the aliphatic chain of SAHA and M344 might have more flexibility and pack 
less snugly into the pocket of the catalytic site of HDLP compared with the double bonds 
of TSA.  
 
At the concentrations used in this study, TSA (Herald C et al 2002; Suzuki T et al 2000), 
M344 (Takai N et al 2006) and SAHA (Borbone E et al 2010; Kuzelová K et al 2010; 
Sangeetha SR, 2009; Yeh CC et al 2009) were shown to induce growth arrest and 
apoptosis in a wide variety of cancer cells in culture. However, in the FLF IMR-90 all the 
three HDACis do not cause significant cell death as seen from the release of G6PD into 
the culture medium. We further confirmed that SAHA does not induce cell apoptosis in 
fetal, adult, IPF lung fibroblast by annexin V and PI staining. These findings are 
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consistent with other papers which reported that HDACis induce apoptosis in tumor cells, 
but not in normal cells (Armeanu S et al 2005; Papeleu P et al 2003; Ailenberg M & 
Silverman M 2003). 
 
4.3 The antifibrotic effects of SAHA on lung fibroblast lines 
In the past 15 years, the incidence and mortality of pulmonary fibrosis, particular 
idiopathic pulmonary fibrosis (IPF), has increased significantly in patients over 50 years 
old (Gribbin J et al 2006). No current treatment can effectively stop the pathological 
scarring process in the lung parenchyma. Several potential antifibrotic drugs are in 
different phases of clinical trials, but a clear benefit is still not in sight (Bhatt N et al 
2006). Therefore, we explored the potential new indication for SAHA already in clinical 
use for the treatment of cutaneous T cell lymphoma, which could potentially broaden and 
accelerate the therapeutic options for one type of the fibroproliferative diseases- 
pulmonary fibrosis (Wang Z et al 2009). 
 
4.3.1 SAHA inhibits TGFβ1-induced collagen and α-SMA expression on 
lung fibroblasts  
 
We first found that SAHA inhibited HDACs activity in the three tested lung fibroblast 
lines by inducing hyperacetylation of histone 3 and α-tubulin. SAHA can diffuse into the 
nucleus and inhibit the activity of HDACs very rapidly as seen from the dynamic study. 
We speculated that this might be related to the small molecular weight of SAHA which is 
around 300 Da. 
 86
 
We showed that the anti-cancer drug SAHA limited the pro-fibrotic response induced by 
TGFβ1 in IPF fibroblasts as well as FLF and ALF without inducing apoptosis. Among 
the three lung fibroblast lines tested, pathological IPF fibroblast line was the most 
responsive to the inducing effect of TGFβ1. The antifibrotic effect of SAHA was 
demonstrated by the restoration of collagen I deposition to normal levels and suppression 
of α-SMA expression, indicating that the compound inhibited the transdifferentiation of 
fibroblasts to myofibroblasts, the cell type primarily responsible for pathological matrix 
accumulation. Apart from the protein level, SAHA was also found to inhibit TGFβ1-
induced COL1A1 and α-SMA at the mRNA level in FLF line IMR-90, which may 
partially explain the inhibitory effect of SAHA for these two genes at the protein level.  
 
4.3.2 SAHA has a diverse effect on the expression of MMPs and TIMPs on 
lung fibroblasts  
 
We also investigated the potential fibrolytic properties of SAHA and tested fibroblast 
collagenase, MMP1 and its inhibitor TIMP1, components responsible for remodeling of 
extracellular matrix at the protein level. Surprisingly, the total potentially activated-
MMP1 was doubled by TGFβ1 in ALF and IPF fibroblasts. SAHA reversed it to the basal 
level. SAHA has been reported to inhibit TGFβ1-induced TIMP1 expression in mouse 
fibroblast (Young DA et al 2005). However, in our hands SAHA had no effect on 
TGFβ1-induced TIMP1 production in human normal and IPF lung fibroblasts, and it even 
induced a further increase of TIMP1 in FLF. 
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At the mRNA level, the expression patterns of MMP1 and TIMP1 were similar as that of 
protein level. Inhibiting TGFβ1-induced MMP2 expression by SAHA might affect the 
activation of TGFβ1 as MMP2 hydrolyzes latent the TGFβ1 complex and mediates its 
activation (Jenkins G 2008). For other TIMPs besides TIMP1, SAHA exhibited 
differential effect on their expression. Overall, it is different to draw any conclusion on 
the fibrolytic effect of SAHA. Therefore, it is conceivable that the net reduction of 
collagen deposition might be accredited to the effects of SAHA on collagen synthesis and 
secretion rather than collagen turnover. 
 
4.4 The antifibrotic effects of SAHA on skin fibroblasts 
4.4.1 The effect of SAHA on the basal and TGFβ1-induced collagen 
production 
 
The results from the NSFs and two types of pathological skin fibroblasts HSFs and KFs 
suggested that SAHA had antifibrotic effects also on these types of fibroblasts by 
inhibiting TGFβ1-induced collagen production. We noticed a difference in the dose of 
SAHA in inhibiting TGFβ1-induced collagen production among the three types of 
fibroblasts. SAHA at 5 μM was sufficient in NSFs, but the dose was 20 μM in HSFs and 
KFs.  
 
For the basal level of collagen deposition, we observed that unstimulated HSFs and KFs 
produce more collagen than NSFs in vitro, which is similarly reported by Tuan TL & 
 88
Nichter LS (1998). Moreover, we observed that SAHA actually increased the production 
in NSFs, but it had no effect on the production in HSFs and KFs. The above data 
suggested that an intrinsic difference in collagen biosynthesis between normal fibroblasts 
and pathological skin fibroblasts.  
 
Of note, we believe that a TGFβ1-stimulated matrix enhancement culture condition might 
resemble the real in vivo environment of these pathological fibroblasts more than normal 
culture condition does because it is reported that TGFβ1 is elevated in keloids and TGFβ 
receptors I and II are increased in keloid fibroblasts (Chin GS et al 2001, Tsujita-Kyutoku 
M et al 2005). More importantly, the potential antifibrotic drug HDACis were conducted 
under conditions of enhanced matrix formation as brought about by macromolecular 
crowding (Lareu RR1’ 2 et al 2007). We believe that such a biophysical culture 
environment is better suited than standard conditions in generating a comprehensive and 
functional extracellular matrix in a short time frame with all biochemical processes in 
place that represent fibrogenesis and fibrolysis (Lareu RR1’ 2 et al 2007). This should add 
further weight to the conclusion derived herein, that HDACis, especially SAHA 
possesses antifibrotic properties and is worth further exploration for a therapeutic option 
for fibroproliferative diseases and a prevention option for peri-implantational fibrosis. 
 
4.4.2 The effect of SAHA on TGFβ1-induced α-SMA expression 
Although a difference existed in the dose of SAHA in inhibiting TGFβ1-induced collagen 
production, SAHA at 5 μM inhibited TGFβ1-stimulated α-SMA expression equally well 
in the three types of fibroblasts. The difference of SAHA concentration in achieving 
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inhibiting collagen production and α-SMA may be because collagen is intrinsically 
expressed by fibroblasts but not α-SMA.  
 
NSFs had very low basal level of α-SMA expression and were much less responsive to 
TGFβ1-induced myofibroblasts transdifferentation than HSFs and KFs. This further 
indicated the intrinsic difference in the regulation of the fibrotic response to TGFβ1 
between NSFs and pathological HSFs and KFs.  
 
4.5 HDAC inhibitors interfere with the pro-fibrotic effect of TGFβ1 
In comparison with published work on TSA, our data suggested that HDACis interfere 
with the pro-fibrotic effects of TGFβ1 in fibroblasts both at the mRNA and protein level. 
However, the effect of TSA on TGFβ1 signaling is still controversial. As is well-known, 
the major type of TGFβ1 signaling follows the Smad-dependent pathway. Briefly, 
binding of TGFβ1 to TGFβ1 receptor II initiates the dimerization of TGFβ1 receptor I 
and II. TGFβ1 receptor I with serine/threonine kinase activity phosphorylates receptor 
activated Smads (R-Smad) Smad2 and 3. Activated R-Smads bind with Smad4, and the 
complex translocates into the nucleus and binds to the promoter region of target genes 
with other transcription factors and CBP/p300 coactivators (Derynck R et al 2003). 
Smad7 inhibits the phosphorylation of Smad2 and 3 by TGFβ receptor I. Zinc finger 
transcription factor Sp1 binding to collagen gene promoter and its interaction with 
Smads/p300 complex is essential for TGFβ1-stimulated collagen production (Zhang W et 
al 2000). In foreskin fibroblast Smad activation and function is not significantly altered, 
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but TGFβ1 fails to induce Sp1 expression and its interaction with Smad complex and 
COL1A2 promoter region in the presence of TSA (Ghosh AK et al 2007). In contrast 
with no impaired TGFβ1 signaling in foreskin fibroblast, TSA was reported to inhibit 
nuclear translocation and DNA binding of Smad3/4 complex in systemic sclerosis (SSc) 
skin fibroblasts (Huber LC et al 2007). 
 
Activating the expression of repressors of TGFβ1 pathway has been reported after the 
treatment of TSA or slicing HDACs expression by RNA interference in fibroblasts and 
chondrocytes. Specific silencing of HDAC1-8 expression by RNA interference revealed 
that HDAC4 inhibition most efficiently represses TGFβ1-induced α-SMA expression 
indicating that HDAC4 is required for TGFβ1-induced myofibroblastic differentiation in 
human skin fibroblast. Silencing HDAC4 stimulates the expression of two endogenous 
repressors of TGFβ1 signaling pathway 5’-TG-3’-Interacting Factor (TGIF) and TGIF2 
homoproteins, but not of inhibitory Smad7 (Glenisson W et al 2007). TSA induces a 
biphasic expression of TGIF, and this pattern does not change in the presence of TGFβ1 
(Rombouts K et al 2002). Transcriptional factor FLI-1 of Ets family is also an inhibitor of 
collagen production via a Sp1-dependent pathway (Czuwara-Ladykowska J et al 2001). 
Its expression is elevated by TSA with a decreased collagen production in SSc fibroblasts 
(Wang Y et al 2006). TSA also induces growth factor Wnt-5a expression in chondrocytes, 
which is known to inhibit collagen II expression (Huh YH et al 2007). Hence, the above 
data indicates that HDACi might indirectly inhibit the expression of a TGFβ1-induced 
gene by directly activating the expression of a transcriptional repressor of the target gene 
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as HDACs are generally believed to function as transcriptional co-repressors in the 
transcriptional repression complex (Bolden JE et al 2006). 
 
Another interesting point is that HDAC1 mediates deacetylation of Smad7, and thus 
decreases the stability of Smad7 by enhancing its ubiquitination (Simonsson M et al 
2005). Therefore, we speculate that SAHA can stabilize Smad7 by inducing its 
hyperacetylation, and also participate in inhibiting TGFβ1 signaling.  
 
4.6 Inhibitory potential of HDAC inhibitors on the motility of 
myofibroblasts 
Our observation that α-tubulin became hyperacetylated in human lung fibroblasts in 
response to SAHA strongly indicates that HDAC6, a microtubule-associated deacetylase 
(Hubbert C et al 2002), is inhibited. This finding is highly relevant to the issue of 
fibroblast motility, which is shown to be strongly compromised in a situation of HDAC6 
overexpression (Tran AD et al 2007). (Cross)inhibition of HDAC6 as done here with 
SAHA would have basically the same effect meaning an inhibition of the invasive and 
contractile motility of myofibroblasts. Another aspect of HDAC6 inhibition is that this 
would prevent the TGFβ1-induced epithelial-mesenchymal transition which is 
accompanied by a HDAC6-dependent deacetylation of α-tubulin (Shan B et al 2008). It is 
therefore tempting to speculate that SAHA potentially prevents the transition of airway 
epithelial cells to mesenchymal cells/myofibroblasts, a mechanism that has been 
implicated in fibroproliferative disorders (Xu J et al 2009). 
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4.7 The anti-inflammatory property of HDAC inhibitors might be beneficial 
for fibroproliferative diseases 
It is well-known that inflammation typically precedes fibrosis in fibroproliferative 
diseases (Wynn TA 2007). From the work of our (Wang Z et al 2009) and other groups 
(Bode KA et al 2007), SAHA is also shown to have an anti-inflammatory potential. A 
reduced secretion of cytokines was observed in activated lymphocytes and PBMC. Our 
observation of reduced secretion of IL-13 from lymphocytes in response to SAHA might 
be significant, as IL-13 is known to play a dominant role in pulmonary fibrosis. 
Overexpression of IL-13 in the lung generates severe subepithelial airway fibrosis (Zhu Z 
et al 1999). IL-13 induces the production of TGFβ1 in macrophages and also indirectly 
activates latent TGFβ1 by stimulating MMP production (Lanone S et al 2002). 
Furthermore, IL-13 increases the expression of α-SMA and collagen III in human 
primary lung fibroblasts, and induces apoptosis in lung epithelia or epithelial cell lines 
(Borowski A et al 2008). We also found that IL-10 was reduced in PBMC and its 
subpopulations. The exact role of this cytokine in pulmonary fibrosis remains to be 
established. Although delivery of IL-10 plasmid inhibits bleomycin-induced pulmonary 
fibrosis (Nakagome K et al 2006), transgenic mice overexpressing IL-10 develop 
pulmonary inflammation and subepithelial fibrosis with an accumulation of TGFβ1 (Lee 
CG et al 2002). In accordance, IL-10 augments the fibrotic responses to inhaled silica 
particles as seen from IL-10 deficient mice (Barbarin V et al 2004) and overexpression of 
IL-10 by adenoviral gene transfer (Barbarin V et al 2005). In vitro, IL-10 also induces 
TGFβ1 expression in alveolar macrophages ((Barbarin V et al 2004). Hence, inhibition of 
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The aim of this study was to evaluate the antifibrotic potential of HDACis in fibroblast 
cultures. Three HDACis TSA, M344, and SAHA were tested. The preliminary data from 
these HDACis showed that they can inhibit TGFβ1-induced pro-fibrotic responses in a 
normal FLF line (i. e. collagen production and α-SMA expression). Preliminary data 
showed that the three HDACis can all inhibit TGFβ1-induced collagen production and α-
SMA expression. This was expected as they all belong to the hydroxamate group and 
have similar chemical structures. Among the three inhibitors, TSA was the most potent 
among the three inhibitors in achieving the antifibrotic effects in the normal FLF line. For 
example, TSA at 1 μM can inhibit TGFβ1-induced collagen production and α-SMA 
expression, which was the 1/5 dose of that of M344 and SAHA. This finding is also in 
line with the potency of the three inhibitors in inhibiting the activity of HDACs in vitro 
(Arts et al 2007). 
 
Although the three inhibitors are all effective, we decided to focus on SAHA because it is 
an FDA-approved drug already in clinical use, and hence is more promising than the 
other two inhibitors at this stage for the translational purposes. We further examined the 
potential antifibrotic effects of SAHA in (i) normal and IPF adult lung fibroblast lines 
and (ii) primary normal skin, hypertrophic scar and keloid fibroblasts. We showed that 
SAHA limited the pro-fibrotic response induced by TGFβ1 in IPF fibroblasts as well as 
fetal and normal adult lung fibroblasts without inducing apoptosis. SAHA also interfered 
with the pro-fibrotic effects of TGFβ1 in normal and fibrotic (hypertrophic scar and 
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keloid) skin fibroblasts. This was demonstrated by the restoration of collagen I deposition 
to normal levels and the suppression of α-SMA expression.  
 
We also investigated the potential fibrolytic properties of SAHA by testing fibroblast 
collagenase MMP1 and its inhibitor TIMP1, both of which are responsible for the 
remodeling of extracellular matrix. Surprisingly, the total potentially activated-MMP1 
was doubled by TGFβ1 in adult lung fibroblasts and IPF fibroblasts. SAHA reversed it to 
the basal level. SAHA has been reported to inhibit TGFβ1-induced TIMP1 expression in 
mouse fibroblast (Young DA 2005). However, in our study, SAHA had no effect on 
TGFβ1-induced TIMP1 production in human normal and IPF lung fibroblasts, and it even 
induced a further increase of TIMP1 in fetal lung fibroblasts. Therefore, it is conceivable 
that the net reduction of collagen deposition might be accredited to the effects of SAHA 
on collagen synthesis and secretion rather than on collagen turnover. Also we are the first 
to show that SAHA inhibited lung fibroblast proliferation in serum. 
 
In conclusion, this study has provided valuable insights into the antifibrotic potential of 
HDACis. The finding may provide a novel solution for treating fibroproliferative diseases 
and preventing peri-implantational fibrosis. Also, it is important to note that a key 
contribution of this study is to demonstrate the antifibrotic potential of SAHA. This study 
has provided the evidence that antifibrosis could be a new indication of SAHA, which 
was originally developed as an anti-cancer drug. Another important aspect of this study is 
to evaluate potential antifibrotic drugs under the conditions of enhanced matrix formation 
brought about by macromolecular crowding. We believe that such a biophysical culture 
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environment is better than standard conditions in generating a comprehensive and 
functional extracellular matrix in a short time frame with all biochemical processes that 
represent fibrogenesis and fibrolysis in place. This should add further weight to the 
conclusion that SAHA possesses antifibrotic properties and is worth further exploration 
as a therapeutic option for fibroproliferative diseases and peri-implanational fibrosis. 
 
Although we have provided convincing data to demonstrate the antifibrotic potential of 
SAHA in lung and skin fibroblast, its mode-of-action is still unknown. It will be 
interesting to investigate how SAHA regulates the expression network of genes involved 
in fibrosis, especially genes regulated by TGFβ1 signaling. In order to address this issue, 
we will conduct gene microarray analysis and verify the gene expression by qPCR in 
future work. Based on the analysis of the gene microarray we will select interesting genes 
to further study the activation of promoter region of these genes by chromatin 
immunoprecipitation (ChIP) assay. Apart from exploring the molecular mechanism of 
SAHA, another aspect of the future work may be focused on the antifibrotic effect of 
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Suberoylanilide hydroxamic acid: a
potential epigenetic therapeutic agent for
lung fibrosis?
Z. Wang*, C. Chen*, S.N. Finger#, S. d/o Kwajah M.M#, M. Jung", H. Schwarz#,
N. Swanson+, R.R. Lareu*,+,1 and M. Raghunath*,e
ABSTRACT: Pulmonary fibrosis represents a fatal stage of interstitial lung diseases of known and
idiopathic aetiology. No effective therapy is currently available. Based on an indication-discovery
approach we present novel in vitro evidence that the histone deacetylases inhibitor
suberoylanilide hydroxamic acid (SAHA), an FDA approved anti-cancer drug, has antifibrotic
and anti-inflammatory potential.
Human lung fibroblasts (fetal, adult and idiopathic adult pulmonary fibrosis) were treated with
transforming growth factor (TGF)-b1 with or without SAHA. Collagen deposition, a-smooth muscle
actin (a-SMA) expression, matrix metalloproteinase (MMP)1 activity, tissue inhibitor of MMP
(TIMP)1 production, apoptosis and cell proliferation were assessed. Pro-inflammatory cytokines
relevant to pulmonary fibrosis were assayed in SAHA-treated human peripheral blood mono-
nuclear cells (PBMC) and its subpopulations.
SAHA abrogated TGF-b1 effects on all the fibroblast lines by preventing their transdifferentia-
tion into a-SMA positive myofibroblasts and increased collagen deposition without inducing
apoptosis. However, MMP1 activity and TIMP1 production was modulated without a clear
fibrolytic effect. SAHA also inhibited serum-induced proliferation of the fibroblast lines and
caused hyperacetylation of a-tubulin and histone. Cytokine secretion was inhibited from PBMC
and lymphocytes at nonapoptotic concentrations.
Taken together, these data demonstrate combined antifibrotic and anti-inflammatory properties
of SAHA, suggesting its therapeutic potential for pulmonary fibrosis.
KEYWORDS: Antifibrotic, collagen, fibroblast, histone deacetylase inhibitor, pulmonary fibrosis,
suberoylanilide hydroxamic acid
I
nterstitial lung diseases constitute a diverse
set of lung disorders with different levels of
inflammation and fibrosis resulting in irre-
versible loss of lung function and ultimately
respiratory failure [1]. The most common repre-
sentative of interstitial lung diseases is idiopathic
pulmonary fibrosis (IPF). The general pathologi-
cal feature of IPF is the excessive deposition of
collagen I which destroys the architecture of the
normal lung parenchyma [2]. Patients with IPF
have a median survival of 2–3 yrs after diagnosis
[1]. The current therapy for IPF is based on
reducing inflammation with corticosteroids and
immunosuppressive drugs. However, the appar-
ent ineffectiveness of this regimen has led to
doubts about the initial role of inflammation in
the pathogenesis of IPF [3, 4] and to the concept
that correcting the activated state of IPF fibro-
blasts/myofibroblasts [5] might be more impor-
tant than an anti-inflammatory strategy. New
therapeutic strategies, including antioxidant
agents, anti-endothelial cell antibody, anti-cyto-
kine therapy and antifibrotic agents, such as
pirfenidone, have been evaluated in clinical trials
without showing significant improvement in the
treatment of IPF [6]. Clearly, IPF remains a large
therapeutic challenge and the development of
effective antifibrotic drugs is urgently required.
To explore new antifibrotic drugs, we have been
investigating the therapeutic potential of histone
deacetylase inhibitors (HDACi). HDACi are
small organic molecules which change gene
expression profiles at the epigenetic level and
change protein function by inhibiting the activity
of histone deacetylases. HDACi are of prime
interest in cancer research because they induce
apoptosis and cell cycle arrest in malignant cells
and are anti-angiogenic [7]. Recently published
studies suggested that HDACi might also inhibit
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collagen production in different fibroblast types. Phenyl-
butyrate decreased basal levels and transforming growth factor
(TGF)-b1-stimulated a1(I) collagen messenger RNA (mRNA)
and protein levels in the lung fetal fibroblast IMR-90 [8].
Trichostatin A (TSA) was reported to inhibit synthesis of
collagen type I and III and a-smooth muscle actin (a-SMA)
both at the protein and mRNA level in primary cultured rat
hepatic stellate cells [9], and in TGF-b1-stimulated rat skin
fibroblasts [10]. In addition, collagen production from systemic
sclerosis fibroblasts was inhibited and total collagen deposition
was reduced in bleomycin-induced skin fibrosis in mice by TSA
[11].
Based on an indication-discovery approach, we evaluated suber-
oylanilide hydroxamic acid (SAHA) (Zolina1 (vorinostat), an
FDA-approved HDACi, which is already in clinical use as a
third-line drug for the treatment of cutaneous T-cell lymphoma
and under evaluation for other types of cancer [12]. Herein, we
studied the antifibrotic potential of SAHA in TGF-b1-treated
fetal lung fibroblasts (FLF), adult lung fibroblasts (ALF) and IPF
lung fibroblast (ILF) lines, and its potential anti-inflammatory
effect in peripheral blood mononuclear cells (PBMC), lympho-
cytes and peripheral monocytes.
MATERIALS AND METHODS
Compounds and reagents
SAHA was synthesised as described previously [13], dissolved
in dimethyl sulfoxide to 50 mM and stored at -80uC. All
reagents were from Sigma Aldrich (St. Louis, MI, USA) unless
stated otherwise.
Treatment of lung fibroblast lines
Normal human FLF IMR-90 (CCL-186; ATCC, Manassas, VA,
USA), ALF CCD-19 Lu (CCL-210; ATCC) and ILF LL29 (CCL-
134; ATCC) were cultured in 10% fetal bovine serum (FBS)
Dulbecco’s modified Eagle medium (GIBCO Invitrogen,
Singapore). Cells, except for proliferation assays, were seeded
at 16104?well-1, 56104?well-1 and 2.56105?well-1 in 96-, 24-
and 6-well plates, respectively. After 24 h, fibroblasts were
treated with different concentrations of SAHA with or without
TGF-b1 (5 ng?mL-1; R&D Systems, Minneapolis, MN, USA) in
serum-free Dulbecco’s modified Eagle medium plus
30 mg?mL-1 ascorbic acid phosphate (Wako Pure Chemicals
Industries Ltd, Osaka, Japan) in the presence of 100 mg?mL-1
dextran sulfate 500 kDa (pK Chemicals A/S, Koge, Denmark),
for the rapid deposition of collagen I within 24 h [14].
Quantitative immunocytochemistry
Fibroblasts cultured in 96-well Lumox plates with an optical
bottom (Greiner BioOne, Gottingen, Germany) were fixed with
absolute methanol and air dried for 15 min. Cell layer was
blocked with 3% bovine serum albumin in PBS for 30 min
followed by incubation with primary antibodies for 90 min.
Secondary antibodies and nuclear stain 4,6-diamidino-2-
phenylindole (DAPI; Invitrogen Molecular Probes, Carlsbad,
CA, USA) were stained for 30 min. The cell layer was washed
with PBS three times after each step. Antibodies against
collagen type I (1:500), a-SMA (1:100; Dako, Glostrup,
Denmark) or acetylated a-tubulin (1:500) were from mouse
and acetylated histone 3 (1:200; Upstate Biotechnology, New
York, NY, USA) from rabbit. Secondary antibodies were Alexa
Fluor (AF) 594 goat anti-mouse and AF488 goat anti-rabbit
(both 1:400; Invitrogen Molecular Probes). The fluorescence
intensity was quantified using the PHERAstar microplate
reader with a focusing lens system (BMG Labtech,
Mornington, Australia). The ratio of the fluorescence intensity
of the AF dye to DAPI was used to normalise the relative
amount of the antigen to cell number. Images were taken with
an Olympus LX71 epifluorescence microscope (Olympus,
Tokyo, Japan).
Biochemical assay of collagen matrix
Deposited collagen was extracted from cell cultures and
analysed as described previously [14]. Briefly, cell layers in
24-well plates were digested in situ with 250 mg?mL-1 porcine
gastric mucosa pepsin (Roche, Basel, Switzerland) in 0.1 M
HCl for 2 h and neutralised with 1 M NaOH. Extracts were
visualised using SDS-PAGE gels with silver staining and
analysed by densitometry.
Western blot
Western blots were performed as previously described [14].
Briefly, proteins were extracted with loading buffer (50 mM
Tris-Cl pH 6.8, 2% SDS, 0.1% bromophenol blue and 10%
glycerol) with 5 mM dithiothreitol and separated on 10% SDS-
PAGE gels. Primary antibodies against acetylated a-tubulin
(1:2500), a-SMA (1:500) and b-actin (1:1000) were from mouse,
and acetylated histone 3 (1:3000; Upstate Biotechnology) from
rabbit. Secondary antibodies were goat anti-mouse and goat
anti-rabbit horse radish peroxidase (both 1:1000; Pierce,
Rockford, IL, UK). Blots were developed with AmershamTM
ECL plus Western blotting detection system (GE Healthcare,
Chalfont St Giles, UK) and chemiluminescence was captured
with a VersaDoc Imaging System model 5000 (Bio-Rad,
Hercules, CA, USA).
Flow cytometry analysis of a-SMA expression
Fibroblasts in suspension were fixed with 2% paraformalde-
hyde in PBS and permeabilised with 0.1% saponin in PBS for
15 min. The suspension was incubated with mouse anti-a-
SMA (1:1000) and AF488 chicken anti-mouse (1:100; Invitrogen
Molecular Probes), each for 30 min at 4uC. The cells were
washed with PBS twice after each step. AF488 was detected by
flow cytometry.
Adherent cytometry
For proliferation assay, cells were seeded at 26104?well-1 in 24-
well plate and cultured in 10% FBS in the presence or absence
of 5 mM SAHA. After 3 days, fibroblasts were stained with
DAPI after methanol fixation. Nine image sites covering 71% of
the total well area were acquired at 26magnification using a
Nikon TE600 fluorescence microscope with an automated Ludl
stage (BioPrecision 2; Ludl Electronic Products Ltd,
Hawthorne, NY, USA) and analysed using the Metamorph1
Imaging System software (Molecular Devices, Downingtown,
PA, USA). A nucleus was defined as a fluorescent region with
a length of 10–15 mm and a pixel intensity value of 10 units
above background.
Carboxyfluoroscein succinimidyl ester labelling and
detection
Fibroblasts at 106?mL-1 were pre-labelled with 2 mM carboxy-
fluoroscein succinimidyl ester (CFSE; Invitrogen Molecular
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FIGURE 1. Suberoylanilide hydroxamic acid (SAHA) induces hyperacetylation of histone and a-tubulin. Fetal lung fibroblasts (FLF), adult lung fibroblasts (ALF) and
idiopathic pulmonary fibrosis lung fibroblasts (ILF) were treated with or without transforming growth factor (TGF)-b1 (5 ng?mL-1) and 5 mM SAHA for 24 h. The acetylation of
histone 3 and a-tubulin were quantified by quantitative immunocytochemistry (QICC) and Western blot. a, b) Immunocytochemistry of acetylation of histone 3 (green) and a-
tubulin (red) in a–d) FLF (IMR-90), e–h) ALF (CCD-19 Lu) and i–l) ILF (LL29). Scale bars550 mm. m–o) Average fold change of acetylation of histone 3 (h) and a-tubulin (&)
from quadruplicates were quantified by QICC. m) FLF, n) ALF and o) ILF. *: p,0.05 compared with untreated control. p) Western blots of acetylated histone 3 and acetylated
a-tubulin.
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Probe). With or without 5 mM SAHA, 16105 cells?well-1 were
seeded into 6-well plate and cultured in 10% FBS. After 3 days,
fibroblasts were trypsinised, washed twice with PBS and CFSE
was detected by flow cytometry.
Matrix metalloproteinase 1 activity and tissue inhibitor of
matrix metalloproteinase 1 ELISA
Fibroblasts were treated with or without TGF-b1 (5 ng?mL-1)
and SAHA at 5 mM for 24 h. Matrix metalloproteinase (MMP)1
activity and tissue inhibitor of MMP (TIMP)1 production were
determined using the Fluorokine E kit and the Quantikine
human TIMP1 kit (both R&D Systems) according to the
manufacturers protocol. 4-aminophenylmercuric acetate
(APMA)-activated MMP1 was detected by cleavage of
fluorescence-labelled substrate peptide. Concentrations of
active MMP1 and TIMP1 were calculated from standard
curves obtained from standards run in parallel.
Apoptosis assay
Briefly, 106 fibroblasts, PBMC, lymphocytes or monocytes were
stained with 100 mL fluorescein isothiocyanate-annexin V and
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FIGURE 2. Suberoylanilide hydroxamic acid (SAHA) inhibits transdifferentiation of fibroblasts into myofibroblasts. a) Fetal lung fibroblasts (FLF), b) adult lung fibroblasts
(ALF) and c) idiopathic pulmonary fibrosis lung fibroblasts (ILF) were treated with or without transforming growth factor (TGF)-b1 (5 ng?mL-1) and increasing concentrations of
SAHA (2.5, 5 and 10 mM) for 24 h. The expression of a-smooth muscle actin (a-SMA) was evaluated by quantitative immunocytochemistry (QICC) and Western blot. a–c)
Representative immunocytochemistry images (a-SMA, red; DAPI, blue). Scale bars550 mm. d) Western blots of a-SMA. e) Average a-SMA fold changes from quadruplicates
were quantified by QICC. *: p,0.05 compared with untreated control. f) Flow cytometry analysis of the percentage of a-SMA positive cells.
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temperature using Annexin-V-FLUOS staining kit (Roche,
Penzberg, Germany) according to the manufacturers protocol.
The percentages of annexin-V single positive, annexin-V/PI
double-positive and annexin-V/PI double-negative cells were
determined by flow cytometry.
Treatment of PBMC and its subpopulations and
cytokines ELISA
Human PBMC were isolated from buffy coats using
Histopaque-1077 (Sigma Aldrich) from blood of healthy
volunteers at the National University Hospital (Singapore)
under informed consent and local international review board
(National University Hospital) approval. Monocytes were
further isolated from PBMC with the human Monocyte
Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany).
Lymphocytes were isolated as the cells remained on the
magnetic column after removal of monocytes. PBMCs, lympo-
cytes and monocytes were seeded at 16106?mL-1 in 10% FBS
RPMI-1640 and incubated with 0.5 ng?mL-1 phorbol myristate
acetate plus 50 nM calcium ionophore A23187 (PMA/CI)
alone or with 0.5 or 1 mM SAHA for 24 or 48 h. Supernatants
were collected and frozen at -20uC. The cytokines assayed were
tumour necrosis factor (TNF)-a, interleukin (IL)-13, IL-10
(eBioscience, San Diego, CA, USA), IL-6, IL-8 and TGF-b1
(R&D Systems) following the manufacturers protocol.
Statistical analysis
Statistical analysis was performed using SPSS 12.0. (SPSS Inc.,
Chicago, IL,USA)EqualityoferrorvarianceswastestedbyLevene’s
test. Data with equal variances were compared by Turkey test and
data with unequal variances by Dunnet’s T3 test. Probability values
of p,0.05 were accepted as the level of statistical significance.
RESULTS
SAHA induces hyperacetylation of histone 3 and a-tubulin
Basal acetylation levels of histone and a-tubulin were noted in
untreated FLF, ALF and ILF, but were significantly increased
in the presence of SAHA after 24 h as assessed by quantitative
immunocytochemistry (QICC; fig. 1a–o) and Western blot
(fig. 1p), indicating that SAHA inhibited HDACs activity.
TGF-b1 did not change the acetylation of histone 3 and a-
tubulin significantly in the presence or absence of SAHA.
SAHA inhibits TGb-1-induced myofibroblast
transdifferentiation
Untreated cell cultures of all the fibroblasts lines showed low
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FIGURE 3. Suberoylanilide hydroxamic acid (SAHA) inhibits transforming growth factor (TGF)-b1-induced collagen production. Fetal lung fibroblasts (FLF), adult lung
fibroblasts (ALF) and idiopathic pulmonary fibrosis lung fibroblasts (ILF) were treated with or without TGF-b1 (5 ng?mL-1) and increasing concentrations of SAHA (2.5, 5, 10
and 20 mM) for 24 h. The expression of collagen I was quantified by quantitative immunocytochemistry (QICC) and SDS-PAGE. a–c) Representative immunocytochemistry
(collagen I, red; DAPI, blue). Scale bars550 mm. d) Representative SDS-PAGE from three independent experiments. e) Average collagen fold changes were quantified from
quadruplicates by QICC and three independent SDS-PAGE gels by biochemical assay. Statistically significant differences in collagen deposition quantified by QICC (h) and
biochemical assay (&).*: p,0.05 compared with untreated control.
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Western blot (fig. 2d), and flow cytometry analyses (fig. 2f).
Microscopy revealed that this was due to a few interspersed cells
that were positive for a-SMA. Although TGF-b1 triggered
transdifferentiation of the majority of fibroblasts into myofibro-
blasts in all three fibroblast lines, ILF were the most responsive
with a 14-fold enhanced a-SMA expression followed by eight-
fold in ALF and five-fold in FLF, as assessed by QICC (fig. 2e).
SAHA abolished this effect in a dose-dependent manner from 2.5
to 10 mM by both reducing the expression of a-SMA and
percentage of a-SMA positive fibroblasts (fig. 2).
SAHA inhibits TGb-1-induced collagen production
Both QICC (fig. 3a–c) and quantitative gel electrophoresis
(fig. 3d) demonstrated increased collagen deposition in
response to TGF-b1. ILF were the most responsive with an
increase of 3–4-fold in comparison with 1.5–2-fold in FLF and
ALF, respectively (fig. 3e). SAHA abrogated TGF-b1-induced
collagen deposition dose-dependently in all the fibroblasts
lines. At 10 mM, SAHA completely counteracted the effect of
TGF-b1 on ILF by limiting collagen deposition to pre-treatment
levels, and 5 mM on FLF and ALF. However, SAHA alone did
not significantly affect the basal level of collagen deposition in
the three fibroblast lines.
SAHA regulates MMP1 and TIMP1 differentially in tested
fibroblasts
TGF-b1 reduced the total potentially activated (APMA-
activated) MMP1 in FLF to one-third, but doubled it in ALF
and ILF. In FLF, 5 mM SAHA had no effect on TGF-b1-reduced
MMP1, whereas it decreased MMP1 to the basal level in ALF
and ILF. SAHA alone inhibited APMA-activated MMP1 in FLF
by ,50%, but did not affect MMP1 in ALF and ILF (fig. 4a–c).
TIMP1 was increased by TGF-b1 in all three fibroblast lines to
2–2.5-fold. It was further induced by SAHA only in FLF, but
remained unchanged in ALF and was reduced slightly in ILF.
SAHA alone did not change TIMP1 production significantly
(fig. 4d–f).
SAHA is not pro-apoptotic in the tested fibroblasts
Annexin V and PI staining showed that SAHA at 5 mM did not
induce apoptosis in all three fibroblast lines in the presence or
absence of TGF-b1 (fig. 5).
SAHA inhibits serum-induced fibroblast proliferation
Adherent cytometry revealed that 5 mM SAHA inhibited
proliferation of the three fibroblast lines in 10% FBS after the












































































































FIGURE 4. Suberoylanilide hydroxamic acid (SAHA) regulates matrix metalloproteinase (MMP)1 and tissue inhibitor of MMP (TIMP)1 differentially in tested fibroblasts. a,
d) Fetal lung fibroblasts (FLF), b, e) adult lung fibroblasts (ALF), and c, f) idiopathic pulmonary fibrosis lung fibroblasts (ILF) were treated with or without transforming growth
factor (TGF)-b1 (5 ng?mL-1) and SAHA at 5 mM for 24 h. Media were collected and analysed for 4-aminophenylmercuric acetate (APMA)-active MMP1 activity and TIMP1 by
ELISA. The experiments were performed three times with three different batches of samples, and one representative result was used to show the averages of a–c) APMA-
activated MMP1 and d–f) TIMP1 from duplicates of each condition. *: p,0.05 compared with untreated control.
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Higher fluorescence intensity of CFSE was detected in SAHA-
treated fibroblasts suggesting reduced cell proliferation
(fig. 6d).
SAHA changes cytokine release in activated PBMC and
its subpopulations
SAHA at concentrations applied for fibroblast cultures induced
apoptosis in PBMC and its subpopulations, and thus its anti-
inflammatory property was tested at lower concentrations (0.5
and 1 mM) without affecting cell viability (data not shown). In
PBMC and lymphocytes stimulated with PMA/CI, secretion of
TNF-a, IL-8, IL-13 and IL-10 were decreased, while levels of
TGF-b1 remained unchanged. SAHA did not alter secretion
of IL-6 in PBMC, but reduced it in lymphocytes. In monocytes
under the same stimulus, SAHA decreased secretion of IL-10
without affecting the other tested cytokines (fig. 7, table 1).
DISCUSSION
In the past 15 yrs, the incidence and mortality of pulmonary
fibrosis, particularly IPF, has increased significantly in patients
aged .50 yrs [15]. No current treatment can effectively stop
the pathological scarring process in the lung parenchyma.
Several potential antifibrotic drugs are in different phases of
clinical trials, but a clear benefit is still not in sight [6].
Therefore, we have explored new indications for drugs already
in clinical use, which could potentially broaden and accelerate
the therapeutic options for pulmonary fibrosis.
We have shown that the anti-cancer drug SAHA limits the pro-
fibrotic response induced by TGF-b1 in ILF, as well as FLF and
ALF, without inducing apoptosis. This was demonstrated by
the restoration of collagen I deposition to normal levels
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FIGURE 5. Suberoylanilide hydroxamic acid (SAHA) is not pro-apoptotic in fetal lung fibroblasts (top row), adult lung fibroblasts (middle row) and idiopathic pulmonary
fibrosis lung fibroblasts (bottom row). Fibroblasts were treated with or without transforming growth factor (TGF)-b1 (5 ng?mL-1) and SAHA at 5 mM for 24 h. Cells were stained
with annexin V and propidium iodide (PI). The percentage of apoptotic (annexin-V single positive) and necrotic (annexin-V/PI double-positive) cells are labelled at the
corresponding regions of each graph, and that of living cells (annexin-V/PI double-negative) above each graph.
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compound inhibited the transdifferentiation of fibroblasts to
myofibroblasts, the cell type primarily responsible for patho-
logical matrix accumulation. We also investigated the potential
fibrolytic properties of SAHA and tested fibroblast collagenase,
MMP1 and its inhibitor TIMP1, components responsible for
remodeling of extracellular matrix. Surprisingly, the total
potentially activated-MMP1 was doubled by TGF-b1 in ALF
and ILF. SAHA reversed it to the basal level. SAHA has been
reported to inhibit TGF-b1-induced TIMP1 expression in
mouse fibroblast [16]. However, in our hands SAHA had no
effect on TGF-b1-induced TIMP1 production in human normal
and ILF, and it even induced a further increase of TIMP1 in
FLF. Therefore, it is conceivable that the net reduction of
collagen deposition might be accredited to the effects of SAHA
on collagen synthesis and secretion rather than collagen
turnover. We have also shown the first evidence that SAHA
inhibited fibroblast proliferation in serum.
SAHA is known as a broad-spectrum HDACi [17]. In
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FIGURE 6. Suberoylanilide hydroxamic acid (SAHA) inhibits fibroblast proliferation. a) Fetal lung fibroblasts (FLF), b) adult lung fibroblasts (ALF) and c) idiopathic
pulmonary fibrosis lung fibroblasts (ILF) were cultured in 10% fetal bovine serum (FBS) with (#) or without (h) SAHA at 5 mM. Averages of cell numbers from triplicates were
quantified by adherent cytometry at each time-point up to 3 days. *: p,0.05 compared with fibroblasts cultured in 10% FBS at the same time-point. d) Changes of
carboxyfluoroscein succinimidyl ester (CFSE) fluorescence intensity after 3 days without SAHA (top row) or with 5 mM SAHA (bottom row).
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FIGURE 7. Suberoylanilide hydroxamic acid (SAHA) changes cytokine release in peripheral blood mononuclear cells (PBMC) and its subpopulations. a–c) tumour
necrosis factor (TNF)-a, d–f) interleukin (IL)-6, g–i) IL-8, j, k) IL-13, l–m) IL-10, and o–q) transforming growth factor (TGF)-b1. SAHA at 0.5 or 1 mM was added to PBMC (a, d, g,
j, l, and o), lymphocytes (b, e, h, k, m and p) or peripheral monocytes (c, f, i, n and q) stimulated by 0.5 ng?mL-1 phorbol myristate acetate plus 50 nM calcium ionophore for
24 h (h) or 48 h (&). The experiments were performed three times with cells from three different donors. The averages of duplicate measurements from one representative
experiment are shown. *: p,0.05 compared with untreated control.
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that inhibiting HDAC activity by SAHA interferes with the
pro-fibrotic effects of TGF-b1. Although Smad expression and
activation are not significantly altered in the presence of TSA,
TGF-b1-induced expression of Sp1, an essential transcription
factor of Smad-dependent collagen synthesis, is inhibited by
TSA in foreskin fibroblasts [18]. Another line of evidence is that
HDAC4, and to a lesser extent HDAC6 and HDAC8, are
required for TGF-b1-induced myofibroblastic differentiation.
In particular, the expression of the endogenous repressor of the
TGF-b1 pathway, 59-TG-39-interacting factor, is stimulated by
silencing HDAC4 [19]. As further evidence for the broad-
spectrum effects of SAHA, we observed hyperacetylated a-
tubulin in human lung fibroblasts in response to SAHA. This
strongly indicates that HDAC6, a microtubule-associated
deacetylase [20], is inhibited. Of note, fibroblast motility is
strongly compromised with HDAC6 inhibition [21]. Therefore,
(cross)inhibition of HDAC6 with SAHA might have an
additional beneficial effect by inhibiting the invasive and
contractile motility of myofibroblasts.
It is well known that inflammation typically precedes fibrosis
in fibroproliferative diseases [22]. However, the role of
inflammation in the early pathogenic stage of IPF is under
debate because current anti-inflammatory therapy seems to be
ineffective in IPF, yet patchy chronic interstitial inflammation
is observed in the pathology of IPF [5]. Therefore, we also
investigated the anti-inflammatory potential of SAHA. As the
concentrations applied in fibroblast cultures caused apoptosis
in PBMC and its subpopulations, we lowered the concentra-
tions by five to 10 times, which is also in accordance with an
earlier study [23]. A reduced secretion of cytokines was
observed in PMA/CI activated lymphocytes and PBMC. Our
observation of reduced secretion of IL-13 from lymphocytes in
response to SAHA might be significant, as IL-13 is known to
play a dominant role in pulmonary fibrosis. Overexpression of
IL-13 in the lung generates severe subepithelial airway fibrosis
[24]. IL-13 induces the production of TGF-b1 in macrophages
and also indirectly activates latent TGF-b1 by stimulating
MMP production [25]. Furthermore, IL-13 increases the
expression of a-SMA and collagen III in human primary lung
fibroblasts, and induces apoptosis in lung epithelia or
epithelial cell lines [26]. We also found that IL-10 was reduced
in PBMC and its subpopulations. The exact role of this
cytokine in pulmonary fibrosis remains to be established.
Although delivery of IL-10 plasmid inhibits bleomycin-
induced pulmonary fibrosis [27], transgenic mice over expres-
sing IL-10 develop pulmonary inflammation and subepithelial
fibrosis with an accumulation of TGF-b1 [28]. In accordance,
IL-10 augments the fibrotic responses to inhaled silica particles
as seen in IL-10 deficient mice [29] and over expression of IL-10
by adenoviral gene transfer [30]. In vitro, IL-10 also induces
TGF-b1 expression in alveolar macrophages [29]. Hence,
inhibition of IL-13 and IL-10 by SAHA may have additional
beneficial effects in IPF.
Of note, this is the first study evaluating a potential antifibrotic
drug under conditions of enhanced matrix formation induced
by macromolecular crowding [14]. We believe that such a
biophysical culture environment is better suited than standard
conditions in generating a comprehensive and functional
extracellular matrix in a short-time frame, with all biochemical
processes in place that represent fibrogenesis and fibrolysis
[14]. This should add further weight to the conclusion derived
herein, that SAHA possesses antifibrotic properties and is
worth further exploration for a therapeutic option for
pulmonary fibrosis.
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The Scar-in-a-Jar: studying potential antifibrotic
compounds from the epigenetic to extracellular
level in a single wellbph_387 1196..1209
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Background and purpose: Fibrosis, a pathological accumulation of collagen in tissues, represents a major global disease
burden. Effective characterization of potential antifibrotic drugs has been constrained by poor formation of the extracellular
matrix in vitro, due to tardy procollagen processing by collagen C-proteinase/BMP-1, and difficulties in relating this matrix to
cell numbers in experimental samples.
Experimental approach: The Scar-in-a-Jar model provided, in vitro, the complete biosynthetic cascade of collagen matrix
formation including complete conversion of procollagen by C-proteinase/BMP-1, its subsequent extracellular deposition and
lysyl oxidase-mediated cross-linking, achieved by applying the biophysical principle of macromolecular ‘crowding’. Collagen
matrix deposition, velocity and morphology can be controlled using negatively charged ‘crowders’ in a rapid (2 days) mode
or a mixture of neutral ‘crowders’ in an accelerated (6 days) mode. Combined with quantitative optical bioimaging, this novel
system allows for in situ assessment of the area of deposited collagen(s) per cell.
Key results: Optical evaluation of known and novel antifibrotic compounds effective at the epigenetic, post-transcriptional/
translational/secretional level correlated excellently with corresponding biochemical analyses. Focusing on quantitation of
deposited collagen, the Scar-in-a-Jar was most effective in assessing novel inhibitors that may have multiple targets, such as
microRNA29c, found to be a promising antifibrotic agent.
Conclusions and implications: This novel screening system supersedes current in vitro fibroplasia models, as a fast, quanti-
tative and non-destructive technique. This method distinguishes a reduction in collagen I deposition, excluding collagen
cross-linking, and allows full evaluation of inhibitors of C-proteinase/BMP-1 and other matrix metalloproteinases.
British Journal of Pharmacology (2009) 158, 1196–1209; doi:10.1111/j.1476-5381.2009.00387.x; published online 28
September 2009
Keywords: fibrosis; drug discovery; collagen quantitation; bioimaging; macromolecular crowding; high content screening
Abbreviations: BAPN, b-aminopropionitrile; CPX, ciclopiroxolamine; DxS, dextran sulphate (rapid deposition mode); FBS,
fetal bovine serum; Fc, Ficoll cocktail (accelerated deposition mode); FIT, fluorescence intensity; Fn, fibronec-
tin; FP, fibroplasia model; I29c, inhibitor miR29c; M29c, mimic miR29c; MMP1, matrix metalloproteinase 1;
miRNA, microRNA; PBS, phosphate-buffered saline; PDCA, 2,4-pyridinedicarboxylic acid; SDS-PAGE,
sodium dodecylsulphate-polyacrylamide gel electrophoresis; TGFb1, transforming growth factor-b1; TSA,
trichostatin A
Introduction
Scarring is a physiological tissue response to wounding that
has been highly conserved in evolution and across species. As
the last phase of wound-healing, it is usually self-contained.
However, if this phase is perpetuated by repeated tissue insults
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and/or ongoing inflammation, fibrosis ensues. Fibrosis is his-
topathologically characterized by an excessive production
and deposition of collagen that converts normal tissue into
scar tissue with associated loss of function. Therefore, causes
as diverse as chronic infections, radio- and chemotherapy,
chronic exposure to alcohol and other toxins can all lead to
fibrosis with a considerable global disease burden. It is esti-
mated that there are five million cases of lung fibrosis world-
wide (Meltzer and Noble, 2008). A major cause for liver
fibrosis is chronic hepatitis virus B (HBV) and C (HCV) infec-
tion. One million people die every year from complications of
chronic HBV, mainly primary hepatocellular carcinoma and
liver fibrosis. Of those exposed to HCV, 12% (about 24
million) develop liver cirrhosis, placing it 18th in terms of
global disease burdens (WHO, 2004). Besides afflicting whole
organs, localized fibrosis can severely impair the quality of life
in millions of patients, for example through implant failure
caused by peri-implantational fibrosis (Gristina, 1994; Tang
and Eaton, 1995).
The development of effective antifibrotic compounds is
therefore an important unmet clinical need. Rapid in vitro
screening of lead compounds before they are tested in animal
modelswill hasten the development process. However, this has
been severely hampered by biological and technical problems.
First, fibrogenic cells in monolayer culture do not lay down
significant amounts of collagen in a useful time window for
screening. It is still not widely known that this is due to a tardy
enzymatic conversion of procollagen to collagen in vitro even
under conditions of full procollagen synthesis (Lareu et al.,
2007a). On the basis of this previously unsolved biological
problem, analytical methods have mostly settled for the mea-
surement of procollagen secreted into culture medium, but
these conditions barely mimic a fibrotic situation. In order to
address this, prolonged cultures (4–6 weeks) or hyperconfluent
cell culture fibroplasia models (FP) (Clark et al., 1997) incorpo-
rating transforming growth factor-b1 (TGFb1) to stimulate
fibroblast proliferation and collagen production have been
developed. The FP model is currently the testing standard in
industry (Fish et al., 2007). Second, quantitation of cell num-
bers, required for data normalization, currently requires the
destruction of cell layers in order to normalize against protein
or DNA (Campa et al., 1990; Tredget et al., 1990). Minimally
deposited collagen in the extracellular matrix (ECM) must be
solubilized prior to analysis (Ramshaw andWerkmeister, 1988;
Anderson and Elliott, 1991), and this also applies to the FP
model (Fish et al., 2007). Third, collagen quantitation based on
the popular Picro-Sirius red dye assay (Xu et al., 2007) is non-
specific. It has low sensitivity in conditions of minimal col-
lagen deposition and is reliable only after a pre-purification
step (R.R. Lareu, D.I. Zeugolis and M. Raghunath, unpubl.
experiments). The tedious determination of hydroxyproline
content is far more collagen-specific but of limited sensitivity.
Other methods that rely on laser scanning confocal micros-
copy (Antonini et al., 1999) are slow during image acquisition
and not suitable for handling multi-well plates.
Lastly, antifibrotic compounds should preferably target col-
lagen, along with additional features characteristic for fibrosis
such as a-smooth muscle actin expression in myofibroblasts
and epithelial-mesenchymal transition. Therefore, it would
be desirable to quantitate simultaneously non-collagenous
proteins and cell proliferation. For the first time, optical
analysis and quantitation of enhanced collagen deposition
has been utilized as a non-destructive, rapid and protein




Normal primary human lung fibroblasts (WI-38 cells) were
selected on the basis of their strong collagen I production in
our hands. The cells were routinely cultured at low passage
(3–8) as outlined earlier (Lareu et al., 2007a). Fibroblasts were
seeded on 24-well plates at 50 000 cells per well in 10% fetal
bovine serum (FBS), 5% CO2 at 37°C. After 16 h, cells were
cultured under ‘crowded’ conditions, that is, with added mac-
romolecules such as negatively charged 500 kDa dextran sul-
phate (DxS) or a mixture of neutral 70 and 400 kDa Ficoll™
(Fc). To achieve this, the medium was changed to Dulbecco’s
modified Eagle’s medium (DMEM) containing 0.5% FBS,
100 mM of L-ascorbic acid 2-phosphate (as the magnesium salt
hexahydrate, a more stable form of ascorbate; Hata and Senoo
1989) with or without 500 kDa DxS (rapid mode) at
100 mg·mL-1 or a mixture of 37.5 mg·mL-1 Fc 70 with
25 mg·mL-1 Fc 400 (accelerated mode), 5 ng·mL-1 TGFb1, and
in combination with or without antifibrotic substances. Only
2,4-pyridinedicarboxylic acid monohydrate (PDCA) and
b-aminopropionitrile (BAPN) were added daily to Fc ‘crowded’
cell cultures (accelerated mode). Other substances were added
only once.
Trichostatin A (TSA, 1 mM), 300 mM PDCA dissolved in
double-distilled H2O with 655 mM sodium bicarbonate
(Sigma-Aldrich, St. Louis, MO, USA) to neutralize the pH, was
prepared and diluted to a working concentration of 10 mM
PDCA in medium. Ciclopiroxolamine (CPX, 0.5 M) stock was
prepared in methanol and diluted to a working concentration
of 1 mM CPX in DMEM prior to cell culture addition with a
final concentration of 8 mM. IC50 values and references for
respective inhibitors are given in Supporting Information
(Table S1). A 100 mM stock of C-proteinase inhibitor, PCP56,
in DMSO was added to cell culture media to get a final con-
centration of 10 mM PCP56. A stock of 10 mM BAPN was
freshly prepared in double-distilled water and was added to
cell culture media to get a final concentration of 0.1 mM
BAPN. ECM was deposited under ‘crowded’ conditions (DxS 2
days and Fc 6 days) prior to addition of 300 mL of recombi-
nant catalytically active human matrix metalloproteinase 1
(MMP1; 0.17 mg·mL-1 or 50 mg per well; 24-well plate)
(50 mM HEPES, 10 mM CaCl2, pH 7.5 buffer). Digestion was
carried out for 16 h at 37°C.
Fibroplasia (FP) models
FP model 1 (Clark et al., 1997): WI-38 fibroblasts were seeded
at a density of 100 000 cells per well in a 24-well plate and
incubated for 3 days in DMEM containing 0.4% FBS, 5% CO2
at 37°C. The cells were then treated with DMEM containing
10% FBS, 100 mM L-ascorbic acid 2-phosphate (as the magne-
sium salt hexahydrate) in the presence or absence of 300 pM
TGFb1 for 14 days, with a media change every 4 days.
Scar-in-a-Jar to assess potential antifibrotics
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FP model 2 (Fish et al., 2007): WI-38 fibroblasts were seeded
at confluency in 24-well plates (100 000 cells per well) and
cultured in DMEM containing 10% FBS, 100 mM of L-ascorbic
acid 2-phosphate (as the magnesium salt hexahydrate) and
3 ng·mL-1 TGFb1, at 5% CO2 at 37°C. Medium was changed
twice a week, and samples were taken for analysis after 8 days.
Optical analysis
A bioimaging station comprising of a Nikon TE600 fluores-
cence microscope plus Xenon illuminator (LB-LS/30, Sutter
Instrument Company, Novato, CA, USA), with an automated
Ludl stage (BioPrecision 2, Ludl Electronic Products Ltd., Haw-
thorne, NY, USA) and shutter, and equipped with a Photomet-
rics CoolSNAP high-sensitivity cooled monochrome
charge-coupled device camera (model HQ, Roper Scientific,
Pleasanton, CA, USA) was used. Screening of 24-well multi-
well plates was made possible by an automated stage and
autofocus capabilities. Nine image sites per well were acquired
at 20¥ original magnification, stored and analysed using the
Metamorph® Imaging System software (Molecular Devices,
Sunnyvale, CA, USA). An image field of 4.48 ¥ 3.34 mm per
site was defined for each 24-well plate to obtain an image
spread of 13.43 ¥ 10.03 mm (134.70 mm2) per well. The
Count Nuclei module was used for cell enumeration with
specific parameters in order for a region to be considered as a
positive count (countable nucleus): (i) areas with pixel inten-
sity value 15 above that of the background; and (ii) fluores-
cent areas with a minimum length of 10 mm and a maximum
length of 15 mm. The Integrated Morphometry Analysis
module was used to quantify the area of fluorescent collagen
I staining, which had been deposited on the cell layer. Experi-
mental controls were used to determine suitable fluorescent
intensity thresholds (300 for the DxS mode and a range
between 500 and 550 for the Fc mode); fluorescent signals
below a defined pixel intensity value were discounted, which
eliminated measurement of the background area. Triangle
masks were added to eliminate quantitation of corner auto-
fluorescence. This analysis resulted in a data set expressed as
area of collagen I per nuclei in mm2 per image field.
Immunocytochemistry
Cell layers were fixed with methanol and blocked with 3%
bovine serum albumin in phosphate-buffered saline (PBS).
Primary antibodies were incubated for 1.5 h followed by
washing three times with PBS. Secondary antibodies and 4′,6-
diamidino-2-phenylindoldilactate (DAPI) were incubated for
30 min and washed three times with PBS. Antibodies used
were mouse anti-human collagen I monoclonal primary anti-
body and rabbit anti-fibronectin, along with AlexaFluor 594
goat anti-mouse and AlexaFluor 488 chicken anti-rabbit sec-
ondary antibodies. Cell nuclei were stained with DAPI.
Biochemical analyses
Sodium dodecylsulphate-polyacrylamide gel electrophoresis
(SDS-PAGE). Triplicate protein samples were pooled and
resolved under non-reducing conditions using in-house 5%
resolving/3% stacking polyacrylamide gels on a Mini-Protean
3 as outlined in Raghunath et al. (1994). Protein standards
used were the Precision Plus Dual Colour and Prestained
Broad Range, and collagen type I standards. Protein bands
were stained with the SilverQuest™ kit according to the
manufacturer’s protocol. Densitometric analysis of wet gels
was performed on both collagen a1(I)- and a2(I)-bands with a
GS-800™ Calibrated Densitometer and Quantity One v4.5.2
image analysis software.
Western blotting. Proteins were extracted from the cell layer,
subjected to non-reducing SDS-PAGE using in-house 4%
resolving/3% stacking polyacrylamide gels on a Mini-Protean
3. Proteins were electroblotted onto nitrocellulose membrane
and immuno-detection was carried out in Tris-buffered saline
Tween-20 pH 7.6 (50 mM Tris-base 150 mM NaCl/0.05%
Tween 20) with 5% non-fat milk. Mouse anti-human procol-
lagen type I C-propeptide was used at 5 mg·mL-1 and incu-
bated for 1.5 h. Subsequently, a secondary goat anti-mouse
conjugated to HRP (Thermo Scientific, Rockford, IL) was used
at 1/1000 dilution for 1 h. The signal was detected by chemi-
luminescence and captured with a VersaDoc Imaging System
model 5000.
microRNA (miRNA) transfection
Prior to addition of DxS, 20 nM of mimic RNA of miR29c
(M29c) and inhibitor of miR29c (I29c) were transfected into
fibroblasts using lipofectamine RNAiMax (Invitrogen, Grand
Island, NY, USA) diluted with Opti-MEM® I reduced serum
medium according to the manufacturer’s forward transfection
protocol. Mock transfection samples were only treated with
lipofectamine and Opti-MEM® I without any RNA.
Statistical analysis
Data are presented as means  SD and as fold changes of
relevant controls. The statistical significance between groups
was determined by Student’s t-test using a two-tailed distri-
bution with unequal variance. An effect was considered sig-
nificant when 1.0 did not occur in the 95% confidence
interval of the collagen I amount in comparison with controls
(P < 0.05).
Materials
WI-38 fibroblasts were obtained from American Tissue
Culture Collection (CCL-75, Manassas, VA, USA). Cell culture
media and serum were obtained from Invitrogen (Grand
Island, NY, USA). All cell culture plastic ware (CELLSTAR®)
was purchased from Greiner BioOne (Frickenhausen,
Germany). L-ascorbic acid 2-phosphate, as the magnesium
salt hexahydrate, was obtained from Wako (Osaka, Japan). All
macromolecules were purchased from GE Healthcare
(Buckinghamshire, UK), and TGFb1 from R&D Systems
(Minneapolis, MN, USA). TSA, PDCA CPX, BAPN and sodium
bicarbonate were from Sigma-Aldrich (St. Louis, MO);
PCP56 [UK-421,045: (3R)-6-cyclohexyl-N-hydroxy-3-(3-
{[(methylsulphonyl)amino]methyl } -1,2,4-oxadiazol-5-yl)hex
anamide)] was from Pfizer Global Research and Develop-
ment (Sandwich, Kent, UK), and recombinant MMP1
Scar-in-a-Jar to assess potential antifibrotics
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corresponding to residues 101–469 in the full-length enzyme
was produced and purified by Aldevron, LLC (Fargo, ND, USA)
as previously described (Kaar et al., 2008). The collagen I and
fibronectin antibody were from Sigma-Aldrich (St. Louis, MO,
USA) and Dako (Glostrup, Denmark) respectively. All second-
ary antibodies for immunocytochemistry and DAPI were pur-
chased from Molecular Probes (Eugene, OR, USA). SDS-PAGE
reagents and equipment were obtained from Bio-Rad Labora-
tories (Hercules, CA, USA); collagen type I standards were
from Koken Co. (Tokyo, Japan). The SilverQuest™ kit was
from Invitrogen (Grand Island, NY, USA). The procollagen
type I C-propeptide antibody used in immunoblotting was
from QED biosciences (San Diego, CA, USA). Secondary anti-
bodies and chemiluminescence substrate were from Pierce
Biotechnology (Rockford, IL, USA). Reagents used for miRNA
transfection were from Invitrogen (Grand Island, NY, USA),
and both precursor and inhibitor miRNAs were purchased
from Ambion (Foster City, CA, USA).
Results
Choosing the appropriate human cell lines and their properties
We initially assessed two well-characterized normal human
embryonic cell lines, IMR-90 and WI-38, because they grow
reliably for a number of passages and deposit substantial
amounts of collagen (1–2 mg per 1.9 cm2, data not shown).
WI-38 was selected because it showed a slower proliferation
rate that was preferable for adherent cytometry for the accel-
erated mode (see below, and Figure S1 online). WI-38 fibro-
blasts remained subconfluent under the specified culture
conditions throughout the length of our study.
Implementation of two collagen deposition protocols
‘Crowding’ of culture medium with dextran sulphate served
as the rapid deposition mode (DxS), as it yields maximal
granular deposition of collagen I by 48 h, exceeding that in
conventional cell cultures within the same time, by more
than 20-fold (Lareu et al., 2007b). This increase was confirmed
optically, with good correlation with quantitative SDS-PAGE
gels of peptic cell layer extracts (Figures 1A and 2D). The
enhanced conversion of procollagen to collagen by procol-
lagen C-proteinase/BMP-1 was confirmed by immunoblotting
(Figure 1B). TGFb1 further increased collagen I deposition by
another 1.5–2-fold on top of the deposition gain observed in
cultures treated with DxS alone (Figure 1D,E). Crowding of
culture medium with neutral mixed Ficoll served as the
accelerated mode (Fc), and 6 days culture resulted in the
doubling of collagen deposition in comparison with non-
crowded cultures (see Figure S1 and S2 online) and an addi-
tional twofold increase in the presence of TGFb1 in
comparison with non-TGFb1 crowded cultures (Figure 1D,E).
Moreover, this mode resulted in a fibrillar collagen meshwork
with a more even spread of immunosignal (Figure 1C vii and
viii, xiii and xiv). Rapid mode (without TGFb1; 2 days) and
accelerated mode (with TGFb1; 6 days) outperformed both FP
models (+TGFb1) (18 and 8 days) with 1.5–3.5 times higher
collagen deposition (Figure 1D,E).
Image processing and capture
Methanol fixation was chosen for immunostaining (see Fig-
ure S3 online). Nine image fields would quantify 70% of the
total well area (190 mm2) in a 24-well plate (Figure 2A i).
Because the curvature of the wells created artificial reflection
and increased auto-fluorescence in the four corner fields
(Figure 2A ii), macros were written that added triangular
masks to conceal these regions during quantitation (Figure 2A
iii and iv). Taking into account cell distribution irregularities
close to the well edges that have to be excluded from analysis,
the final quantitation area represents 83% of the relevant area
(105 mm2 – 54% of the total well area) (Figure 2A iv). A
long-range 2¥ objective (20¥ total original magnification)
renders the bioimaging station independent of the use of
expensive optical plates. A 24-well format was selected as the
96-well format resulted in higher well-to-well variances of cell
distribution (not shown). Quantitation of nuclei and the area
of collagen I was demonstrated in Figure 2B with background
correction in Figure 2C. Optical analysis to quantify both area
and fluorescence intensity of collagen I per cell was compared
with densitometric measurements of silver-stained SDS-PAGE
collagen I bands (Figure 2D). As the results from these two
assays were closely correlated, the area was selected as the
measure of collagen I deposition. A variation of 10% in cell
numbers was attributed to cell seeding errors, and the image
acquisition and enumeration errors were considered negli-
gible (<0.3%) (data not shown).
Testing known and novel antifibrotics, in comparison with
SDS-PAGE
Known and novel agents with anti-fibrotic potential were
employed to interfere with various key steps along the col-
lagen biosynthesis pathway. Reduction of collagen I deposi-
tion relative to untreated controls in both deposition modes
was used as a read-out for antifibrotic efficacy. Optical analy-
ses for all antifibrotic substances were validated by biochemi-
cal analyses illustrated in Figures 3, 4, S4 and S5, and a very
good correlation was determined between optical and densi-
tometric quantitation (data not shown).
Epigenetic interference with collagen deposition. TSA, a histone
deacetylase inhibitor, was previously suggested as a potential
antifibrotic compound (Huber et al., 2007). In the absence of
TGFb1, TSA reduced collagen I deposition to 60% (rapid
mode) and 43% (accelerated mode). In the presence of TGFb1,
collagen I was reduced to 65% (rapid mode) and 29% (accel-
erated mode), close to baseline amounts of normal conditions
without TGFb1 (Figure 5A,B). Fibronectin signals remained
unchanged (Figure 5C,D), but cell proliferation was inhibited
(Figure 5E).
Post-transcriptional interference with collagen deposition. We
had recently predicted miRNA 29c (miR29c) would target
procollagen a1(I) mRNA by the rna22 algorithm (Miranda
et al., 2006) and tested mimic and I29c in the rapid deposition
mode. Both negative controls (scrambled oligos) did not affect
collagen I deposition. In contrast, M29c reduced collagen I
deposition in the absence of TGFb1. Particularly in the pres-
ence of this growth factor, 10 and 1 nM M29c reduced
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collagen I to 13% and 28% of mock transfected controls
(Figure 6A). Fibronectin deposition also appeared to be sig-
nificantly reduced by M29c and in the presence of TGFb1
(Figure 6B). I29c did not cause a significant change in col-
lagen I deposition, but caused a reduction of deposited
fibronectin in the presence of TGFb1 (Figure 6A,B). Cell pro-
liferation was not inhibited (Figure 6C).
Post- or co-translational interference with collagen deposition.
Collagen prolyl-4-hydroxylase inhibitors like 2,4-PDCA
(Tschank et al., 1987) and CPX (Clement et al., 2002) render
collagen triple helices less thermostable and thus prevent
their secretion. Reduction of collagen I was observed in both
deposition modes (Figure 7A,B). Particularly in the presence
of TGFb1, 2,4-PDCA reduced collagen I deposits to 24% (rapid
mode) and 23% (accelerated mode). In the absence of TGFb1,
CPX reduced collagen I to 2% (rapid mode) and 20% (accel-
erated mode), and in the presence of TGFb1, to 1% (rapid
mode) and 12% (accelerated mode) (Figure 7C,D). Either
inhibitor did not significantly reduce fibronectin deposition
(Figure 7E,F), and both compounds appeared to dampen cell
proliferation moderately (Figure 7G). Effects of the hydro-
philic 2,4-PDCA were evident in the accelerated mode only if
added daily after the first 48 h. In contrast, the highly lipo-
philic CPX only required a single treatment.
Post-secretional interference with collagen deposition. Procol-
lagen C-proteinase/BMP-1 controls the supramolecular
assembly of collagen into fibrils via removal of the C-terminal
propeptide from the procollagen I molecule. Optical analysis
reported that the sulphonamide PCP56 reduced the deposited
area of collagen I to 40% (rapid mode) and 52% (accelerated
mode), and in the presence of TGFb1 to 82% (rapid mode)
and 43% (accelerated mode). Only in the rapid mode was
fibronectin reduced to 46% (control) and 36% (TGFb1)
(Figure 3A,B). The accelerated mode showed a 17% decrease
Figure 1 Rapid and accelerated collagen deposition modes versus in vitro fibroplasia. (A) Silver stained SDS PAGE: markedly increased
collagen deposition in the presence of DxS (B) procollagen C-propeptide immunoblot shows intact secreted procollagen in routine culture, and
complete cleavage of procollagen C-propetide in the presence of DxS (C) Immunocytochemistry: standard culture with reticular fibronectin
matrix and minimal collagen I deposition (i–vi), Fc (accelerated): enhanced reticular collagen I/fibronectin matrix (vii–xii). DxS (rapid): granular
aggregates of collagen I/fibronectin (xiii–xviii) with highest ECM content (¥400 magnification). (D) SDS-PAGE analyses of collagen matrix
content in both deposition modes in the absence/presence of TGFb1 and fibroplasia models. With TGFb1 both deposition modes give more
and faster matrix formation including stronger lysyl oxidasemediated cross-linking than both FPs. Note presence of collagen V in FP and
accelerated mode and its absence in rapid mode. (E) Densitometric evaluation of (D).
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in cell numbers with PCP56 in the presence of TGFb1.
Although cell numbers were reduced, the absence of detached
cells suggested slower proliferation rather than toxicity
(Figure 3C). Biochemical analysis demonstrated that PCP56
treatment also resulted in accumulation of procollagen in the
medium (Figure 3D,E).
b-Aminopropionitrile irreversibly inhibits lysyl oxidase, an
amine oxidase that is crucial in stabilizing ECM by cross-
linking collagen chains (Wilmarth and Froines, 1992). In both
deposition modes, BAPN caused no reduction of area collagen
I per cell (Figure 4A), but the area of fibronectin per cell was
reduced to 62% (rapid mode) and 69% (accelerated mode) in
the absence of TGFb1 (Figure 4B). Cell proliferation was not
affected (Figure 4C). SDS-PAGE revealed a reduction of
b-bands representing cross-linked collagen I a-chains
(Figure 4D,E), to 26% (control) and 33% (TGFb1) in rapid
mode, and to 62% and 32% (TGFb1) in accelerated mode by
densitometry (Figure 4F,G).
Matrix metalloproteinase 1 controls collagen turnover in
the ECM (Gross and Nagai, 1965) by cleaving collagen at a
single site. Cell layers with ECM created under both deposi-
tion modes were exposed to exogenous recombinant MMP1.
We observed detachment of cells during MMP1 treatment
especially in matrix derived from the rapid mode (Figure 8C).
Therefore, the total area of collagen I per well was quantified
without normalization for cell numbers. MMP1 reduced the
area of deposited collagen I to 0.03% and 0.6% in the rapid
and accelerated modes respectively (Figure 8A), and fibronec-
tin deposition to 2% (rapid mode) and 19% (accelerated
mode) (Figure 8B).
Figure 2 Image acquisition and quantitation of rapid collagen deposition mode. (A) (i) 20¥ original magnification of cells in a 1.9 cm2 well
with superimposed original rectangular image acquisition area (red box). (ii) Enlarged red box: corner auto-fluorescence (arrows). (iii and iv)
Acquisition area after application of triangular masks to eliminate corner auto-fluorescence. (B) Cytometry and quantitation of the area of
deposited collagen I. (i) DAPI-stained nuclei at 20¥ original magnification in monochrome pseudocolor, scale bar, 1 mm. 600¥ original
magnification (inset). (ii) Red scored nuclei by Count Nuclei module for cytometry. (iii) Immunostained deposited collagen I. (iv) Regions with
fluorescent pixel intensity above a selected value based on controls are demarcated by the software in green for quantitation of deposited
collagen I area at 100¥ original magnification. (C) Shading correction for non-homogenous fluorescence during image acquisition for unbiased
quantitation at 20¥ original magnification. (i) Non-homogenous fluorescence background. (ii) Fibronectin immunofluorescence acquired with
uneven fluorescence. (iii) Same image after background fluorescence removal. (D) Densitometry versus image analysis for collagen I (Col I)
quantitation. Optically, fluorescence intensity (FIT) and area were similar, correlating well with densitometry. TGFb1-induced increase of
collagen I deposition was detected in similar amount and tendency optically and biochemically. Data are expressed as mean  SD, calculated
from triplicates and as a relative percentage of all treatments. Ctrl, control; DAPI, 4′,6-diamidino-2-phenylindoldilactate; DxS, dextran sulphate
(rapid deposition mode); TGFb1, transforming growth factor-b1.
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Discussion
Fibrosis has remained an unsolved therapeutic problem. An
important obstacle in the development of antifibrotic com-
pounds has been the lack of a comprehensive in vitro screen-
ing system, although all relevant biochemical steps of
collagen matrix formation have been known for quite some
time. The confounding factor of cell culture in standard
aqueous media is its characteristic difference from the natural,
‘crowded’ state of tissue. Thus, the enzymatic conversion of
procollagen to collagen by C-proteinase is too slow to allow
the deposition of a substantial collagen matrix in a useful
time window (Lareu et al., 2007a,b). This already forecasts
that the effects of C-proteinase inhibitors would be invisible
under routine culture conditions, and IC50 values from cell-
free assays used to test inhibitors of isolated enzymes and
their corresponding substrates would not be an accurate
physiological reflection of the inhibitors’ efficacy in vivo.
Thus, the risk of obtaining inconclusive results in experimen-
tal animals is considerable.
This is where the Scar-in-a-Jar takes model monolayer
culture to a new pathophysiological level. Collagen deposi-
tion and cross-linking is substantially increased in vitro, with
the option of two deposition modes. The rapid deposition
mode produces granular collagen I aggregates within 48 h
(Lareu et al., 2007a,b), and a combination of neutral Ficoll 70
and 400 was found to produce collagen I with a reticular
deposition pattern within 6 days. Thus amount, velocity and
morphology of collagen deposition can be controlled depend-
ing on the macromolecules used. The accelerated mode (Fc)
Figure 3 Optical evaluation of extracellular interference with collagen deposition. (A) C-proteinase inhibitor PCP56 reduced collagen I
(Col I) area per cell to 40% (control, P = 0.003) and 82% (TGFb1, P = 0.047) in rapid mode, and 52% (control, P = 0.036) and 43% (TGFb1,
P = 0.018) in accelerated mode. There were no significant effects with FSY002 (data not shown). (B) Area of fibronectin (Fn) per cell was
reduced to 46% (control, P = 0.037) and 36% (TGFb1, P = 0.005) by PCP56 in rapid mode, and increased to 123% (TGFb1, P = 0.004) in
accelerated mode. (C) Cell numbers with PCP56 were slightly reduced to 91% (control, P = 0.012) and 94% (TGFb1, P = 0.006) in rapid mode,
and 92% (control, P = 0.035) and 83% (TGFb1, P = 0.002) in accelerated mode. *P < 0.05 versus respective controls (D,E) Biochemical analysis
of deposited collagen I reduction by PCP56 in the rapid mode of collagen deposition. (D) Collagen I deposited on the cell layer is visibly
reduced with PCP56 treatment. (E) Pepsin digested procollagen I is increased in the medium fraction of cell culture with PCP56 treatment. Data
are expressed as mean SD, calculated from triplicates and as fold changes over respective controls. Ctrl, control; DxS, dextran sulphate (rapid
deposition mode); Fc, Ficoll cocktail (accelerated deposition mode); TGFb1, transforming growth factor-b1.
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with its longer culture time also produces collagen with a
larger extent of cross-linking. Optical quantitation of two-
dimensional images of three-dimensional granular aggregates
as produced in the rapid mode can result in under-reporting
of deposited collagen, but less so with a reticular network
(accelerated mode). The rapid mode (DxS), however, allows
for a faster data output due to a shorter culture time. TGFb1,
a notorious culprit in fibrotic conditions (Varga and Jimenez,
1986), resulted in an additional 1.5–2-fold increase of col-
lagen deposition in comparison with controls under both
modes of crowding. TGFb1 has pleiotropic effects; it slows
down matrix turnover by reducing MMP1 expression,
up-regulates lysyl oxidase activity and increases the presence
of tissue inhibitors of MMPs (Overall et al., 1989). These
effects are only apparent with a deposited matrix, underlining
the importance of this novel screening system.
We compared our system with a FP model (Clark et al.,
1997) that consists of TGFb1-exposed hyperconfluent fibro-
blasts that form cell sheets. Destructive methods were
employed to quantify hydroxyproline without the option to
correct for cell number or total protein content. A modified
version has been recently used by Fish et al. (2007) to assess
Figure 4 Optical evaluation of extracellular interference with collagen stabilization. (A) BAPN did not change area of collagen I (Col I) per cell,
but reduced area of fibronectin (Fn) per cell to 62% (DxS, P = 0.006) and 69% (Fc, P = 0.012) in the absence of TGFb1 (B) without affecting
cell numbers (C). Effects of BAPN were evident after SDS-PAGE (D,E); densitometry qualitatively shows that b-cross-links were reduced to 24%
and 33% (TGFb1), and to 62% and 32% (TGFb1) in the rapid (F) and accelerated mode (G) respectively. Each lane represents pooled triplicates,
and data are represented as fold change in comparison with respective control. *P < 0.05 versus respective controls. Data are expressed as mean
 SD, calculated from triplicates and as fold changes over respective controls. BAPN, b-aminopropionitrile; Ctrl, control; DxS, dextran sulphate
(rapid deposition mode); Fc, Ficoll cocktail (accelerated deposition mode); SDS-PAGE, SDS-polyacrylamide gel electrophoresis; TGFb1,
transforming growth factor-b1.
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C-proteinase inhibitors. In comparison, the FP models con-
tained considerably less deposited collagen after 8 and 18 days
than crowded subconfluent cultures, even in the absence of
TGFb1 for the latter. Of note, the ECM of FP contained col-
lagen V, which is usually absent from fibrotic tissue (Kisseleva
and Brenner, 2008). Thus, the ECM lacking collagen V under
the rapid deposition mode would emulate a fibrotic matrix
more closely. Also, there was a 1.5–2-fold increase of lysyl
oxidase-mediated cross-links under crowded conditions in
contrast to FP models, and this improvement of enzyme activ-
ity in vitro will facilitate the screening of another important
therapeutic target in anti-fibrosis research.
Known and novel antifibrotic compounds were evaluated,
and an overall close correlation between optical and bio-
chemical quantitation methods was found. However, the
Scar-in-a-Jar provides the option for simultaneous evaluation
of other antigens and cell enumeration within the same
well. This proved crucial in the case of TSA, which is known
to be anti-proliferative in cancer cells (Wetzel et al., 2005;
Platta et al., 2007), as it also inhibited fibroblast growth.
After correction for cell numbers, our findings agree excel-
lently with earlier work based on metabolic labelling and
immunoprecipitation of collagen I, which showed that TSA
suppressed TGFb1-induced fibrogenesis in vitro (Rombouts
et al., 2002). This and other current work suggests a new role
for this class of compounds in fibrosis treatment (Wang
et al., 2009).
We demonstrate the first instance of evaluating prolyl
hydroxylase inhibitors under conditions of full matrix depo-
sition. PDCA causes intracellular procollagen retention
(Tschank et al., 1991), and related compounds are currently
under evaluation for their cross-inhibitory effects on HIF-1-a
prolyl hydroxylase (Asikainen et al., 2005). Its dual potential
of inhibiting fibrosis while inducing angiogenesis was
recently demonstrated in transgenic zebrafish (Raghunath
et al., 2009). CPX is FDA-approved for the topical treatment of
cutaneous mycoses (Batrafen®). As an iron chelator it was
predicted to interfere with prolyl hydroxylases (Clement
et al., 2002). We show here profound effects of CPX on the
deposition of collagen, a novel example for indication discov-
ery and an interesting antifibrotic, off-label potential, for this
compound.
Figure 5 Epigenetic interference with collagen deposition. Area of collagen I (Col I) (A) was normalized to cell numbers (B). TSA reduced
collagen I per cell to 60% (control, P = 0.02) and 65% (TGFb1, P = 0.001) in rapid mode, and 43% (control, P = 0.007) and 29% (TGFb1,
P = 0.004) in accelerated mode. Comparing (C) area of fibronectin (Fn) with (D) area of fibronectin per cell highlights the importance of
normalization to cell numbers. In rapid mode, TSA did not change fibronectin area per cell, but doubled it in the accelerated mode. TSA
reduced cell numbers (E) to 65% (DxS, P = 2.52 ¥ 10-5), 75% (DxS + TGFb1, P = 0.001), 47% (Fc, P = 0.0005) and 43% (Fc + TGFb1, P = 0.003).
*P < 0.05 versus respective controls. Data are expressed as mean  SD, calculated from triplicates and as fold changes over respective controls.
Ctrl, control; DxS, dextran sulphate (rapid deposition mode); Fc, Ficoll cocktail (accelerated deposition mode); TGFb1, transforming growth
factor-b1; TSA, trichostatin A.
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Targeting enzymes responsible for the proteolytic trimming
of procollagen is another feasible antifibrotic strategy. To
interfere with this step, a variety of procollagen C-proteinase/
bone morphogenic protein-1 inhibitors have been designed
(Burchardt et al., 1999; Robinson et al., 2003; Fish et al., 2007).
Procollagen cleavage by C-proteinase is enhanced under mac-
romolecular crowding in vitro. This feature enables the Scar-
in-a-Jar to assess C-proteinase inhibitors in a native enzyme/
substrate system under pathological scarring conditions,
which was not possible prior to this model. The novel sul-
phonamide inhibitor, PCP56, demonstrated efficacy in excel-
lent agreement with an earlier report (Fish et al., 2007).
Biochemically, we noted the re-appearance of collagen I in the
culture medium under PCP56 during crowding, proving the
exclusion of the non-converted procollagen from matrix
building. Another PCP inhibitor (FSY002) did not work in our
system although an IC50 value was obtained with purified
procollagen C-proteinase (Burchardt et al., 1999) (data not
shown).
Based on observations in heritable connective tissue disor-
ders (Pinnell, 1982), interfering with collagen cross-linking
has been proposed to make scar tissue more susceptible to
degradation (Vater et al., 1979; Kagan, 2000). Biochemical
analysis clearly demonstrated the reduction of collagen cross-
linking by BAPN in the rapid mode (DxS) and when added
daily after the first 48 h in the accelerated mode (Fc), but
overall collagen I amount was not reduced (Figure 4D–G).
Similarly, optical analysis did not detect a reduction of col-
lagen I matrix in either deposition mode, but was unable to
differentiate and quantify cross-linked collagen. These results
correspond with earlier findings that BAPN neither affects the
amount of collagen synthesized nor the hydroxyproline dis-
tribution between cell layer and medium (Layman et al.,
1971). However, a contrasting report found reduced collagen
matrix in hyperconfluent cells (under non-crowded condi-
tions) under TGFb1/BAPN treatment for 3 days (Clark et al.,
1997). Collagen cross-link reduction does not necessarily
translate to reduced pericellular collagen. Perhaps under
crowded conditions, increased collagen turnover due to
reduced collagen cross-links might not be perceptible within
this time frame due to enhanced collagen deposition.
Matrix metalloproteinase 1 has an important remodelling
role in fibrosis. In contrast to other methods of evaluating
MMP1 activity involving synthetic fluorescent substrates or
zymography (Lombard et al., 2005; Troeberg and Nagase,
2007), we applied recombinant MMP1 to cell layers with a
complex ECM bioassembled via both deposition modes (DxS
and Fc). Efficient matrix degradation by MMP1 caused cell
detachment of varying degrees and precluded application of
the cytometry feature of our model. Optical quantitation of
the total post-depositional reduction of collagen and
fibronectin per well was performed instead. This represents an
important step to evaluate MMP1 formulations designed to
locally modulate tissue composition in a wound-healing
setting.
Current reports have suggested that the miR29 family of
miRNA at the gene expression level plays a role in ECM gene
regulation of COL1A1, COL1A2, COL3A1, COL4A1, COL4A2,
COL5A2, SPARC and FBN1 in tumour cells (Sengupta et al.,
2008) and miR29b, in particular, regulates COL1A1, COL1A2,
COL3A1 and FBN1 in cardiac fibrosis (van Rooij et al., 2008).
Mcl-1 protein regulation by miR29c resulted in apoptosis
induction (Mott et al., 2007) and recently, the miR29 family
was also found to reduce p85a and CDC42 mRNA levels in
HeLa cells (Park et al., 2009). The Scar-in-a-Jar demonstrates
for the first time evidence for a potential antifibrotic effect of
M29c at the protein level and confirms the mathematical
prediction of rna22. This tool has the advantage of a read-out
system focused on the net reduction of collagen I, regardless
of multiple targets being affected simultaneously. For
example, miR29c may regulate other key genes involved in
the collagen biosynthetic cascade other than those targeting
collagen I. Further work is underway to study the specific
effects of miR29c on protein and gene expression level and to
identify other targets in the collagen biosynthesis pathway
that might be regulated by miR29c.
In conclusion, the Scar-in-a-Jar offers a novel pathophysi-
ologically relevant screening and evaluation tool for antifi-
brotic lead compounds interfering with different key points of
the collagen biosynthesis pathway, ranging from the epige-
netic to the extracellular level.
Figure 6 Post-transcriptional regulation of collagen deposition. (A)
Mimic miRNA29c (M29c): scrambled controls 1,2 or inhibitory
miR29c (I29c) did not affect collagen (Col I) deposition. However,
M29c reduced it to 13% and 28% (TGFb1, transforming growth
factor-b1, P = 0.003 and P = 0.003). (B) Area of fibronectin (Fn) per
cell was significantly reduced in the presence of TGFb1 by M29c, as
well as by 10 nM I29c to 43% (P = 0.024), 45% (P = 0.016) and 57%
(P = 0.043) respectively. (C) Cell numbers were unaffected. *P < 0.05
versus respective controls. Data are expressed as mean  SD, calcu-
lated from triplicates and as fold changes over respective controls.
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Figure 7 Optical analyses of the effects of co-translational inhibition of prolyl hydroxylase on collagen I (Col I) deposition. (A,B) Immuno-
cytochemistry: perturbed ECM formation in both deposition modes at 100¥ original magnification. Area of collagen I (C) normalized to cell
numbers (D). PDCA significantly reduced collagen I deposition, particularly in the presence of TGFb1, in both modes. Collagen I per cell
dropped to 24% (DxS, P = 0.015) and 23% (Fc, P = 0.005). CPX (8 mM) diminished collagen I area to 2% (control, P = 0.013) and 1% (TGFb1,
P = 0.001) in the rapid mode, and 20% (control, P = 1.26 ¥ 10-5) and 12% (TGFb1, P = 0.0006) in accelerated mode. (E) CPX caused a
significant decrease of fibronectin (Fn) area in rapid mode, after normalization only in presence of TGFb1 (62%, P = 0.005) (F). CPX also caused
a significant increase in the area of fibronectin per cell in accelerated mode to 256% (control, P = 0.003) and 247% (TGFb1, P = 0.007) and
showed (G) anti-proliferative effects. *P < 0.05 versus respective controls. Data are expressed as mean  SD, calculated from triplicates and
as fold changes over respective controls. CPX, ciclopiroxolamine; Ctrl, control; DxS, dextran sulphate (rapid deposition mode); ECM,
extracellular matrix; Fc, Ficoll cocktail (accelerated deposition mode); PDCA, 2,4-pyridinedicarboxylic acid; TGFb1, transforming growth
factor-b1.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Appendix S1 Optimization of cell numbers and collagen
deposition for the collagen deposition modes, and biochemi-
cal validation of antifibrotic inhibitors. (Figure S1) Correla-
tion of collagen deposition in the rapid and accelerated
modes with cell density. (Figure S2) Correlation of collagen
deposition with time in the accelerated mode. (Figure S3)
Optimization of fixative methods for optical analysis. Bio-
chemical validation of intracellular (Figure S4) and extracel-
lular (Figure S5) collagen biosynthesis inhibitors.
Figure S1 Correlation of rapid (DxS) (A,B) and accelerated
(Fc) collagen deposition mode (C,D) with cell density by the
optical analysis method. (A) Rapid mode: under DxS treat-
ment the total area of deposited collagen I shows an expo-
nential increase up to 25 000 above which the rate of collagen
I addition becomes linear; the total collagen I deposited per
cell peaks at 50 000 cells per 24-well. (B) The area of collagen
I deposition per cell peaks at 25 000 cells per 24-well. (C)
Accelerated mode: under Fc treatment total area of collagen I
deposition increased exponentially from 10 000 cells per
24-well onwards. (D) The area of collagen I per cell shows a
similar exponential behaviour (C).
Figure S2 Accelerated matrix formation under neutral
macromolecular crowding at days 2, 4 and 6 analysed by
densitometry and optical analysis. (A) Densitometric evalua-
tion of sodium dodecylsulphate-polyacrylamide gel electro-
phoresis gels revealed over 6 days that a twofold and 6.5-fold
increase of collagen I deposition had occurred in the absence
and presence of transforming growth factor-b1 (TGFb1)
respectively. (B) Collagen I on the cell layer was immun-
ostained and quantified using optical analysis. Over 6 days,
collagen I deposition was enhanced twofold and ninefold in
the absence and presence of TGFb1 respectively. Densitom-
etry data were calculated from pooled triplicate samples, and
optical analysis data were expressed as mean  SD, as fold
change in comparison with non-crowded controls.
Figure S3 Preservation and quantitation of deposited col-
lagen I and cell enumeration is dependent on the fixative
used. (A–C) Comparisons between live staining, 4% PFA and
MeOH fixation. (A) MeOH yielded the greatest quantified area
of collagen I deposited, followed by live staining and 4% PFA
as the lowest. (B) Adherent cell enumeration revealed cell loss
during live staining with the lowest cell retention level in
comparison with 4% PFA and MeOH. (C) The area of collagen
I per cell was calculated for normalization purposes.
Figure S4 Biochemical validation of intracellular collagen
biosynthesis inhibitors by silver stained sodium
dodecylsulphate-polyacrylamide gel electrophoresis. The
(A,C,E,G) rapid (DxS) and (B,D,F) accelerated (Fc) modes of
collagen deposition were treated with (A,B) 1 mM trichostatin
A (TSA), (C,D) 10 mM 2,4-pyridinedicarboxylic acid (PDCA),
(E,F) 8 mM ciclopiroxolamine (CPX) and (G) 10 nM mimic
miR29c (M29c). Inhibitor treatment at the epigenetic, post-
transcriptional and post-translational level resulted in a
decrease of deposited collagen in the absence and presence of
transforming growth factor-b1 (TGFb1). Each lane represents
pooled triplicates.
Figure S5 Biochemical validation of extracellular collagen
biosynthesis inhibitors by silver stained sodium
dodecylsulphate-polyacrylamide gel electrophoresis.
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extracellular matrix was deposited using the (A) rapid (DxS)
and (B) accelerated (Fc) modes prior to addition of 50 mg per
24-well of exogenous matrix metalloproteinase 1 (MMP1).
MMP1 digested the collagen I deposited in both modes. Each
lane represents pooled triplicates.
Table S1 IC50 of tested compounds
Please note: Wiley-Blackwell are not responsible for the
content or functionality of any supporting materials supplied
by the authors. Any queries (other than missing material)
should be directed to the corresponding author for the article.
Scar-in-a-Jar to assess potential antifibrotics
CZC Chen et al 1209
British Journal of Pharmacology (2009) 158 1196–1209
FEBS Letters 581 (2007) 2709–2714Collagen matrix deposition is dramatically enhanced in vitro
when crowded with charged macromolecules: The biological relevance
of the excluded volume eﬀect
Ricky R. Lareua,b, Karthik Harve Subramhanyaa, Yanxian Penga, Paula Bennya, Clarice Chena,
Zhibo Wanga, Raj Rajagopalanc, Michael Raghunatha,d,*
a Tissue Modulation Laboratory, Division of Bioengineering, Faculty of Engineering, National University of Singapore, Singapore
b NUS Tissue Engineering Program, Department of Orthopedic Surgery, Yong Loo Lin School of Medicine, National University of
Singapore, Singapore
c Department of Chemical and Biomolecular Engineering, Faculty of Engineering, National University of Singapore, Singapore
d Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Division Oﬃce Block EA# 03-12,
9 Engineering Dr. 1, Singapore 117576, Singapore
Received 23 February 2007; revised 4 April 2007; accepted 8 May 2007
Available online 21 May 2007
Edited by Felix WielandAbstract The excluded volume eﬀect (EVE) rules all life pro-
cesses. It is created by macromolecules that occupy a given vol-
ume thereby conﬁning other molecules to the remaining space
with large consequences on reaction kinetics and molecular
assembly. Implementing EVE in ﬁbroblast culture accelerated
conversion of procollagen to collagen by procollagen C-protein-
ase (PCP/BMP-1) and proteolytic modiﬁcation of its allosteric
regulator, PCOLCE1. This led to a 20–30- and 3–6-fold
increased collagen deposition in two- and three-dimensional
cultures, respectively, and creation of crosslinked collagen foot-
prints beneath cells. Important parameters correlating with
accelerated deposition were hydrodynamic radius of macromole-
cules and their negative charge density.
 2007 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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C-proteinase1. Introduction
Tissue engineering combines cell biology and materials sci-
ence to provide therapeutic strategies for the generation of tis-
sues in vitro and/or in vivo when situations result in completeAbbreviations: EVE, excluded volume eﬀect; PCP, procollagen C-
proteinase; ECM, extracellular matrix; DxS, dextran sulfate; PSS,
polysodium-4-styrene sulfonate; Fc, Ficoll; PLLA, poly L-lactic acid;
PCOLCE1, PCP enhancer protein 1; DAPI, 4 0,6-diamidino-2-pheny-
lindole; DLS, dynamic light scattering; MMP2, matrix metallopro-
teinase 2
*Corresponding author. Address: Division of Bioengineering, Faculty
of Engineering and Department of Biochemistry, Yong Loo Lin
School of Medicine, National University of Singapore, Division Oﬃce
Block EA# 03-12, 9 Engineering Dr. 1, Singapore 117576, Singapore.
Fax: +65 6872 3069.
E-mail address: bierm@nus.edu.sg (M. Raghunath).
URL: www.tissuemodulation.com
0014-5793/$32.00  2007 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.febslet.2007.05.020organ failure or ineﬀectual natural or augmented repair pro-
cesses. As with every cell culture, be it two- or three-dimen-
sional, cells are isolated from preexisting tissue. They are
either terminally diﬀerentiated or show various degrees of
‘‘stemness’’ e.g. adult bone marrow-derived and embryos.
The isolation and seeding process removes the harvested cells
from a context of highly complex and dense arrays of macro-
molecules, the extracellular matrix (ECM), and places them
abruptly onto a naked or thinly-coated tissue culture plastic
while being bathed in large volumes of non-crowded aqueous
medium. This situation is far from physiological given the fact
that the total concentration of protein and RNA inside pro-
and eukaryotic cells is in the range of 300–400 g/l [1–3] and
that the extracellular space is usually dominated by dense
arrays of ECM macromolecules. Even blood has a solute con-
centration of 80 g/l [4]. The addition of fetal calf serum in rou-
tine culture media, however, fails to create a crowded
environment [5]. As the cells are confronted with an environ-
ment devoid of ECM they start to rebuild their environment
by producing their own ECM. While ﬁbronectin is deposited
rapidly in vitro [6], the deposition of a collagen matrix, the pri-
mary structural biological material in all tissues and organs, is
enzymatically rate-limited. As the current culturing practices
are characterized by a lack of macromolecular crowding and
hence excluded volume eﬀect (EVE), the procollagen conver-
sion and as a consequence, collagen matrix deposition, is noto-
riously slow in vitro [5]. Many weeks are needed to create
cohesive tissue sheets that contain suﬃcient ECM [7]. This rep-
resents a major bottle-neck in tissue engineering and impedes
the studies of ECM formation in vitro. In order to overcome
this obstacle we tested a series of polymeric macromolecules
for their ability to exclude volume and speed-up speciﬁc enzy-
matic steps required for collagen deposition in vitro.2. Materials and methods
2.1. Tissue culture
Low passage (3–8) normal primary embryonic lung ﬁbroblasts
(WI-38; American Tissue Culture Collection, VA, USA) were rou-
tinely cultured as outlined in Lareu et al. [5]. Fibroblasts were seeded
on 24-well plates at 50000/well and the following day the media wasation of European Biochemical Societies.
2710 R.R. Lareu et al. / FEBS Letters 581 (2007) 2709–2714replaced with 0.5% FBS, 100 lM of L-ascorbic acid with or without
macromolecules. The macromolecules employed were 500 kDa
dextran sulfate (DxS) and 10 kDa DxS at 100 lg/ml (pK Chemicals
A/S, Koge, Denmark), 200 kDa polysodium-4-styrene sulfonate
(PSS) at 100 lg/ml (Sigma–Aldrich, Singapore), 400 kDa Ficoll
(Fc) and 70 kDa Fc at 50 mg/ml (Amersham Pharmacia, Uppsala,
Sweden). The medium and cell layer fractions were harvested sepa-
rately. Collagen from medium, cell layer and footprints was extracted
with pepsin under acidic conditions [5]. For footprint analysis, cell
layers were washed twice with HBSS and solublized three times with
0.5% sodium deoxycholate (Sigma–Aldrich) on ice for 10 min as out-
lined in [8].2.2. Three-dimensional (D) culture and bioreactors
250000 WI-38 ﬁbroblasts were seeded onto either Biobrane (3.5 cm
diameter) (Bertek Pharmaceuticals Inc, WV, USA) or poly L-lactic
acid (25 · 50 · 3 mm) (PLLA, 0410-2 · 45; Transome Inc., FL, USA)
felt scaﬀolds in 6 well plates and cultured routinely in 10% FBS for
1 and 2 days, respectively. For static treatment, ascorbic acid and with
or without 100 lg/ml of DxS 500 kDa were supplemented and incu-
bated for 3 and 5 days, respectively. The PLLA scaﬀolds were placed
in modular parallel-plate bioreactors design according to Gemmiti
and Guldberg [9] and incubated initially as for static culture following
transfer to the bioreactor modules for 5 days. Treatments were as forFig. 1. EVE enhanced collagen deposition. (A) SDS–PAGE (NuPage) and de
onto the cell layer after 48 h in absence and presence of diﬀerent macromole
fraction of the above treatments. Each lane contains three pooled individua
nuclei counterstained with DAPI) and ﬁbronectin (green) in the ECM in the a
10·. (D) Transmission electron micrograph of the pericellular matrix in the
collagen-typical ﬁbrillar formations in the presence of EVE. Abbreviations
molecular weight standards.static culture. Bioreactor ﬂow rate was 0.2 ml/min. After culture treat-
ments, the scaﬀolds were removed form the bioreactor modules and
pepsin-treated for deposited collagen as above.
2.3. Sodium dodecylsulfate–polyacrylamide gel electrophoresis (SDS–
PAGE)
Protein samples were separated under non-reducing conditions
either using pre-cast gradient NuPage 3–8% Tris-acetate polyacryl-
amide gels (Invitrogen, Singapore) or 5% resolving/3% stacking poly-
acrylamide gels as outlined in [10]. Protein standards used were the
Precision Plus Dual Color and Prestained Broad Range (Bio-Rad, Sin-
gapore), and collagen type I (Koken Co., Tokyo, Japan). Protein
bands were stained with the SilverQuest kit (Invitrogen) and densito-
metric analysis was performed on the collagen a-bands with a GS-
800 Calibrated Densitometer (Bio-Rad).
2.4. Western immunoblotting
Proteins were extracted from the cell layer, subjected to reducing-
SDS–PAGE (NuPage 3–8% Tris-acetate gels) and immunoblotted [5].
Primary antibodies for procollagen C-proteinase (PCP; rabbit anti-
human BMP-1, AB81031; Chemicon International, CA, USA) and
PCP enhancer protein 1 (PCOLCE1; rabbit anti-human PCOLCE1,
CL1PCOLE1; Cedarlane Laboratories Ltd, Ontario, Canada) were
used at 1/2500 dilutions. The signal was detected with chemilumines-nsitometric analysis of collagen deposition (fold-change relative to Cnt)
cules. (B) SDS–PAGE (NuPage) analysis of collagen from the medium
l samples. (C) Double immunoﬂuorescence staining of collagen (red;
bsence and presence of DxS 500 kDa (100 lg/ml). All magniﬁcations at
absence and presence of DxS 500 kDa (100 lg/ml). Arrows indicate
: Col I, collagen type 1; Cnt, control; Fbn, ﬁbronectin; MW STD,
R.R. Lareu et al. / FEBS Letters 581 (2007) 2709–2714 2711cence (Super Signal West Dura kit; Pierce Biotechnology Inc., IL,
USA) and captured with a VersaDoc Imaging System model 5000
(Bio-Rad).
2.5. Immunocytochemistry
Cell layers or footprints were ﬁxed with 2% paraformaldehyde (Sig-
ma–Aldrich) and double-immunoﬂuorescence was carried-out in PBS
with 3% BSA. Primary antibodies used were mouse anti-human
collagen I at 1:100 (AB745; Chemicon International) and rabbit anti-
human ﬁbronectin at 1:200 (F7387; Sigma–Aldrich). Secondary anti-
bodies were goat anti-mouse AlexaFluor594 (Molecular Probes, OR,
USA) and chicken anti-rabbit AlexaFluor488 at 1/400 dilutions,
respectively. Cell nuclei were counterstained with DAPI (4 0,6-diami-
dino-2-phenylindole; Molecular Probes). Images were captured with
an Eclipse TE2000-E inverted epiﬂuorescence microscope (Nikon, Sin-
gapore). All digital images were background-subtracted based on con-
jugate control.
2.6. Transmission electron microscopy
3.4 million ﬁbroblasts were seeded in 35 mm dishes and were allowed
to attach for 16 h after which they were treated with ascorbate in the
presence or absence of DxS for 48 h as described above. Cultures were
then washed in PBS and ﬁxed in 2.5% glutaraldehyde in PBS, pH 7.4,
for 16 h at 4 C. Cell layers were scraped, pelleted and embedded in
0.5% agarose. Agarose cylinders containing cell pellets were then pro-
cessed for electron microscopy (osmication, dehydration, inﬁltration,
araldite embedding). Thin sections were viewed in a JEOL 1220 (To-
kyo, Japan) electron microscope. Digital images were taken with a
ES 500 DDC camera (Gatan GmbH, Munich, Germany) using Digital
Micrograph software.
2.7. Biophysical measurements
Dynamic light scattering (DLS) measurements on macromolecules
were performed in HBSS, pH 7.4, and corrected for viscosities accord-
ing to Harve et al. [11]. For zeta (f)-potential measurements, macro-
molecules were dissolved in water and measured using a ZetaPlus
analyzer (Brookhaven Instruments Corporation, NY, USA) at 25 C.
f-potential was expressed as the mean of 10 readings and tabulated
with the standard error of mean.Fig. 2. Biophysical properties of the macromolecules. (A) Net charge,
hydrodynamic (Hydro.) radius and percentage fraction volume occu-
pancy (% fract. vol. occ.) are shown for the macromolecules. (B) f-
potential values of DxS 500 kDa and PSS 200 kDa at various
concentrations measuring surface charge density. * indicates below
sensitivity of instrument. Abbreviations: N, neutral; -ve, negative.
Fig. 3. Western immunoblot of PCP and PCOLCE1 proteins after
48 h of culturing in 10% FBS in the absence or presence of DxS
500 kDa (100 lg/ml). Arrow indicates the 34–36 kDa C-terminus
activated form of PCOLCE1.3. Results and discussion
3.1. EVE enhances collagen deposition
Only the large negatively charged polymeric macromolecules
induced collagen deposition above control levels (Fig. 1A). As
described previously [5], the benchmarked polymer DxS
500 kDa resulted in enhanced collagen deposition (23-fold).
More remarkably, PSS (200 kDa), a sulfonated anionic poly-
mer, caused an even greater collagen deposition (36-fold).
PSS enabled virtually the complete conversion of procollagen
into collagen. This was apparent by its complete absence from
the medium fraction (Fig. 1B). Neither DxS 10 kDa nor the Fc
range caused substantial collagen deposition above control.
Immunochemistry of extracellular collagen deposition in the
presence of DxS (500 kDa) corroborated the quantitative bio-
chemical data above (Fig. 1C). In contrast, the ﬁbronectin pat-
tern and staining intensity were not signiﬁcantly enhanced. In
the absence of EVE, collagen staining was wispier and strictly
colocalized with ﬁbronectin, whereas under EVE both the
collagen and ﬁbronectin deposition patterns become more
granular and not always showed complete colocalization.
Furthermore, preliminary ultrastructural studies conﬁrmed
the presence of ﬁbrillar pericellular matrix in crowded versus
not crowded cultures (Fig. 1D). On several occasions, aggre-
gates of a width of 25–80 nm with collagen-typical cross-stria-
tion were observed.3.2. Biophysical characterization of macromolecules
Biophysical characterization of the macromolecules was
studied to establish correlates with their ability to create eﬀec-
tive EVE and thus enhance collagen ﬁbrillogenesis through
enzymatic processes (see below). Molecular size in solution
and net surface charge density were the key parameters. The
hydrodynamic radius describes the eﬀective size of a macro-
molecule in a physiological, aqueous environment. It combines
the physical size with the space its hydration shell(s) occupies.
Although anionic DxS (500 kDa) and neutral Fc 400 have
comparable molecular weights, DxS had a larger hydrody-
namic radius, and hence greater percentage fraction volume
occupancy (Fig. 2A). Astonishingly, this was at 500 times low-
er concentration. These data corroborate the ﬁndings in [5],
where comparison between anionic and neutral dextrans (500
and 670 kDa, respectively) demonstrated a greater-than 2-fold
hydrodynamic radius for the smaller but negatively-charged
dextran, enabling dramatically greater procollagen conversion
in vitro. An investigation into the surface charge density of
2712 R.R. Lareu et al. / FEBS Letters 581 (2007) 2709–2714DxS and PSS revealed that PSS had a 3–4 times higher f-po-
tential (Fig. 2B). This would account for the more potent vol-
ume exclusion with respect to collagen deposition for PSS even
though the percentage fraction volume occupancy for DxS
(500 kDa) was 4.3-fold greater at the same concentration. Pro-
collagen, a negatively charged macromolecule (pI of 5.2 at
physiological pH of 7.4) would have additional volume exclu-
sion due to electrostatic repulsion, which is a key parameter
that inﬂuences EVE [12]. Therefore, the potency of EVE
in our system, with negatively charged macromolecules, is
the combined eﬀect of steric and electrostatic repulsion. The
latter property, which is appreciably stronger for PSS, wouldFig. 4. EVE enhanced the rate of collagen deposition on the supporting mat
deposition after 2 days culturing in the presence of DxS 500 kDa (100 lg/ml
change values are relative to 2 days culturing in the absence of DxS. (B) SDS–
deposition (CL) and footprints (FP; after cell solublization with detergent) in
Double immunoﬂuorescence staining of collagen (red) and ﬁbronectin (gree
magniﬁcations at 10·. All lanes contain three pooled individual samples.explain the enhanced procollagen conversion of PSS over
DxS 500 kDa.
3.3. Enhanced extracellular enzymatic activity
Although increased procollagen conversion and subsequent
collagen deposition due to the establishment of EVE in tissue
culture is a deﬁnitive functional assay for PCP activity, Wes-
tern immunoblotting for the PCP protein did not detect a
quantitative diﬀerence in the presence of EVE (DxS
500 kDa, 100 lg/ml) (Fig. 3). However, although PCP has
many extracellular target proteins, an allosteric enhancer of
PCP-procollagen-speciﬁc activity, PCOLCE1, has been shownerial. (A) SDS–PAGE (NuPage) and densitometric analysis of collagen
; grey column) and in its absence for 2 days and up to 4 weeks. Fold-
PAGE (NuPage) and densitometric analysis of 2 days for total collagen
the absence (reference) and presence of DxS 500 kDa (100 lg/ml). (C)
n) of the footprints in the absence and presence of DxS 500 kDa. All
R.R. Lareu et al. / FEBS Letters 581 (2007) 2709–2714 2713to enhance PCP activity 10-fold [13–15]. Only in the presence
of crowding did we detect a 36 kDa active form of this PCP
enhancer protein (Fig. 3). Furthermore, the PCOLCE1 C-ter-
minus, a fragment with an apparent MW of 16.5 kDa, has
been shown to inhibit matrix metalloproteinase 2 (MMP2)
with greater eﬃciency than tissue inhibitor of MMP2 [16].
Therefore, by introducing EVE, we not only accelerated PCP
enzymatic activity but also the proteolytic conversion of
PCOLCE1 into a PCP-enhancing element and an additional
strong metalloproteinase inhibitor. This would complement the
matrix deposition process by inhibiting proteins that destroy
the ECM. Finally, the ECM forming process is augmented un-
der EVE with an increased lysyl oxidase activity resulting in an
enhanced presence of collagen beta crosslinks [5].Fig. 5. EVE enhanced matrix deposition onto 3-D scaﬀolds. (A)
Biobrane and (B) PLLA 3-D scaﬀolds analyzed by SDS–PAGE (in-
house) and densitometry of collagen deposition in the absence and
presence of DxS 500 kDa (100 lg/m). Biobrane was cultured for 3 days
under static conditions whereas PLLA was used under both static (5
days) and bioreactor (5 days) conditions. Fold-change values are
relative to static cultures in the absence of DxS.3.4. EVE enhances collagen deposition onto the supporting
material
Although several studies have been continuously hinting at
the potential of EVE [17,18] it has not been exploited for appli-
cations in biological in vitro systems. We were able to dramat-
ically enhance collagen deposition quantitatively and
temporally in the presence of DxS 500 kDa. In the presence
of EVE, 48 h of culturing resulted in greater-than 5- and 2-fold
collagen deposition compared to the control cultures (without
EVE) for 1 and 4 weeks, respectively (Fig. 4A). In addition, the
amount of ECM, with respect to collagen and ﬁbronectin, was
also enhanced on the tissue culture plastic. Both quantitative
(SDS–PAGE; Fig. 4B) and immunostaining (Fig. 4C) of
ECM footprints after detergent removal of the cellular layer
revealed substantial amounts of collagen and ﬁbronectin
deposited directly on the culture plate when cultured in the
presence of DxS. There was an almost complete ﬁne granular
conﬂuent coverage of the supporting surface, which was con-
trasted by the small amounts of patchy coverage in its absence.
Therefore, the application of EVE is an important tool in cre-
ating greater and more conﬂuent ECM coverage of the sup-
porting material. This is particularly important for the 3-D
bioreactor setting, where ﬂow rates and scaﬀold design can
generate strong local shear forces which detach cells [19,20].
To attain suitable seeding rates onto scaﬀolds, incubations
are usually ﬁrst performed under static culture conditions for
several days [21,22]. Therefore, speeding up the matrix forma-
tion within scaﬀolds would greatly enhance cell adhesion,
survival, migration and biological functionality. We investi-
gated the enhanced deposition of collagen onto 3-D scaﬀolds
through the addition of DxS 500 kDa (100 lg/ml) in the media.
Under static culture, the presence of DxS resulted in more than
6-fold increased collagen incorporation into both Biobrane
(Fig. 5A) and PLLA scaﬀolds (Fig. 5B). Under bioreactor con-
ditions, there was a 3-fold increase in collagen matrix forma-
tion on the PLLA scaﬀold compared to the control
(Fig. 5B). Of note, although the bioreactor experiments were
neither optimized for cell seeding density or ﬂow rate, the ben-
eﬁcial eﬀects of EVE were immediately evident.3.5. Mechanism of EVE
The successful application of EVE in our in vitro system can
be explained by a spectrum of thermodynamic eﬀects [17] such
as driving optimal folding of proteins enhancing their function
[23], enhancing enzyme catalytic activity [24], speciﬁcally creat-
ing substrate–enzyme complexes with longer half-lives [25],and enhancing protein aggregation and speciﬁc polymerization
of monomers into greater order structures [26]. Accordingly,
we propose that in our system EVE (1) shifted the enzymatic
reaction equilibrium towards procollagen conversion by stabi-
lizing the PCP-procollagen transition complex, (2) caused a
tighter or more frequent binding of the enhancer protein
(PCOLCE1) to PCP increasing its activity by allosteric regula-
tion, (3) induced proteolytic conversion of PCOLCE1 into a
PCP-enhancing fragment and a MMP inhibiting fragment,
and (4) promoted self-assembly of the collagen triplehelices
into insoluble ﬁbers. Supporting evidence for point 4 comes
from groups that have shown that collagen in solution self-
assembles faster in the presence of macromolecules [27–29].
However, further work needs to be done to address these issues
in more detail.
In conclusion, EVE is an indispensable component of intra-
and extracellular biochemistry and can be regarded, in its
various forms, as a creator and keeper of organic life through
biochemistry. Authorities in the ﬁeld state that many estimates
of reaction rates and equilibria made with uncrowded solu-
tions in the test tube diﬀer by orders of magnitude from those
of the same reactions operating under crowded conditions
within cells or the extracellular compartment [1,30]. Along this
line, our data show that when EVE is applied to a biological
system with living cells, its eﬀects are striking and from a bio-
technological point of view, highly promising for providing
solutions to advanced tissue engineering and certainly any
other biological processes that are emulated in vitro.
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course if: 
This license was made in connection with a course, 
This permission is granted for 1 year only. You may obtain a license for future website 
posting,  
All content posted to the web site must maintain the copyright information line on the 
bottom of each image,  
A hyper-text must be included to the Homepage of the journal from which you are licensing 
at http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books 
at http://www.elsevier.com , and 
Central Storage: This license does not include permission for a scanned version of the 
material to be stored in a central repository such as that provided by Heron/XanEdu.  
17. Author website  for journals with the following additional clauses:  
All content posted to the web site must maintain the copyright information line on the 
bottom of each image, and 
he permission granted is limited to the personal version of your paper.  You are not allowed 
to download and post the published electronic version of your article (whether PDF or 
HTML, proof or final version), nor may you scan the printed edition to create an electronic 
version,  
A hyper-text must be included to the Homepage of the journal from which you are licensing 
at http://www.sciencedirect.com/science/journal/xxxxx , As part of our normal production 
process, you will receive an e-mail notice when your article appears on Elsevier’s online 
service ScienceDirect (www.sciencedirect.com).   That e-mail will include the article’s 
Digital Object Identifier (DOI).  This number provides the electronic link to the published 
article and should be included in the posting of your personal version.  We ask that you wait 
until you receive this e-mail and have the DOI to do any posting.  
Central Storage: This license does not include permission for a scanned version of the 
material to be stored in a central repository such as that provided by Heron/XanEdu. 
18. Author website for books with the following additional clauses:  
Authors are permitted to place a brief summary of their work online only. 
A hyper-text must be included to the Elsevier homepage at http://www.elsevier.com  
All content posted to the web site must maintain the copyright information line on the 
bottom of each image 
  You are not allowed to download and post the published electronic version of your chapter, 
nor may you scan the printed edition to create an electronic version.  
Central Storage: This license does not include permission for a scanned version of the 
material to be stored in a central repository such as that provided by Heron/XanEdu. 
  
19. Website (regular and for author): A hyper-text must be included to the Homepage of the 
journal from which you are licensing at 
http://www.sciencedirect.com/science/journal/xxxxx.  or for books to the Elsevier homepage 
at http://www.elsevier.com 
20. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be 
submitted to your institution in either print or electronic form. Should your thesis be 
published commercially, please reapply for permission. These requirements include 
permission for the Library and Archives of Canada to supply single copies, on demand, of 
the complete thesis and include permission for UMI to supply single copies, on demand, of 
the complete thesis. Should your thesis be published commercially, please reapply for 
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permission.  
21. Other Conditions: None 
  
v1.6 
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable 
license for your reference. No payment is required. 
If you would like to pay for this license now, please remit this license along with your 
payment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise you will be 
invoiced within 48 hours of the license date. Payment should be in the form of a check 
or money order referencing your account number and this invoice number 
RLNK10760464. 
Once you receive your invoice for this order, you may pay your invoice by credit card. 
Please follow instructions provided at that time. 
 
Make Payment To: 
Copyright Clearance Center 
Dept 001 
P.O. Box 843006 
Boston, MA 02284-3006 
 
If you find copyrighted material related to this license will not be used and wish to 
cancel, please contact us referencing this license number 2399280731477 and noting 
the reason for cancellation. 
 
Questions? customercare@copyright.com or +1-877-622-5543 (toll free in the US) or 
+1-978-646-2777.  
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NATURE PUBLISHING GROUP LICENSE 
TERMS AND CONDITIONS 
Mar 31, 2010 
 
This is a License Agreement between ZHIBO WANG ("You") and Nature Publishing Group 
("Nature Publishing Group") provided by Copyright Clearance Center ("CCC"). The license 
consists of your order details, the terms and conditions provided by Nature Publishing 
Group, and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
License Number 2399281264805 
License date Mar 31, 2010 
Licensed content publisher Nature Publishing Group 
Licensed content publication Nature 
Licensed content title Controlling the double helix 
Licensed content author Gary Felsenfeld and Mark Groudine 
Volume number 421 
Issue number 6921 
Pages pp448-453 
Year of publication 2003 
Portion used Figures / tables 
Number of figures / tables 1 
Requestor type Student 
Type of Use Thesis / Dissertation 
Billing Type Invoice 
Company ZHIBO WANG 
Billing Address #06-284, BLK611 
  Clementi West Street 1 
  Singapore, other 120611 
  Singapore 
Customer reference info 
Total 0.00 USD 
Terms and Conditions 
Terms and Conditions for Permissions 
Nature Publishing Group hereby grants you a non-exclusive license to reproduce this 
material for this purpose, and for no other use, subject to the conditions below:  
1. NPG warrants that it has, to the best of its knowledge, the rights to license reuse of 
this material. However, you should ensure that the material you are requesting is 
original to Nature Publishing Group and does not carry the copyright of another entity 
(as credited in the published version). If the credit line on any part of the material you 
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have requested indicates that it was reprinted or adapted by NPG with permission 
from another source, then you should also seek permission from that source to reuse 
the material.  
   
2. Permission granted free of charge for material in print is also usually granted for any 
electronic version of that work, provided that the material is incidental to the work as 
a whole and that the electronic version is essentially equivalent to, or substitutes for, 
the print version. Where print permission has been granted for a fee, separate 
permission must be obtained for any additional, electronic re-use (unless, as in the 
case of a full paper, this has already been accounted for during your initial request in 
the calculation of a print run). NB: In all cases, web-based use of full-text articles 
must be authorized separately through the 'Use on a Web Site' option when requesting 
permission. 
   
3. Permission granted for a first edition does not apply to second and subsequent editions 
and for editions in other languages (except for signatories to the STM Permissions 
Guidelines, or where the first edition permission was granted for free).  
   
4. Nature Publishing Group's permission must be acknowledged next to the figure, table 
or abstract in print. In electronic form, this acknowledgement must be visible at the 
same time as the figure/table/abstract, and must be hyperlinked to the journal's 
homepage.  
5. The credit line should read: 
 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
 
For AOP papers, the credit line should read: 
 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME], 
advance online publication, day month year (doi: 10.1038/sj.[JOURNAL 
ACRONYM].XXXXX)  
   
6. Adaptations of single figures do not require NPG approval. However, the adaptation 
should be credited as follows: 
 
Adapted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication)  
   
7. Translations of 401 words up to a whole article require NPG approval. Please visit 
http://www.macmillanmedicalcommunications.com for more information. 
Translations of up to a 400 words do not require NPG approval. The translation should 
be credited as follows: 
 
Translated by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication).  
We are certain that all parties will benefit from this agreement and wish you the best in the 
use of this material. Thank you. 
v1.1 
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable 
license for your reference. No payment is required. 
If you would like to pay for this license now, please remit this license along with your 
Page 2 of 3Rightslink Printable License
3/31/2010https://s100.copyright.com/App/PrintableLicenseFrame.jsp?publisherID=52&licenseID...
payment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise you will be 
invoiced within 48 hours of the license date. Payment should be in the form of a check 
or money order referencing your account number and this invoice number 
RLNK10760468. 
Once you receive your invoice for this order, you may pay your invoice by credit card. 
Please follow instructions provided at that time. 
 
Make Payment To: 
Copyright Clearance Center 
Dept 001 
P.O. Box 843006 
Boston, MA 02284-3006 
 
If you find copyrighted material related to this license will not be used and wish to 
cancel, please contact us referencing this license number 2399281264805 and noting 
the reason for cancellation. 
 
Questions? customercare@copyright.com or +1-877-622-5543 (toll free in the US) or 
+1-978-646-2777.  
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JOHN WILEY AND SONS LICENSE 
TERMS AND CONDITIONS 
Mar 31, 2010 
 
This is a License Agreement between ZHIBO WANG ("You") and John Wiley and Sons 
("John Wiley and Sons") provided by Copyright Clearance Center ("CCC"). The license 
consists of your order details, the terms and conditions provided by John Wiley and Sons, 
and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
License Number 2399290145274 
License date Mar 31, 2010 
Licensed content publisher John Wiley and Sons 
Licensed content publication BioEssays 
Licensed content title Roles of histone acetyltransferases and deacetylases in gene 
regulation 
Licensed content author Kuo Min-Hao, Allis C. David 
Licensed content date Dec 7, 1998 
Start page 615 
End page 626 
Type of use Dissertation/Thesis 
Requestor type University/Academic 
Format Electronic 
Portion Figure/table 
Number of figures/tables 1 
Original Wiley figure/table 
number(s) 
Figure 1 
Will you be translating? No 
Order reference number 
Total 0.00 USD 
Terms and Conditions 
TERMS AND CONDITIONS  
 
This copyrighted material is owned by or exclusively licensed to John Wiley & Sons, Inc. or one if 
its group companies (each a “Wiley Company”) or a society for whom a Wiley Company has 
exclusive publishing rights in relation to a particular journal (collectively “WILEY”). By clicking 
“accept” in connection with completing this licensing transaction, you agree that the following 
terms and conditions apply to this transaction (along with the billing and payment terms and 
conditions established by the Copyright Clearance Center Inc., (“CCC’s Billing and Payment terms 
and conditions”), at the time that you opened your Rightslink account (these are available at any 
time at http://myaccount.copyright.com).  
 
Terms and Conditions  
 
1. The materials you have requested permission to reproduce (the "Materials") are protected by 
copyright.  
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2. You are hereby granted a personal, non-exclusive, non-sublicensable, non-transferable, 
worldwide, limited license to reproduce the Materials for the purpose specified in the licensing 
process. This license is for a one-time use only with a maximum distribution equal to the number 
that you identified in the licensing process. Any form of republication granted by this licence must 
be completed within two years of the date of the grant of this licence (although copies prepared 
before may be distributed thereafter). Any electronic posting of the Materials is limited to one 
year from the date permission is granted and is on the condition that a link is placed to the 
journal homepage on Wiley’s online journals publication platform at www.interscience.wiley.com. 
The Materials shall not be used in any other manner or for any other purpose. Permission is 
granted subject to an appropriate acknowledgement given to the author, title of the 
material/book/journal and the publisher and on the understanding that nowhere in the text is a 
previously published source acknowledged for all or part of this Material. Any third party material 
is expressly excluded from this permission.  
 
3. With respect to the Materials, all rights are reserved. No part of the Materials may be copied, 
modified, adapted, translated, reproduced, transferred or distributed, in any form or by any 
means, and no derivative works may be made based on the Materials without the prior 
permission of the respective copyright owner. You may not alter, remove or suppress in any 
manner any copyright, trademark or other notices displayed by the Materials. You may not 
license, rent, sell, loan, lease, pledge, offer as security, transfer or assign the Materials, or any of 
the rights granted to you hereunder to any other person.  
 
4. The Materials and all of the intellectual property rights therein shall at all times remain the 
exclusive property of John Wiley & Sons Inc or one of its related companies (WILEY) or their 
respective licensors, and your interest therein is only that of having possession of and the right to 
reproduce the Materials pursuant to Section 2 herein during the continuance of this Agreement. 
You agree that you own no right, title or interest in or to the Materials or any of the intellectual 
property rights therein. You shall have no rights hereunder other than the license as provided for 
above in Section 2. No right, license or interest to any trademark, trade name, service mark or 
other branding ("Marks") of WILEY or its licensors is granted hereunder, and you agree that you 
shall not assert any such right, license or interest with respect thereto.  
 
5. WILEY DOES NOT MAKE ANY WARRANTY OR REPRESENTATION OF ANY KIND TO YOU OR ANY 
THIRD PARTY, EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE MATERIALS OR THE 
ACCURACY OF ANY INFORMATION CONTAINED IN THE MATERIALS, INCLUDING, WITHOUT 
LIMITATION, ANY IMPLIED WARRANTY OF MERCHANTABILITY, ACCURACY, SATISFACTORY 
QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY, INTEGRATION OR NON-
INFRINGEMENT AND ALL SUCH WARRANTIES ARE HEREBY EXCLUDED BY WILEY AND WAIVED BY 
YOU.  
 
6. WILEY shall have the right to terminate this Agreement immediately upon breach of this 
Agreement by you.  
 
7. You shall indemnify, defend and hold harmless WILEY, its directors, officers, agents and 
employees, from and against any actual or threatened claims, demands, causes of action or 
proceedings arising from any breach of this Agreement by you.  
 
8. IN NO EVENT SHALL WILEY BE LIABLE TO YOU OR ANY OTHER PARTY OR ANY OTHER PERSON 
OR ENTITY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR 
PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN CONNECTION WITH THE 
DOWNLOADING, PROVISIONING, VIEWING OR USE OF THE MATERIALS REGARDLESS OF THE 
FORM OF ACTION, WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, TORT, 
NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, WITHOUT LIMITATION, DAMAGES 
BASED ON LOSS OF PROFITS, DATA, FILES, USE, BUSINESS OPPORTUNITY OR CLAIMS OF THIRD 
PARTIES), AND WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF 
SUCH DAMAGES. THIS LIMITATION SHALL APPLY NOTWITHSTANDING ANY FAILURE OF 
ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED HEREIN.  
 
9. Should any provision of this Agreement be held by a court of competent jurisdiction to be 
illegal, invalid, or unenforceable, that provision shall be deemed amended to achieve as nearly as 
possible the same economic effect as the original provision, and the legality, validity and 
enforceability of the remaining provisions of this Agreement shall not be affected or impaired 
thereby.  
 
10. The failure of either party to enforce any term or condition of this Agreement shall not 
constitute a waiver of either party's right to enforce each and every term and condition of this 
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Agreement. No breach under this agreement shall be deemed waived or excused by either party 
unless such waiver or consent is in writing signed by the party granting such waiver or consent. 
The waiver by or consent of a party to a breach of any provision of this Agreement shall not 
operate or be construed as a waiver of or consent to any other or subsequent breach by such 
other party.  
 
11. This Agreement may not be assigned (including by operation of law or otherwise) by you 
without WILEY's prior written consent.  
 
12. These terms and conditions together with CCC’s Billing and Payment terms and conditions 
(which are incorporated herein) form the entire agreement between you and WILEY concerning 
this licensing transaction and (in the absence of fraud) supersedes all prior agreements and 
representations of the parties, oral or written. This Agreement may not be amended except in a 
writing signed by both parties. This Agreement shall be binding upon and inure to the benefit of 
the parties' successors, legal representatives, and authorized assigns.  
 
13. In the event of any conflict between your obligations established by these terms and 
conditions and those established by CCC’s Billing and Payment terms and conditions, these terms 
and conditions shall prevail.  
 
14. WILEY expressly reserves all rights not specifically granted in the combination of (i) the 
license details provided by you and accepted in the course of this licensing transaction, (ii) these 
terms and conditions and (iii) CCC’s Billing and Payment terms and conditions.  
 
15. This Agreement shall be governed by and construed in accordance with the laws of England 
and you agree to submit to the exclusive jurisdiction of the English courts.  
 
BY CLICKING ON THE "I ACCEPT" BUTTON, YOU ACKNOWLEDGE THAT YOU HAVE READ AND 
FULLY UNDERSTAND EACH OF THE SECTIONS OF AND PROVISIONS SET FORTH IN THIS 
AGREEMENT AND THAT YOU ARE IN AGREEMENT WITH AND ARE WILLING TO ACCEPT ALL OF 
YOUR OBLIGATIONS AS SET FORTH IN THIS AGREEMENT.  
 
V1.2 
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable 
license for your reference. No payment is required. 
If you would like to pay for this license now, please remit this license along with your 
payment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise you will be 
invoiced within 48 hours of the license date. Payment should be in the form of a check 
or money order referencing your account number and this invoice number 
RLNK10760474. 
Once you receive your invoice for this order, you may pay your invoice by credit card. 
Please follow instructions provided at that time. 
 
Make Payment To: 
Copyright Clearance Center 
Dept 001 
P.O. Box 843006 
Boston, MA 02284-3006 
 
If you find copyrighted material related to this license will not be used and wish to 
cancel, please contact us referencing this license number 2399290145274 and noting 
the reason for cancellation. 
 
Questions? customercare@copyright.com or +1-877-622-5543 (toll free in the US) or 
+1-978-646-2777.  
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ELSEVIER LICENSE 
TERMS AND CONDITIONS 
Mar 31, 2010 
 
This is a License Agreement between ZHIBO WANG ("You") and Elsevier ("Elsevier") 
provided by Copyright Clearance Center ("CCC"). The license consists of your order details, 
the terms and conditions provided by Elsevier, and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 





Registered Company Number 1982084 
Customer name ZHIBO WANG 
Customer address #06-284, BLK611 
  Singapore, other 120611 
License Number 2399290474867 
License date Mar 31, 2010 
Licensed content publisher Elsevier 
Licensed content publication Journal of Molecular Biology 
Licensed content title Molecular Evolution of the 
Histone Deacetylase Family: 
Functional Implications of 
Phylogenetic Analysis 
Licensed content author IvanV Gregoretti, Yun-Mi 
Lee, Holly V Goodson 
Licensed content date 16 April 2004 
Volume number 338 
Issue number 1 
Pages 15 
Type of Use Thesis / Dissertation 
Portion Figures/tables/illustrations 
Number of Figures/tables/illustrations 1 
Format Electronic 
You are an author of the Elsevier article No 
Are you translating? No 
Order Reference Number 
Expected publication date  Apr 2010 
Elsevier VAT number GB 494 6272 12 
Permissions price 0.00 USD 
Value added tax 0.0% 0.00 USD 
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Total 0.00 USD 
Terms and Conditions 
INTRODUCTION 
1. The publisher for this copyrighted material is Elsevier.  By clicking "accept" in 
connection with completing this licensing transaction, you agree that the following terms 
and conditions apply to this transaction (along with the Billing and Payment terms and 
conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you 
opened your Rightslink account and that are available at any time at 
http://myaccount.copyright.com).  
GENERAL TERMS 
2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to 
the terms and conditions indicated. 
3. Acknowledgement: If any part of the material to be used (for example, figures) has 
appeared in our publication with credit or acknowledgement to another source, permission 
must also be sought from that source.  If such permission is not obtained then that material 
may not be included in your publication/copies. Suitable acknowledgement to the source 
must be made, either as a footnote or in a reference list at the end of your publication, as 
follows: 
“Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of 
chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE 
SOCIETY COPYRIGHT OWNER].” Also Lancet special credit - “Reprinted from The 
Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with 
permission from Elsevier.” 
4. Reproduction of this material is confined to the purpose and/or media for which 
permission is hereby given. 
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be 
altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions 
and/or any other alterations shall be made only with prior written authorization of Elsevier 
Ltd. (Please contact Elsevier at permissions@elsevier.com)  
6. If the permission fee for the requested use of our material is waived in this instance, 
please be advised that your future requests for Elsevier materials may attract a fee. 
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the 
combination of (i) the license details provided by you and accepted in the course of this 
licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment 
terms and conditions. 
8. License Contingent Upon Payment: While you may exercise the rights licensed 
immediately upon issuance of the license at the end of the licensing process for the 
transaction, provided that you have disclosed complete and accurate details of your proposed 
use, no license is finally effective unless and until full payment is received from you (either 
by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions.  If 
full payment is not received on a timely basis, then any license preliminarily granted shall be 
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deemed automatically revoked and shall be void as if never granted.  Further, in the event 
that you breach any of these terms and conditions or any of CCC's Billing and Payment 
terms and conditions, the license is automatically revoked and shall be void as if never 
granted.  Use of materials as described in a revoked license, as well as any use of the 
materials beyond the scope of an unrevoked license, may constitute copyright infringement 
and publisher reserves the right to take any and all action to protect its copyright in the 
materials. 
9. Warranties: Publisher makes no representations or warranties with respect to the licensed 
material. 
10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and 
their respective officers, directors, employees and agents, from and against any and all 
claims arising out of your use of the licensed material other than as specifically authorized 
pursuant to this license. 
11. No Transfer of License: This license is personal to you and may not be sublicensed, 
assigned, or transferred by you to any other person without publisher's written permission. 
12. No Amendment Except in Writing: This license may not be amended except in a writing 
signed by both parties (or, in the case of publisher, by CCC on publisher's behalf). 
13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any 
purchase order, acknowledgment, check endorsement or other writing prepared by you, 
which terms are inconsistent with these terms and conditions or CCC's Billing and Payment 
terms and conditions.  These terms and conditions, together with CCC's Billing and Payment 
terms and conditions (which are incorporated herein), comprise the entire agreement 
between you and publisher (and CCC) concerning this licensing transaction.  In the event of 
any conflict between your obligations established by these terms and conditions and those 
established by CCC's Billing and Payment terms and conditions, these terms and conditions 
shall control. 
14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described 
in this License at their sole discretion, for any reason or no reason, with a full refund payable 
to you.  Notice of such denial will be made using the contact information provided by you.  
Failure to receive such notice will not alter or invalidate the denial.  In no event will Elsevier 
or Copyright Clearance Center be responsible or liable for any costs, expenses or damage 
incurred by you as a result of a denial of your permission request, other than a refund of the 
amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied 
permissions. 
LIMITED LICENSE 
The following terms and conditions apply only to specific license types: 
15. Translation: This permission is granted for non-exclusive world English rights only 
unless your license was granted for translation rights. If you licensed translation rights you 
may only translate this content into the languages you requested. A professional translator 
must perform all translations and reproduce the content word for word preserving the 
integrity of the article. If this license is to re-use 1 or 2 figures then permission is granted for 
non-exclusive world rights in all languages. 
16. Website: The following terms and conditions apply to electronic reserve and author 
websites: 
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Electronic reserve: If licensed material is to be posted to website, the web site is to be 
password-protected and made available only to bona fide students registered on a relevant 
course if: 
This license was made in connection with a course, 
This permission is granted for 1 year only. You may obtain a license for future website 
posting,  
All content posted to the web site must maintain the copyright information line on the 
bottom of each image,  
A hyper-text must be included to the Homepage of the journal from which you are licensing 
at http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books 
at http://www.elsevier.com , and 
Central Storage: This license does not include permission for a scanned version of the 
material to be stored in a central repository such as that provided by Heron/XanEdu.  
17. Author website  for journals with the following additional clauses:  
All content posted to the web site must maintain the copyright information line on the 
bottom of each image, and 
he permission granted is limited to the personal version of your paper.  You are not allowed 
to download and post the published electronic version of your article (whether PDF or 
HTML, proof or final version), nor may you scan the printed edition to create an electronic 
version,  
A hyper-text must be included to the Homepage of the journal from which you are licensing 
at http://www.sciencedirect.com/science/journal/xxxxx , As part of our normal production 
process, you will receive an e-mail notice when your article appears on Elsevier’s online 
service ScienceDirect (www.sciencedirect.com).   That e-mail will include the article’s 
Digital Object Identifier (DOI).  This number provides the electronic link to the published 
article and should be included in the posting of your personal version.  We ask that you wait 
until you receive this e-mail and have the DOI to do any posting.  
Central Storage: This license does not include permission for a scanned version of the 
material to be stored in a central repository such as that provided by Heron/XanEdu. 
18. Author website for books with the following additional clauses:  
Authors are permitted to place a brief summary of their work online only. 
A hyper-text must be included to the Elsevier homepage at http://www.elsevier.com  
All content posted to the web site must maintain the copyright information line on the 
bottom of each image 
  You are not allowed to download and post the published electronic version of your chapter, 
nor may you scan the printed edition to create an electronic version.  
Central Storage: This license does not include permission for a scanned version of the 
material to be stored in a central repository such as that provided by Heron/XanEdu. 
  
19. Website (regular and for author): A hyper-text must be included to the Homepage of the 
journal from which you are licensing at 
http://www.sciencedirect.com/science/journal/xxxxx.  or for books to the Elsevier homepage 
at http://www.elsevier.com 
20. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be 
submitted to your institution in either print or electronic form. Should your thesis be 
published commercially, please reapply for permission. These requirements include 
permission for the Library and Archives of Canada to supply single copies, on demand, of 
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the complete thesis. Should your thesis be published commercially, please reapply for 
permission.  
21. Other Conditions: None 
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If you would like to pay for this license now, please remit this license along with your 
payment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise you will be 
invoiced within 48 hours of the license date. Payment should be in the form of a check 
or money order referencing your account number and this invoice number 
RLNK10760478. 
Once you receive your invoice for this order, you may pay your invoice by credit card. 
Please follow instructions provided at that time. 
 
Make Payment To: 
Copyright Clearance Center 
Dept 001 
P.O. Box 843006 
Boston, MA 02284-3006 
 
If you find copyrighted material related to this license will not be used and wish to 
cancel, please contact us referencing this license number 2399290474867 and noting 
the reason for cancellation. 
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("Nature Publishing Group") provided by Copyright Clearance Center ("CCC"). The license 
consists of your order details, the terms and conditions provided by Nature Publishing 
Group, and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
License Number 2396430508841 
License date Mar 26, 2010 
Licensed content publisher Nature Publishing Group 
Licensed content publication Nature Reviews Cancer 
Licensed content title Histone deacetylase inhibitors and the promise of epigenetic (and 
more) treatments for cancer 
Licensed content author Saverio Minucci and Pier Giuseppe Pelicci 
Volume number 6 
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Pages pp38-51 
Year of publication 2006 
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Number of figures / tables 1 
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Billing Address #06-284, BLK611 
  Clementi West Street 1 
  Singapore, other 120611 
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Terms and Conditions 
Terms and Conditions for Permissions 
Nature Publishing Group hereby grants you a non-exclusive license to reproduce this 
material for this purpose, and for no other use, subject to the conditions below:  
1. NPG warrants that it has, to the best of its knowledge, the rights to license reuse of 
this material. However, you should ensure that the material you are requesting is 
original to Nature Publishing Group and does not carry the copyright of another entity 
(as credited in the published version). If the credit line on any part of the material you 
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have requested indicates that it was reprinted or adapted by NPG with permission 
from another source, then you should also seek permission from that source to reuse 
the material.  
   
2. Permission granted free of charge for material in print is also usually granted for any 
electronic version of that work, provided that the material is incidental to the work as 
a whole and that the electronic version is essentially equivalent to, or substitutes for, 
the print version. Where print permission has been granted for a fee, separate 
permission must be obtained for any additional, electronic re-use (unless, as in the 
case of a full paper, this has already been accounted for during your initial request in 
the calculation of a print run). NB: In all cases, web-based use of full-text articles 
must be authorized separately through the 'Use on a Web Site' option when requesting 
permission. 
   
3. Permission granted for a first edition does not apply to second and subsequent editions 
and for editions in other languages (except for signatories to the STM Permissions 
Guidelines, or where the first edition permission was granted for free).  
   
4. Nature Publishing Group's permission must be acknowledged next to the figure, table 
or abstract in print. In electronic form, this acknowledgement must be visible at the 
same time as the figure/table/abstract, and must be hyperlinked to the journal's 
homepage.  
5. The credit line should read: 
 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
 
For AOP papers, the credit line should read: 
 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME], 
advance online publication, day month year (doi: 10.1038/sj.[JOURNAL 
ACRONYM].XXXXX)  
   
6. Adaptations of single figures do not require NPG approval. However, the adaptation 
should be credited as follows: 
 
Adapted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication)  
   
7. Translations of 401 words up to a whole article require NPG approval. Please visit 
http://www.macmillanmedicalcommunications.com for more information. 
Translations of up to a 400 words do not require NPG approval. The translation should 
be credited as follows: 
 
Translated by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication).  
We are certain that all parties will benefit from this agreement and wish you the best in the 
use of this material. Thank you. 
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Please follow instructions provided at that time. 
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Copyright Clearance Center 
Dept 001 
P.O. Box 843006 
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If you find copyrighted material related to this license will not be used and wish to 
cancel, please contact us referencing this license number 2396430508841 and noting 
the reason for cancellation. 
 
Questions? customercare@copyright.com or +1-877-622-5543 (toll free in the US) or 
+1-978-646-2777.  
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Group, and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
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Terms and Conditions for Permissions 
Nature Publishing Group hereby grants you a non-exclusive license to reproduce this 
material for this purpose, and for no other use, subject to the conditions below:  
1. NPG warrants that it has, to the best of its knowledge, the rights to license reuse of 
this material. However, you should ensure that the material you are requesting is 
original to Nature Publishing Group and does not carry the copyright of another entity 
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(as credited in the published version). If the credit line on any part of the material you 
have requested indicates that it was reprinted or adapted by NPG with permission 
from another source, then you should also seek permission from that source to reuse 
the material.  
   
2. Permission granted free of charge for material in print is also usually granted for any 
electronic version of that work, provided that the material is incidental to the work as 
a whole and that the electronic version is essentially equivalent to, or substitutes for, 
the print version. Where print permission has been granted for a fee, separate 
permission must be obtained for any additional, electronic re-use (unless, as in the 
case of a full paper, this has already been accounted for during your initial request in 
the calculation of a print run). NB: In all cases, web-based use of full-text articles 
must be authorized separately through the 'Use on a Web Site' option when requesting 
permission. 
   
3. Permission granted for a first edition does not apply to second and subsequent editions 
and for editions in other languages (except for signatories to the STM Permissions 
Guidelines, or where the first edition permission was granted for free).  
   
4. Nature Publishing Group's permission must be acknowledged next to the figure, table 
or abstract in print. In electronic form, this acknowledgement must be visible at the 
same time as the figure/table/abstract, and must be hyperlinked to the journal's 
homepage.  
5. The credit line should read: 
 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
 
For AOP papers, the credit line should read: 
 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME], 
advance online publication, day month year (doi: 10.1038/sj.[JOURNAL 
ACRONYM].XXXXX)  
   
6. Adaptations of single figures do not require NPG approval. However, the adaptation 
should be credited as follows: 
 
Adapted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication)  
   
7. Translations of 401 words up to a whole article require NPG approval. Please visit 
http://www.macmillanmedicalcommunications.com for more information. 
Translations of up to a 400 words do not require NPG approval. The translation should 
be credited as follows: 
 
Translated by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication).  
We are certain that all parties will benefit from this agreement and wish you the best in the 
use of this material. Thank you. 
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If you would like to pay for this license now, please remit this license along with your 
payment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise you will be 
invoiced within 48 hours of the license date. Payment should be in the form of a check 
or money order referencing your account number and this invoice number 
RLNK10760482. 
Once you receive your invoice for this order, you may pay your invoice by credit card. 
Please follow instructions provided at that time. 
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Copyright Clearance Center 
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P.O. Box 843006 
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If you find copyrighted material related to this license will not be used and wish to 
cancel, please contact us referencing this license number 2399290710195 and noting 
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information listed at the bottom of this form. 
License Number 2399291026508 
License date Mar 31, 2010 
Licensed content publisher John Wiley and Sons 
Licensed content publication British Journal of Pharmacology 
Licensed content title The Scar-in-a-Jar: studying potential antifibrotic compounds from 
the epigenetic to extracellular level in a single well 
Licensed content author Chen CZC, Peng YX, Wang ZB, et al 
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TERMS AND CONDITIONS  
 
This copyrighted material is owned by or exclusively licensed to John Wiley & Sons, Inc. or one if 
its group companies (each a “Wiley Company”) or a society for whom a Wiley Company has 
exclusive publishing rights in relation to a particular journal (collectively “WILEY”). By clicking 
“accept” in connection with completing this licensing transaction, you agree that the following 
terms and conditions apply to this transaction (along with the billing and payment terms and 
conditions established by the Copyright Clearance Center Inc., (“CCC’s Billing and Payment terms 
and conditions”), at the time that you opened your Rightslink account (these are available at any 
time at http://myaccount.copyright.com).  
 
Terms and Conditions  
 
1. The materials you have requested permission to reproduce (the "Materials") are protected by 
copyright.  
 
2. You are hereby granted a personal, non-exclusive, non-sublicensable, non-transferable, 
worldwide, limited license to reproduce the Materials for the purpose specified in the licensing 
process. This license is for a one-time use only with a maximum distribution equal to the number 
that you identified in the licensing process. Any form of republication granted by this licence must 
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be completed within two years of the date of the grant of this licence (although copies prepared 
before may be distributed thereafter). Any electronic posting of the Materials is limited to one 
year from the date permission is granted and is on the condition that a link is placed to the 
journal homepage on Wiley’s online journals publication platform at www.interscience.wiley.com. 
The Materials shall not be used in any other manner or for any other purpose. Permission is 
granted subject to an appropriate acknowledgement given to the author, title of the 
material/book/journal and the publisher and on the understanding that nowhere in the text is a 
previously published source acknowledged for all or part of this Material. Any third party material 
is expressly excluded from this permission.  
 
3. With respect to the Materials, all rights are reserved. No part of the Materials may be copied, 
modified, adapted, translated, reproduced, transferred or distributed, in any form or by any 
means, and no derivative works may be made based on the Materials without the prior 
permission of the respective copyright owner. You may not alter, remove or suppress in any 
manner any copyright, trademark or other notices displayed by the Materials. You may not 
license, rent, sell, loan, lease, pledge, offer as security, transfer or assign the Materials, or any of 
the rights granted to you hereunder to any other person.  
 
4. The Materials and all of the intellectual property rights therein shall at all times remain the 
exclusive property of John Wiley & Sons Inc or one of its related companies (WILEY) or their 
respective licensors, and your interest therein is only that of having possession of and the right to 
reproduce the Materials pursuant to Section 2 herein during the continuance of this Agreement. 
You agree that you own no right, title or interest in or to the Materials or any of the intellectual 
property rights therein. You shall have no rights hereunder other than the license as provided for 
above in Section 2. No right, license or interest to any trademark, trade name, service mark or 
other branding ("Marks") of WILEY or its licensors is granted hereunder, and you agree that you 
shall not assert any such right, license or interest with respect thereto.  
 
5. WILEY DOES NOT MAKE ANY WARRANTY OR REPRESENTATION OF ANY KIND TO YOU OR ANY 
THIRD PARTY, EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE MATERIALS OR THE 
ACCURACY OF ANY INFORMATION CONTAINED IN THE MATERIALS, INCLUDING, WITHOUT 
LIMITATION, ANY IMPLIED WARRANTY OF MERCHANTABILITY, ACCURACY, SATISFACTORY 
QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY, INTEGRATION OR NON-
INFRINGEMENT AND ALL SUCH WARRANTIES ARE HEREBY EXCLUDED BY WILEY AND WAIVED BY 
YOU.  
 
6. WILEY shall have the right to terminate this Agreement immediately upon breach of this 
Agreement by you.  
 
7. You shall indemnify, defend and hold harmless WILEY, its directors, officers, agents and 
employees, from and against any actual or threatened claims, demands, causes of action or 
proceedings arising from any breach of this Agreement by you.  
 
8. IN NO EVENT SHALL WILEY BE LIABLE TO YOU OR ANY OTHER PARTY OR ANY OTHER PERSON 
OR ENTITY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR 
PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN CONNECTION WITH THE 
DOWNLOADING, PROVISIONING, VIEWING OR USE OF THE MATERIALS REGARDLESS OF THE 
FORM OF ACTION, WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, TORT, 
NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, WITHOUT LIMITATION, DAMAGES 
BASED ON LOSS OF PROFITS, DATA, FILES, USE, BUSINESS OPPORTUNITY OR CLAIMS OF THIRD 
PARTIES), AND WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF 
SUCH DAMAGES. THIS LIMITATION SHALL APPLY NOTWITHSTANDING ANY FAILURE OF 
ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED HEREIN.  
 
9. Should any provision of this Agreement be held by a court of competent jurisdiction to be 
illegal, invalid, or unenforceable, that provision shall be deemed amended to achieve as nearly as 
possible the same economic effect as the original provision, and the legality, validity and 
enforceability of the remaining provisions of this Agreement shall not be affected or impaired 
thereby.  
 
10. The failure of either party to enforce any term or condition of this Agreement shall not 
constitute a waiver of either party's right to enforce each and every term and condition of this 
Agreement. No breach under this agreement shall be deemed waived or excused by either party 
unless such waiver or consent is in writing signed by the party granting such waiver or consent. 
The waiver by or consent of a party to a breach of any provision of this Agreement shall not 
operate or be construed as a waiver of or consent to any other or subsequent breach by such 
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12. These terms and conditions together with CCC’s Billing and Payment terms and conditions 
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this licensing transaction and (in the absence of fraud) supersedes all prior agreements and 
representations of the parties, oral or written. This Agreement may not be amended except in a 
writing signed by both parties. This Agreement shall be binding upon and inure to the benefit of 
the parties' successors, legal representatives, and authorized assigns.  
 
13. In the event of any conflict between your obligations established by these terms and 
conditions and those established by CCC’s Billing and Payment terms and conditions, these terms 
and conditions shall prevail.  
 
14. WILEY expressly reserves all rights not specifically granted in the combination of (i) the 
license details provided by you and accepted in the course of this licensing transaction, (ii) these 
terms and conditions and (iii) CCC’s Billing and Payment terms and conditions.  
 
15. This Agreement shall be governed by and construed in accordance with the laws of England 
and you agree to submit to the exclusive jurisdiction of the English courts.  
 
BY CLICKING ON THE "I ACCEPT" BUTTON, YOU ACKNOWLEDGE THAT YOU HAVE READ AND 
FULLY UNDERSTAND EACH OF THE SECTIONS OF AND PROVISIONS SET FORTH IN THIS 
AGREEMENT AND THAT YOU ARE IN AGREEMENT WITH AND ARE WILLING TO ACCEPT ALL OF 
YOUR OBLIGATIONS AS SET FORTH IN THIS AGREEMENT.  
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license for your reference. No payment is required. 
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payment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise you will be 
invoiced within 48 hours of the license date. Payment should be in the form of a check 
or money order referencing your account number and this invoice number 
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Please follow instructions provided at that time. 
 
Make Payment To: 
Copyright Clearance Center 
Dept 001 
P.O. Box 843006 
Boston, MA 02284-3006 
 
If you find copyrighted material related to this license will not be used and wish to 
cancel, please contact us referencing this license number 2399291026508 and noting 
the reason for cancellation. 
 
Questions? customercare@copyright.com or +1-877-622-5543 (toll free in the US) or 
+1-978-646-2777.  
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Value added tax 0.0% 0.00 USD 
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Terms and Conditions 
INTRODUCTION 
1. The publisher for this copyrighted material is Elsevier.  By clicking "accept" in 
connection with completing this licensing transaction, you agree that the following terms 
and conditions apply to this transaction (along with the Billing and Payment terms and 
conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you 
opened your Rightslink account and that are available at any time at 
http://myaccount.copyright.com).  
GENERAL TERMS 
2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to 
the terms and conditions indicated. 
3. Acknowledgement: If any part of the material to be used (for example, figures) has 
appeared in our publication with credit or acknowledgement to another source, permission 
must also be sought from that source.  If such permission is not obtained then that material 
may not be included in your publication/copies. Suitable acknowledgement to the source 
must be made, either as a footnote or in a reference list at the end of your publication, as 
follows: 
“Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of 
chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE 
SOCIETY COPYRIGHT OWNER].” Also Lancet special credit - “Reprinted from The 
Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with 
permission from Elsevier.” 
4. Reproduction of this material is confined to the purpose and/or media for which 
permission is hereby given. 
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be 
altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions 
and/or any other alterations shall be made only with prior written authorization of Elsevier 
Ltd. (Please contact Elsevier at permissions@elsevier.com)  
6. If the permission fee for the requested use of our material is waived in this instance, 
please be advised that your future requests for Elsevier materials may attract a fee. 
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the 
combination of (i) the license details provided by you and accepted in the course of this 
licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment 
terms and conditions. 
8. License Contingent Upon Payment: While you may exercise the rights licensed 
immediately upon issuance of the license at the end of the licensing process for the 
transaction, provided that you have disclosed complete and accurate details of your proposed 
use, no license is finally effective unless and until full payment is received from you (either 
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by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions.  If 
full payment is not received on a timely basis, then any license preliminarily granted shall be 
deemed automatically revoked and shall be void as if never granted.  Further, in the event 
that you breach any of these terms and conditions or any of CCC's Billing and Payment 
terms and conditions, the license is automatically revoked and shall be void as if never 
granted.  Use of materials as described in a revoked license, as well as any use of the 
materials beyond the scope of an unrevoked license, may constitute copyright infringement 
and publisher reserves the right to take any and all action to protect its copyright in the 
materials. 
9. Warranties: Publisher makes no representations or warranties with respect to the licensed 
material. 
10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and 
their respective officers, directors, employees and agents, from and against any and all 
claims arising out of your use of the licensed material other than as specifically authorized 
pursuant to this license. 
11. No Transfer of License: This license is personal to you and may not be sublicensed, 
assigned, or transferred by you to any other person without publisher's written permission. 
12. No Amendment Except in Writing: This license may not be amended except in a writing 
signed by both parties (or, in the case of publisher, by CCC on publisher's behalf). 
13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any 
purchase order, acknowledgment, check endorsement or other writing prepared by you, 
which terms are inconsistent with these terms and conditions or CCC's Billing and Payment 
terms and conditions.  These terms and conditions, together with CCC's Billing and Payment 
terms and conditions (which are incorporated herein), comprise the entire agreement 
between you and publisher (and CCC) concerning this licensing transaction.  In the event of 
any conflict between your obligations established by these terms and conditions and those 
established by CCC's Billing and Payment terms and conditions, these terms and conditions 
shall control. 
14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described 
in this License at their sole discretion, for any reason or no reason, with a full refund payable 
to you.  Notice of such denial will be made using the contact information provided by you.  
Failure to receive such notice will not alter or invalidate the denial.  In no event will Elsevier 
or Copyright Clearance Center be responsible or liable for any costs, expenses or damage 
incurred by you as a result of a denial of your permission request, other than a refund of the 
amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied 
permissions. 
LIMITED LICENSE 
The following terms and conditions apply only to specific license types: 
15. Translation: This permission is granted for non-exclusive world English rights only 
unless your license was granted for translation rights. If you licensed translation rights you 
may only translate this content into the languages you requested. A professional translator 
must perform all translations and reproduce the content word for word preserving the 
integrity of the article. If this license is to re-use 1 or 2 figures then permission is granted for 
non-exclusive world rights in all languages. 
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16. Website: The following terms and conditions apply to electronic reserve and author 
websites: 
Electronic reserve: If licensed material is to be posted to website, the web site is to be 
password-protected and made available only to bona fide students registered on a relevant 
course if: 
This license was made in connection with a course, 
This permission is granted for 1 year only. You may obtain a license for future website 
posting,  
All content posted to the web site must maintain the copyright information line on the 
bottom of each image,  
A hyper-text must be included to the Homepage of the journal from which you are licensing 
at http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books 
at http://www.elsevier.com , and 
Central Storage: This license does not include permission for a scanned version of the 
material to be stored in a central repository such as that provided by Heron/XanEdu.  
17. Author website  for journals with the following additional clauses:  
All content posted to the web site must maintain the copyright information line on the 
bottom of each image, and 
he permission granted is limited to the personal version of your paper.  You are not allowed 
to download and post the published electronic version of your article (whether PDF or 
HTML, proof or final version), nor may you scan the printed edition to create an electronic 
version,  
A hyper-text must be included to the Homepage of the journal from which you are licensing 
at http://www.sciencedirect.com/science/journal/xxxxx , As part of our normal production 
process, you will receive an e-mail notice when your article appears on Elsevier’s online 
service ScienceDirect (www.sciencedirect.com).   That e-mail will include the article’s 
Digital Object Identifier (DOI).  This number provides the electronic link to the published 
article and should be included in the posting of your personal version.  We ask that you wait 
until you receive this e-mail and have the DOI to do any posting.  
Central Storage: This license does not include permission for a scanned version of the 
material to be stored in a central repository such as that provided by Heron/XanEdu. 
18. Author website for books with the following additional clauses:  
Authors are permitted to place a brief summary of their work online only. 
A hyper-text must be included to the Elsevier homepage at http://www.elsevier.com  
All content posted to the web site must maintain the copyright information line on the 
bottom of each image 
  You are not allowed to download and post the published electronic version of your chapter, 
nor may you scan the printed edition to create an electronic version.  
Central Storage: This license does not include permission for a scanned version of the 
material to be stored in a central repository such as that provided by Heron/XanEdu. 
  
19. Website (regular and for author): A hyper-text must be included to the Homepage of the 
journal from which you are licensing at 
http://www.sciencedirect.com/science/journal/xxxxx.  or for books to the Elsevier homepage 
at http://www.elsevier.com 
20. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be 
submitted to your institution in either print or electronic form. Should your thesis be 
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published commercially, please reapply for permission. These requirements include 
permission for the Library and Archives of Canada to supply single copies, on demand, of 
the complete thesis and include permission for UMI to supply single copies, on demand, of 
the complete thesis. Should your thesis be published commercially, please reapply for 
permission.  
21. Other Conditions: None 
  
v1.6 
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable 
license for your reference. No payment is required. 
If you would like to pay for this license now, please remit this license along with your 
payment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise you will be 
invoiced within 48 hours of the license date. Payment should be in the form of a check 
or money order referencing your account number and this invoice number 
RLNK10760488. 
Once you receive your invoice for this order, you may pay your invoice by credit card. 
Please follow instructions provided at that time. 
 
Make Payment To: 
Copyright Clearance Center 
Dept 001 
P.O. Box 843006 
Boston, MA 02284-3006 
 
If you find copyrighted material related to this license will not be used and wish to 
cancel, please contact us referencing this license number 2399291276383 and noting 
the reason for cancellation. 
 
Questions? customercare@copyright.com or +1-877-622-5543 (toll free in the US) or 
+1-978-646-2777.  
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